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ABSTRACT 
High throughput proteomics and transcriptomics has provided a platform to 
further understand viral – host interaction. This provides a window into the host 
proteome and transcriptome with and without infection. This leads to 
identification of potential biomarkers, understanding IAV pathogenesis and 
also drawing a comparison of how hosts respond to viral infection.  
This thesis used two independent high throughput approaches to explore the 
proteome and transcriptome of samples from hosts (in vitro and in vivo) 
infected with influenza A virus (IAV) compared to samples from hosts (in vitro 
and in vivo) non-infected with IAV. The independent high throughput 
approaches used were; proteomics on a Q-Exactive platform and 
transcriptomics on a MinION sequencer. These approaches were used to 
further understand IAV infection in these different hosts and secondly to 
explore and search further for a potential biomarker for the diagnosis of IAV 
and potential drug targets. To our knowledge, this is the first study that has 
used high throughput approaches to analyses samples from different hosts. 
This allowed for comparison across hosts but also provides vast amounts of 
data that are reliable and consistent.   
A549 cells that were mock-infected and IAV- infected were subjected to the 
Q-Exactive platform and MinION sequencing. This provided insight into the in 
vitro host-viral interaction on a cellular level. For the first time, showed the 
potential of MinION sequencing as a method for understanding the viral-host 
interaction of IAV infected cells and identifying potential biomarkers. This 
highlighted transcripts such as NUP54, RBM42, HPGD, GCLC, ANPEP, 
AKAP13, RACGAP1, CREB1, MAN2B1 and PRKCI. These transcripts were 
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identified by bioinformatic analysis as host factors that play a crucial role in 
replication of IAV in the host. The corresponding proteins to these transcripts 
were also identified by proteomics. To better understand IAV in hosts, in vivo, 
Non-human primates (NHP) were infected with IAV and the broncho-alveolar 
fluid (BALF) was collected and compared to BALF from naïve NHP. After 
analysis on the Q-Exactive platform, the results obtained drew parallels on a 
cellular level to that observed in vitro models. Proteins such as; DDX58, 
EIF3A, HSP90AA1, MAPK1, MX1 and STAT1 involved in the “replication of 
IAV” were highlighted. In addition to the cellular changes, the NHP studies 
provided insight into an immune response similar to that observed in humans 
following IAV infection. This provided an added dimension in understanding 
IAV infection. Finally, nasopharyngeal aspirates (NAs) from humans IAV-
infected and IAV non-infected from three different cohorts (Alder Hey 
Children’s hospital (AHCH), Liverpool, Great Ormond Street Hospital (GOSH), 
London and Institute Pasteur Dakar (IPD)) were analysed on the Q-Exactive 
platform. This provided a full circle loop to compare if the changes observed 
in vitro model – A549 cells and in vivo model-NHP were relatable back to 
humans. Proteins identified in vitro and in vivo studies were concordant with 
proteins identified in the human NAs. These proteins include; COPA, STAT1, 
TUBB and HSPB1. Additionally, three proteins were identified in human NAs 
across all three cohorts; BPIFA1/SPLUNC1, Lactotransferrin and Fibrinogen 
A, B and G. These proteins play crucial roles in elucidating IAV infection in the 
host. This study presents the first time these proteins have been highlighted 
using label-free Mass spectrometry in human NAs across three cohorts from 
different geographical locations.  
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This thesis illustrates how proteomic analysis of IAV-infected samples 
compared to non-infected samples can be used to identify markers that may 
serve as potential diagnostic indicators for IAV infection.
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CHAPTER 1: INTRODUCTION 
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1.1 General introduction 
The influenza virus has been associated with human disease and epidemics 
since 412 BC, as described by Hippocrates. An epidemic in 412 BC, which 
affected medical personnel, showed the clinical symptoms of debility, coughs, 
and headaches. These were principal factors associated with the influenza 
virus (1, 2). This information demonstrates just how long the influenza virus 
has been associated with humans. Influenza viruses have been, and still are, 
a major source of morbidity and mortality around the world, affecting large 
groups of people yearly (3). In the United States alone, influenza virus 
infections cause an annual mortality of 36,000 (4). In addition to humans being 
infected by influenza viruses, many animal species can be infected. Four types 
of influenza virus have been classified; A, B, C, and the recently classified D 
virus (5, 6). Influenza viruses’ A and B cause seasonal disease epidemics. 
The influenza A virus (IAV) can cause pandemics due to its great genetic 
diversity. IAV infects a wide range of host species and causes severe disease 
in humans (7). Some viral proteins have an essential part to play in affecting 
IAV’s virulence, NS1 is an example of such a protein (8). NS1 plays a role in 
inhibiting an innate host response by targeting interferon (IFN) production and 
IFN-induced antiviral effectors. NS1 protein has been extensively studied in 
IAV, but not extensively in influenza B (9). Influenza type C infections do not 
cause epidemics but rather cause mild respiratory illness. Influenza D viruses 
mainly affect cattle and its ability to be a potential public health threat in 
humans is low (4) (10). IAV has given rise to pandemic strains in humans, as 
in the case of the 2009 H1N1 pandemic. IAV pandemics date back to 1918 
(11). In 1918, the human influenza A (H1N1) virus (IAV) spread globally and 
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killed between 40 and 50 million people. There were similarities in the clinical 
presentation and pathologic features of IAV in humans and swine. These 
similarities triggered the hypothesis that the pandemic human influenza, in 
1918, infected pigs (12). 
 
IAV was the first swine influenza virus isolated in a laboratory in 1931, where 
it was recorded and confirmed by laboratory diagnosis (13). Robert Shope 
successfully transmitted the infectious agent from sick pigs via transmission of 
secretions to healthy animals. Smith, Andrews, and Laidlaw were able to 
establish and document IAV infection in the ferret model and subsequently the 
transmissibility of both human and swine viruses (13). This was the first 
isolated human influenza virus and so was termed IAV. In 1940, an 
antigenically different virus was isolated, and after isolation, was termed the 
influenza type B virus (B/Lee/40) (14). The first influenza C virus was isolated 
in 1947 (15). The diagnosis of influenza viruses has frequently been via clinical 
symptoms (which can be similar with other respiratory infections) and the time 
of the year. Influenza virus infections can present as a sudden onset of three-
day fever as well as muscle pain. Influenza viruses can rapidly become 
epidemic and infect a large percentage of people. For these reasons, influenza 
viruses have been one of the most studied viruses up until the emergence of 
the human immunodeficiency virus (HIV), over three decades ago (16).  
 
 22 
1.2 Introduction to the classification of families 
1.2.1 The Orthomyxoviridae family  
The International Committee on Taxonomy of Viruses (ICTV) has recognised 
a hierarchy of viral taxa as follows: order, family, (subfamily), genus, and 
species. The viruses within the Orthomyxoviridae family are negative sense 
RNA viruses with seven genera and nine species (17).  
 
Table 1.1 Classification of Family Orthomyxoviridae, according to the 
International Committee on Taxonomy of Viruses (ICTV) released in 
2017 (17) 
Genus Species 
Alphainfluenzavirus Influenza A virus 
Betainfluenzavirus Influenza B virus 
Deltainfluenzavirus Influenza D virus 
Gammainfluenzavirus Influenza C virus 
Isavirus Salmon isavirus 
Quaranjavirus Johnston Atoll quaranjavirus 
Quaranfil quaranjavirus 
Thogotovirus Dhori thogotovirus 
Thogoto thogotovirus 
 
Virions of viruses within the Orthomyxoviridae family are both spherical and 
pleomorphic and are 80–120nm in diameter (18). Many members of the 
Orthomyxoviridae family are known animal or human pathogens. For example, 
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IAV accounts for seasonal epidemics and pandemics, resulting in many 
deaths over the past century (19).  
 
Unlike influenza viruses, thogotoviruses which are in the Thogotovirus genus 
are mainly transmitted through tick vectors and are subsequently called ‘tick-
borne viruses’ (19-21). These viruses are frequently found in domestic 
animals; sheep, cattle and camels. These viruses can cause neural diseases 
and abortion (19, 22). Thogotovirus (thogotovirus thogoto [THOV]) and the 
Dhori virus (thogotovirus dhori [DHOV]) infect humans and are known to cause 
human deaths (23, 24). Tick vectors are popularly known to transmit THOV 
and DHOV, but DHOV has been reported to cause human infections in a 
vector-free manner, perhaps through aerosols (24). This makes the 
transmission route unclear and not fully characterised. A farmer in the United 
States was infected, and subsequently killed, by a virus called the ‘Bourbon 
virus’ (BOUV). In 2014, this virus was identified and classified as an unknown 
type of thogotovirus (19, 25). These viruses are capable of harming the human 
population and their characterisation is important for public health (19).  
 
The envelope of thogotovirus consists of only one glycoprotein (Gp). This 
glycoprotein is responsible for virus entry, attachment, entry, and fusion (19, 
26). Within the Orthomyxovirdae family, quaranjavirus is the closest to 
thogotovirus. The Gp found in quaranjavirus shares a sequence identity of 
26% with the thogotovirus Gp.  
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The quaranjavirus genus contains the two species: Quaranfil virus (QRFV) 
and Johnston Atoll virus (JAV) (ICTV Report Taxonomy, 2009). In 1964, JAV 
was first isolated from ticks (Ornithodoros capensis) from Sand Island in the 
central pacific (27, 28). In 1953, the Quaranfil virus was first isolated from 
children in Quaranfil, Egypt, and subsequently in numerous other geographic 
areas from ticks and birds (27, 29). Through high throughput sequencing, the 
QRFV was completely sequenced and classified as a novel orthomyxovirus. 
QRFV had a genome made up of several RNA segments containing proteins 
that had similarities to other proteins within the orthomyxoviridae family such 
as polymerase (PA, PB1 and PB2) and hemagglutinin (HA) (27). Considering 
JAV and Lake Chad virus (LKCV) were both unclassified viruses, they were 
sequenced and analysed in comparison to QRFV. QRFV and JAV had a high 
amino acid similarity to each other of 80% and 70% in PB1 and HA 
respectively. As a result of this and further phylogenetic analyses, QRFV, JAV, 
and LKCV were proposed to belong to the Orthomyxoviridae family (27).  
 
Influenza viruses are categorised in separate genera to thogotovirus and 
isavirus. Influenza viruses have two major internal proteins; nucleoprotein and 
matrix protein that influence their classification (30) (31) (32, 33). IAVs affect 
mammals and birds. These viruses are further classified into subtypes based 
on the HA and neuraminidase (NA) proteins. These consist of 18 HA and 11 
NA proteins (33) (34-36). Newly isolated influenza viruses and laboratory 
strains frequently differ in shape: filamentous and spherical, respectively (37). 
All influenza viruses have distinguishing features, which allow the 
differentiation and categorisation of each virus.  
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Table 1.2: D
ifferentiation and categorisation of each influenza virus (adapted from
 talk.ictvonline.org ) 
 
Influenza viruses 
Influenza virus A
 (IA
V) 
Influenza virus B
 
(IB
V) 
Influenza virus C
 
(IC
V) 
Influenza virus D
 
(ID
V) 
D
istinguishing 
features – G
enom
e 
segm
ents 
E
ight genom
e segm
ents. 
E
ight genom
e 
segm
ents. 
S
even genom
e 
segm
ents and are 
lacking 
neuram
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identical structural 
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V
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It has correlating 
functions to H
A
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A
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V
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D
ue to its sim
ilarity 
to IC
V
, the 3’ and 5’ 
sequences are 
identical to IC
V. The 
only difference is on 
the 3’ end, w
here 
the nucleotide at 
position 5 is an 
adenine in ID
V
 but a 
cytosine in IC
V
. 
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Shape and size 
S
pherical or filam
entous 
and 100nm
 in diam
eter 
S
pherical or 
filam
entous and 
100nm
 in diam
eter 
O
n infected 
surfaces, form
 long 
cordlike structures – 
on order of 500Pm
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1.3 Antigenic drift, antigenic shift, and recombination 
IAV has properties that are a result of the size of the genome and its 
segmented nature. These properties include the ability to exchange gene 
segments (called reassortment) within a co-infected cell and mutations, as 
replication of the IAV genome is prone to errors (38). These mutations and 
gene segment exchanges can lead to viruses that are genetically different to 
the parental viruses. These exchanges can occur across species and have the 
potential to result in epidemics and pandemics in humans, lower animals, and 
birds (39, 40) (Table 1.3). There are three mechanisms by which IAV change 
is evolutionary. These are: antigenic drift (mutation – Figure 1.1), antigenic 
shift (re-assortment – Figure 1.2), and less rarely, a recombination. 
Reassortment was detected in some IAV strains that circulate seasonally and 
have epidemiological importance (38, 41-45). Pandemics are known to occur 
when these gene exchanges allow an IAV strain to be both antigenically novel 
and also have the ability to spread through a human population (38) (Figure 
1.3). 
 
1.3.1 Antigenic drift – mutation 
IAV replication is prone to errors due to the absence of proofreading 
mechanisms in the viral RNA-dependent RNA polymerase. These errors lead 
to about two mutations for each genome that is replicated (38, 46). These 
mutations are necessary for IAV adaptation in a new host (47). When IAV is in 
the host, anti-HA antibodies are directed to HA viral proteins. Mutations that 
allow IAV to escape host immunity, evade vaccines, and become resistant to 
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drugs, are a positively selected (40) evolution of IAV (Figure 1.1) and 
reassortment (Figure 1.2). These anti-HA antibodies encourage antigenic drift, 
therefore, encouraging antibody escape. The effect of these changes is that 
the immune system can no longer identify this virus and as a result, immune 
protection from the host has lost its effectivity (40). Over time, and due to the 
continuous pressure on the virus to evade host immune response, these 
mutations contribute to the evolution of the virus and potentially result in a new 
subtype (40, 48).  
 
 
Figure 1.1. Illustration of antigenic drift also known as mutation. The yellow 
circles represent the gene segments that undergo mutation that causes a 
change in shape. This can affect antibody binding and thus host immune 
response. 
 
1.3.2 Antigenic shift – reassortment 
Antigenic shift is the process by which RNA segments, from genotypically 
different IAVs, can be exchanged and is also referred to as reassortment (49). 
This changes the antigenicity of IAV (38). Reassortment could be a result of 
transmission between hosts for example the virus from birds to humans. IAV 
also infects an intermediate host – frequently a pig – or virus transmission from 
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bird to pig (intermediate host) to humans (50). Pigs can be infected by human 
IAV strains, as well as avian IAV strains (Figure 1.3). As a result, pigs are 
called the ‘mixing vessel’. Avian and human IAV have been isolated from 
naturally and experimentally infected pigs (47). This reassortment can be seen 
in the 2009 H1N1 pandemic (pH1N1); viruses from avian, human, classical 
swine, and Eurasian swine circulated in pigs. This was then transmitted into 
the human population causing a pandemic (47, 51, 52). This can also be seen 
in the 1957 and 1968 pandemics (38, 53). The 1957 pandemic is thought to 
have occurred because viral proteins; PB1, HA, and NA from an avian H2N2 
virus entered the human population with the already circulating H1N1 and 
formed the H2N2 pandemic (38). Additionally, the 1968 pandemic occurred as 
a result of the viral proteins; PB1 and HA from the avian H3 virus entering the 
human population with the already circulating H2N2, forming the 1968 H3N2 
pandemic (38, 54). The result of this reassortment generates a ‘novel’ virus 
that is capable of creating a pandemic IAV strain (40, 55, 56) (see Figures 1.2 
and 1.3). 
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Figure 1.2: Illustration of antigenic shift, also known as reassortment. The 
coloured circles (yellow, blue, and orange) represent gene segments from 
different IAV strains that exchange, reassort, and form new subtypes and 
strains, containing a mix of parental segments. This mix frequently happens in 
pigs.  
 
1.3.3 Recombination 
Recombination is another means by which influenza viruses achieve evolution 
(40). Genetic recombination produces genetic diversity through two main 
mechanisms: non-homologous recombination which occurs between two RNA 
fragments (57, 58) and homologous recombination, that involves the switching 
of templates and is frequently thought to be absent or rare (59). This 
mechanism is thought to occur while the polymerase complex is copying the 
RNA. The process of recombination contributes to genetic diversity and only 
occurs when viruses replicate within the same cells (40).  
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i)
 
ii) 
 
Figure 1.3: (i) Host transfer of the influenza virus in the natural avian cycle, the 
transfer into the natural reservoir (waterfowl), infection of domestic birds, its 
transfer to swine (where re-assortment of strains occurs), and infection to 
human host. This shows the movement of the influenza virus from animal to 
human hosts; (ii) Adaptation of IAV in swine (mixing vessel) and reassortment. 
A) Two strains of IAV enter the swine, one human IAV (denoted by yellow 
circles) and another avian IAV (denoted by blue circles). B) Replication occurs 
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in the cells of the swine and produce both strain subtypes. C) Gene segments 
of both IAV strains are exchanged in the same swine cell. D) IAV containing 
gene segments from both human IAV and avian IAV are produced.  
 
1.4 Influenza epidemics and pandemics 
Influenza causes both morbidity and mortality, and the proportion of each 
depends on the severity of the virus and its fluctuation during each season. 
For example, the 2015–2016 influenza season was relatively mild. All efforts 
to reduce the impact of future epidemics or pandemics are essential, through 
the implementation of the universal influenza vaccination and initiation of 
antiviral therapy. It is therefore crucial to maintain continual research amidst 
the variety of emerging viral epidemics such as Ebola and Zika (60). 
Understanding the state of epidemics and pandemics in the United Kingdom 
and globally, in recent times, and over the years, is essential to put the severity 
of IAV infection in context.  
 
1.4.1 Epidemics 
Over the years, influenza epidemics have been almost an annual occurrence 
with unpredictable severity (61). These epidemics tend to occur when it is cold, 
when there is crowding of people and lower humidity, during the Northern or 
Southern hemisphere winter periods. Influenza outbreaks are known to be well 
correlated to seasonal changes in temperature and absolute humidity; the 
annual climate cycles in tropical countries are much weaker and outbreaks 
show less seasonality, therefore reducing environmental correlations. Moving 
beyond the correlation, outbreak patterns between temperate and tropical 
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countries, are also driven by absolute humidity, and, to a lesser extent, global 
temperature (62). While environmental factors play a great role in influencing 
the seasonality of influenza outbreaks, other non-environmental factors, such 
as seasonal changes in behaviour, family, and social structure, pre-existing 
immunity, and the nature of the virus to transcend these factors, can affect 
seasonal epidemics (63). The presence of a variant virus showing antigenic 
changes from previous strains plays a part in the propagation of epidemics. 
 
1.4.2 Pandemics 
For an outbreak to be classified as a pandemic, it arises in a definite 
geographical area and eventually spreads to new towns, cities and countries. 
Following this, the percentage of individuals infected increases and there is an 
increase in mortality rates. This can be as a result of new IAV subtypes 
introduced in the population prior to the outbreak (16). Pandemics affect 20–
40% of the world’s population. Pandemics are thought to have occurred over 
many centuries, although consistent records only date back to the 1918/1919 
pandemic (64). See Table 1.3 for the list of IAV outbreaks.  
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Table 1.3: Influenza A
 virus outbreaks in the past 40 years (adapted from
 (6, 65-67)). 
 
Influenza A virus  
Year 
O
utbreak location 
N
um
ber of hum
an cases 
H
5N
6 
2014 
C
hina 
9 
H
10N
8 
2013 
C
hina 
2 
H
6N
1 
2013 
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an 
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H
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9 
2013 
C
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2 
2012 
U
nited States 
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H
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1 
2011 
U
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N
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H
3N
2 
2011 
U
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1 
H
10N
7 
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A
ustralia 
N
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H
1N
1 09 (P
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ic) 
2009 
M
exico, C
anada, and the 
U
nited States 
E
stim
ated !24%
 population in 
19 countries 
H
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3 
2004 
C
anada 
19 
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H
7N
2 
2003 
U
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16 
H
1N
2 
2000 
S
ingapore 
N
o global estim
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H
7N
7 
1979 
U
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94 
H
9N
2 
1999 
H
ong K
ong 
28 
H
5N
1 
1997 
H
ong K
ong 
850 
H
1N
2 
1998 
C
hina 
N
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H
1N
1 
1977 
C
hina 
E
stim
ated 3–5 m
illion cases 
(severe illness) per year 
H
3N
2 (P
andem
ic) 
1968 
H
ong K
ong 
N
o global estim
ates 
H
2N
2 (P
andem
ic) 
1957 
C
hina 
N
o global estim
ates 
H
1N
1 (P
andem
ic) 
1918 
N
orth Am
erica, E
urope,  
and Africa 
E
stim
ated 500 m
illion cases 
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1.5 Influenza virion structure, genome organisation, and proteins 
1.5.1 Virion structure 
Influenza viruses are single-stranded, segmented RNA viruses that are 
enveloped in a lipid membrane (68). These viral RNA segments form a 
ribonucleoprotein complex (RNP), which exist in enveloped virions. These 
RNPs consist of an RNA-dependent RNA polymerase complex and copies of 
nucleoproteins (68). The lipid membrane, that encloses virions, originates from 
a host cellular membrane through budding. The virions of IAV display spherical 
or filamentous shapes with a diameter between 80 and 120nm. IAV, which 
have been laboratory adapted, tend to present a spherical or elliptical shape, 
while IAV, from clinical isolates, mostly present a filamentous shape. The 
process of adaptation of IAV in eggs, leads to the loss of their filamentous 
shape (68-70). 
  
The role of the filamentous shape of the virion still remains unclear but is 
thought to be vital. In clinical isolates, influenza viruses still form filamentous 
phenotypes. This could suggest the importance of the filamentous shape for 
its survival in nature (68). The filamentous phenotype is considered to be a 
genetic trait and other proteins of the influenza virus play a part in determining 
this shape (71). These proteins include M1 and M2 proteins as important 
causes of the filamentous virion shape (72-74).  
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i. 
 
 
ii. 
 
Figure 1.4: (i) Structure of the influenza virion (infectious particle). The virus is 
roughly spherical, enveloped with a lipid membrane on the outer layer 
obtained from the host cell in which the virus multiplies. The HA and NA, 
present on the lipid membrane, are glycoproteins, that contribute to 
determining the subtype of the influenza virus. The M1 protein forms a shell 
that strengthens and renders the lipid envelope rigid. The virions contain eight 
viral RNA segments for IAV that encode proteins shown in the diagram: PB1, 
PB2, PA, and NP (Table 1.4). (ii) Electron micrographs of influenza virions in 
different shapes: (A) spherical virions (A/WSN/33 [H1N1]); (B) filamentous 
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virions (A/Udorn/307/72 [H3N2]); and (C) irregular shaped virions (A/Puerto 
Rico 8/34). This image was taken from Noda et al., 2011 (68). 
 
1.5.2 Genome structure, organisation, and viral proteins 
Influenza A and B viruses differ in various ways, including their epidemiology 
and immunological specificity, but they also share numerous biochemical 
similarities (75). IAV and IBV are both negative-sense, single-stranded with 
eight viral RNA segments while ICV and IDV are both negative-sense, single-
stranded with seven RNA segments (76). The genome of the influenza virus 
was initially thought to encode a single viral protein per genome segment. 
However, several novel IAV proteins have been identified (77). These proteins 
have different functions; some of these proteins play vital roles in efficient virus 
replication in cells and the formation of virions (68), while other proteins have 
unknown functions (Table 1.4). The full process of viral replication is explained 
in section 1.6 in the IAV replication cycle.  
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Table 1.4 G
enom
ic segm
ents and viral proteins of influenza A viruses adapted from
 (76, 78-80)  
 
S
egm
ent 
E
ncoded 
proteins 
S
egm
ent length in 
nucleotides 
P
rotein length in 
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ino acids 
P
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4 
H
A
 
1778 
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binding and fusion 
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(86) 
5 
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P
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N
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nuclear im
port regulation, 
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6 
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P
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A
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S
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N
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N
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 the nucleus of 
the host (Figure 1.5 below
) 
(87, 92)  
N
S
3 
 
188 
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ole in host adaptation 
(93)  
N
E
G
8 
 
216 
U
nknow
n function 
(94)  
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1.6 Influenza A virus replication cycle 
IAV is an enveloped virus with its nucleic acid capsuled in a protein shell and 
a relatively simple structure, but the ability to obtain sophisticated mechanisms 
from their hosts to replicate, survive, and even thrive (95). Through each stage 
of the viral life cycle, it succeeds to integrate with, or disrupt, the host cell 
machinery for its replication (95). IAV is known to infect the epithelial cells in 
the upper respiratory tract, but also in alveolar macrophages and dendritic 
cells (96-98). In tissue culture, IAV replicates in 8–10 hours (95). After 
infection, several host-viral interactions occur to ensure viral pathogenesis and 
host an immune response (99). Figure 1.5 presents a schematic diagram of 
the IAV life cycle adapted from (100). 
 
1.6.1 Virus attachment and entry to host cell surface receptors 
For the virus to be present and replicate in the host cell, the life cycle starts 
with the virus binding to the host cell. The HA protein of the virus, as described 
above, plays a crucial role in ensuring the virus’s attachment and entry into 
the host. HA proteins bind to sialic acids on glycoproteins or glycolipids present 
on the host’s epithelial cells in the upper respiratory tract (99, 101-107). These 
sialic acids differ with each host. In humans, IAVs recognise sialic acid linked 
to galactose by an D2-6-linkage (Sia-D2,6-Gal). These are sialic acids linked 
from C2 of sialic acid to C6 of galactose (108-113). Contrarily, in avian species, 
IAV binds to Sia-D2,3-Gal. These are sialic acids linked from C2 of sialic acid 
to C3 of galactose. This is primarily present on epithelial cells in the duck 
intestine; various studies have shown that this is the site in which avian 
influenza replicates (110, 114-116). While humans and avian recognise only 
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one sialic acid linkage, swine recognise both. This has a factor to play in 
swine’s ability to be a mixing vessel for both avian and human influenza, and 
produce pathogenic viral strains (117, 118). 
 
Structurally, HA is a homotrimer that is found on the surface of the viral lipid 
membrane in a ‘spike-like’ shape. The HA precursor, HA0, contains two 
subunits with two distinct and essential functions that are linked by disulphide 
bonds: HA1 – receptor binding domain and HA2 – containing the fusion 
peptide (117, 119). Upon HA binding to the cell, IAV proceeds to enter the cell 
through receptor-mediated endocytosis. The primary, but not only, method of 
endocytosis is Clathrin-mediated endocytosis (120). Other mechanisms that 
IAV uses to enter the host cell; independent of Clathrin-mediated endocytosis 
to enter the cell, have been identified (121, 122), including micropinocytosis 
and micropinocytosis (123, 124). IAV therefore enters the cell in an endosome, 
which has a low pH of about five or six (117). The low pH in the endosome 
triggers various reactions; it causes the viral membrane to fuse with the 
endosomal membrane. It proceeds to induce a conformational change in the 
HA0 precursor, that reveals the HA2 fusion peptide. The fusion peptide closes 
the gap between the viral and endosomal membrane by inserting itself into the 
endosomal membrane (118, 119). It further causes the M2 ion to open and 
form a proton-selective ion channel (117, 125, 126), which then acidifies the 
viral core. This change in pH to an acidic setting causes the vRNP to be 
released from M1 into the host cell cytoplasm (117, 127). The vRNPs, by 
nature of the structure of IAV, contain viral proteins: NP, PA, PB1, and PB2. 
These proteins possess nuclear localisation signals (NLSs), that bind to 
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nuclear import factors: importin-D (Karyopherin-D) and importin-E 
(Karyopherin-E) (99, 117, 128-135). The M1 protein is transported separately 
into the nucleus (99, 136).  
 
1.6.2 Replicating their genome 
IAV is a negative-strand RNA that is first replicated by conversion into a 
positive-sense RNA, serving as a template for the production of viral RNA. The 
viral replication and transcription of IAV depends on the viral RNA dependent 
RNA polymerase (RdRp) that initiates RNA synthesis internally on viral RNA 
(137-140). The process of viral transcription cannot be completed solely by 
the virus due to its small coding capacity. As a result, the virus employs 
mechanisms using elements of the host cell to ensure its replication in the host 
(117). 
 
Structurally, the host’s mature cellular messenger RNAs (mRNA) has a 5’ 
methylated cap and a poly(A) tail, while the vRNPs have poly(A) tails but no 
5’ caps (141, 142). During transcription, the virus employs a mechanism 
termed ‘cap-snatching’ which enables it to obtain the 5’ cap from cellular 
mRNAs (143-150). The viral RdRp, which consists of three viral proteins – 
PB1, PB2, and PA plays a vital role in the ‘cap-snatching’ mechanism. It binds 
to the 5’ methylated caps of cellular mRNAs and the protein PB2, which has 
endonuclease activity that cleaves the cellular mRNAs 10 to 15 nucleotides to 
the cap structure. This fragment is used by the viral RdRp to prime viral 
transcription (117, 151). Cellular transcription begins with the RNA 
Polymerase II (Pol II) binding to the DNA. The C-terminal repeat domain (CTD) 
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of the RNA Polymerase II contains a serine 5, which is phosphorylated during 
transcription initiation. This phosphorylation leads to the activation of the 
cellular cap synthesis complex. It has been demonstrated that this form of Pol 
II is the preferred binding site for influenza RdRp, and, therefore, is thought to 
be the point at which ‘cap snatching’ occurs (117, 152). 
 
Once this is completed, the process of polyadenylation of the viral mRNA 
occurs through a mechanism called ‘stuttering’ (117). This process relies on 
the viral RdRp remaining bound to the 5’ end of the template viral RNA (153, 
154). These viral segments have five to seven U residues, which are 17 
nucleotides long at the 5’ end, upon which the polyadenylation signal is based. 
The RdRp, through the stuttering mechanism, moves back and forth over the 
U residues and this forms a poly(A) tail (155, 156).  
 
1.6.3 vRNPs leaving the nucleus 
Only negative sense vRNPs are exported from the nucleus (157). This process 
is thought to be carried out through the nuclear pores in a chromosomal 
maintenance 1 (CRM1), also known as Exportin 1 dependent pathway (117). 
CRM1 is a mammalian export protein that assists and eases the transport of 
molecules from the nuclear membrane to the cytoplasm. These molecules 
include RNA and protein (158). Other viral proteins within the virus are thought 
to play a role in interacting with CRM1 and enabling the vRNP export. NP 
interacts directly with CRM1. M1 also enables the export of the vRNPs by 
interacting directly with them through the C-terminal end of the protein and 
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binding of the N-terminal of the protein to NEP that subsequently binds to 
CRM1 (117, 159-161) (Figure 1.5).  
 
1.6.4 Assembly and release 
The viral particles are released from the cell’s apical side (117, 162). This is 
the side in a polarised cell that faces the lumen. As a result, the protein 
segments HA, NA, and M2 are transported to this site within the cell. Through 
this process, M2 plays a crucial role in the viral formation and budding process 
(117). Upon budding, the IAV can be spherical (~ 100 nm diameter) and 
filamentous (~ 100 nm x 2 to 20 um) in shape (163). M2 plays a vital role in 
the shape of filament formation (163). These differences were observed in 
viruses in which the M2 tails were deleted or mutated: they formed elongated 
particles (117, 164). In addition to M2, M1 plays a crucial role in the process 
of closing and budding off the viruses from plasma membranes (117, 162, 
165). Viral genomic segments are packaged into the virions in two 
hypothesised models: the random packaging model (117, 166, 167), in which, 
as the name suggests, the viral genomic segments are randomly packaged 
into virions, and the specific packaging model (52, 117), which is dictated by 
signals present in the viral segments (117). The specific packaging model is 
more widely adopted to be true as specific signals were identified in the 5’ and 
3’ non-coding and coding regions of the viral segments (117, 120-123, 168). 
Finally, for the new viral particle to leave the plasma membrane, NA cleaves 
the sialic acid residue from glycoproteins and glycolipids. This is necessary for 
the total release of the viral particle from the plasma membrane (117, 124).
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Figure 1.5: Adapted from Paterson et al., 2012 (100): A) Enveloped influenza 
virion containing hemagglutinin (HA), neuraminidase (NA), Matrix 1 (M1), 
Nuclear export protein (NEP), vRNPs, which contain PA, PB1 and PB2. B) 
NEP enables and triggers the synthesis of the viral cRNP. This results in 
increased vRNPs, which are packaged into progeny virions. NEP is thought to 
act with small viral RNAs (svRNAs). C) NEP acts as an adaptor protein and 
along with Crm1 and the viral protein M1, binds with vRNPs to export the 
vRNPs from the nucleus. D) NEP binds to and recruits F1Fo ATPase, which 
plays a part in the budding of progeny virions. E) vRNPs exported into new 
progeny virions.  
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1.7 Viral pathogenesis and host immune response 
IAVs in the host are responsible for acute respiratory inflammation in humans. 
The symptoms observed in infected humans include a high fever, body aches, 
and fatigue (169). The incubation period for IAV, which is described as the 
time from infection to symptom onset, is between one and four days (170). 
Typically, the symptoms ameliorate after several days of the symptom’s onset. 
However, this varies based on the IAV strain (169). The 2009 pandemic H1N1 
influenza virus and the highly pathogenic H5N1 viruses have a higher 
pathogenicity than the seasonal IAV strains. The effect of their pathogenicity 
and virulence lead to severe pneumonia, and, as observed in the aftermath of 
the 1918 pandemic virus, it resulted in estimated 50 million deaths worldwide 
(169). The pathogenesis of the IAV is dependent both on host and viral 
contributions. The host’s immune response and the virus’s virulence factors 
play crucial roles in determining the pathogenicity of the IAV in the host (169, 
171).  
 
1.7.1 Host immune response  
The immune system of the host protects it from infection with the IAV. IAV’s 
entry into the host, through the respiratory epithelial cells or alveolar 
macrophages, is recognised by toll-like receptor (TLR) 7 and retinoic acid-
inducible gene-I (RIG-I) (Figure 1.6) (172, 173). TLR7 and RIG-I induce type I 
interferons (IFNs) through their signalling pathways to activate antiviral host 
responses (174). Nonetheless, IAV has mechanisms to escape the host 
immune response. NS1 a viral protein enables IAV to escape this antiviral host 
response by interfering with the RIG-I signalling pathway. NS1 inhibits TRIM 
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25, which plays an essential role in the ubiquitination of RIG-I and 
subsequently the production of type I IFN response (169, 174). The effect of 
NS1 was observed in the 1918 pandemic, during which it efficiently 
suppressed the expression of IFN-regulated genes, controlled the antiviral 
innate immune response, and, thus, increased the viral pathogenesis in the 
host (169, 175). NS1 further binds to protein kinase R (PKR) inhibiting PKR’s 
antiviral function (176). PKR is activated by the presence of dsRNA from viral 
replication or Type I IFN. PKR is ubiquitously present in the cells and is an 
intracellular receptor for dsRNA. PKR binds to dsRNA, which changes its 
conformation and is activated. Activated PKR goes on to phosphorylate the 
alpha-subunit of eukaryotic initiation factor 2 (eIF-2alpha). This impedes 
protein translation and subdues viral replication (177, 178) due to the 
efficiency of PKR IAV through the action of NS1-developed mechanisms to 
evade these anti-viral effects (169, 178). In addition to the type I IFN response, 
IAV upon entry into the host induces the production of numerous inflammatory 
cytokines and chemokines, including IL-1Beta, IL-6, IL-8, TNF alpha, CCL2, 
CCL3, CCL5, and CXCL10 (169, 179). Amongst these, CCL2 recruits’ 
macrophages to the virus-infected lung. Macrophages with CCR2, a receptor 
of CCL2, express tumour necrosis factor-related, apoptosis-inducing ligand 
(TRAIL), which go on to induce apoptosis in alveolar epithelial cells. The 
effects of these is seen in IAV-infected hosts with CCR2 deficiency; 
macrophages are inhibited from migrating to the lung and thus play a crucial 
role in increasing pathogenesis in pulmonary inflammation (180, 181). In 
addition, neutrophils contribute to the pathogenesis of IAV as they are 
recruited to the inflamed lung of hosts infected with the 1918 virus or avian 
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H5N1 viruses (169, 182). In conclusion, the host’s innate immune response is 
like a two-edged sword, playing different roles in the elucidation and 
pathogenesis of IAV. Contrarily, adaptive immunity is specific and efficient in 
eliminating virus-infected cells and enabling the host’s recovery from viral 
infectious diseases. 
 
Figure 1.6: Pathways by which IAV and IAV-derived ribonucleic acids are 
recognised upon entry into the host. In infected hosts, sensing of IAV relies on 
the use of pattern-recognition receptors. These include toll-like receptor 7 
(TLR7) and retinoic acid inducible gene-1 (RIG-I). Sensing IAV double 
stranded RNA (dsRNA) occurs through the TLR3 pathway, which 
subsequently activates the NFNB pathway. Single-stranded RNA (ssRNA) is 
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recognised through the RIG-I and TLR7. RIG-I interacts with mitochondrial 
antiviral-signalling (MAVS) and further activates the NFNB pathway as well as 
interferon regulated factor 3 (IRF3). TLR7 interacts with Myeloid differentiating 
factor 88 (MyD88), which is essential in signalling in the toll-like receptor 
pathway. TLR3 stimulates the proinflammatory response, while RIG-I and 
TLR7 stimulate the type 1 IFN-dependent antiviral signalling and interferon 
stimulated genes (ISG) (adapted from RIG-I & TLR3 from (183). 
 
1.7.2 Virus factors that influence viral pathogenesis 
Viral proteins and their functions have been described. These viral proteins 
have parts to play in the virulence of influenza A viral strains and thus influence 
its viral pathogenicity. Mutations in these viral proteins, which lead to viral 
pathogenicity, are elaborated in Table 1.5. 
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Table 1.5, from
 Fukuyam
a et al., 2011 (169), highlights m
utations in viral proteins that influence viral pathogenicity 
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1.8 Treatment and vaccines  
The effects of an IAV infection on a population is continually felt through 
seasonal epidemics and pandemics. During these outbreaks, hospital 
admissions for respiratory diseases increase along with mortality from various 
causes (201, 202). Vaccinations and antivirals are two methods of preventing 
or treating IAV infections. 
 
Vaccination is the foundation for influenza prevention (202). Influenza 
vaccines are traditionally trivalent (covering influenza A H3N2, H1N1, and the 
influenza B strain) or quadrivalent (to cover influenza A H3N2, H1N1, and two 
influenza B strains) (203). Due to the circulation of constantly changing strains 
of influenza, in February of each year, an expert panel, including the World 
Health Organisation (WHO) reviews data from the Northern and Southern 
hemisphere and decides which circulating strains should be included in the 
vaccines for the influenza season (203). This production begins in March in 
the hope that no antigenic changes occur – this is a limitation of this approach. 
The two main types of vaccines are ‘parenteral inactivated vaccine’ (the virus 
is killed) or ‘intranasal live-attenuated’ (the virus is weakened) (203). The 
inactivated vaccines contain virus antigens, specifically the surface 
glycoprotein; hemagglutinin, thus, stimulates the body to create antibodies 
against these specific strains. Antibodies to hemagglutinin and neuraminidase 
glycoproteins are known to protect against infection and enable quick recovery 
from infection (202). Live-attenuated vaccines (LAIV) produce a more 
complex, multifaceted, and broad immune response, which leads to longer 
periods of protection. Inactivated influenza vaccines are safe and effective and 
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are widely recommended for children from six months old, while live 
attenuated vaccines are recommended for children above the age of two years 
(203).  
 
The use of anti-virals to combat IAV infections is dependent on two types of 
compounds: amantadine and rimantadine that are both M2 ion channel 
inhibitors and Zanamivir and Peramivir that are NA inhibitors (99). As the name 
suggests, M2 ion channel inhibitors inhibit the ion channel in the viral envelope 
formed by the M2 protein. These inhibitors block the process of pH changing 
in the endosome. This process is crucial for the release of vRNPs into the 
cytoplasm after IAV enters into the cell. These inhibitors stop the flow of 
hydrogen ions from the acidic late endosome to the interior of the virion (99). 
However, these compounds are no longer the preferred recommendation for 
human use as the IAV has gained resistance to the compounds (204). The NA 
inhibitors, again, as the name suggests, inhibit the enzymatic activity of the 
NA. This is essential in the release of the virus following viral replication (205-
208). These compounds are the only antivirals to IAV currently recommended 
for human use worldwide. While resistance has been described to NA 
inhibitors, it is not common amongst IAV strains that are currently circulating 
(99, 209). 
 
1.9 Quantitative proteomic techniques used to characterise viral-host 
interactions 
The integration of virology and proteomics has led to a significant increase and 
contribution in understanding virology. Understanding viral evolution and 
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simultaneously understanding how the host responds to these changes has 
provided a platform to understand viral-host interaction. This is a crucial step 
in the search for novel biomarkers for the detection of the severity of disease 
and finding novel mechanisms of the host response to a viral infection. 
 
1.9.1 Quantitative proteomics using two-dimensional gel electrophoresis 
(2D-DIGE) 
The development of quantitative proteomics has provided global cellular 
proteome comparable studies (210). Quantitative proteomic analysis has seen 
evolution over the past decade with a multitude of strategies employed, 
originating with two-dimensional gel electrophoresis (2D-DIGE) and 
progressing to label-based strategies, including stable isotope labelling by 
amino acids in cell culture (SILAC) and label-free strategies coupled with mass 
spectrometry. Mass-spectrometry-based techniques have been employed for 
high-throughput, bio-analytical methods to understand cellular proteomes and 
interactions with various respiratory viruses and diseases (211-214). These 
have been used previously to characterise IAV infection in vitro. Quantitative 
mass spectrometry was introduced by 2D-DIGE in the mid-1970s. This was 
the first combination of two methods for separating proteins: isoelectric points 
and separation according to polypeptide sizes (215). While this was novel, the 
number of separated proteins remained low (in the lower hundreds) (216).  
2D-DIGE coupled with mass spectrometry has been instrumental in detecting 
the mechanisms underlying the Hepatitis B-Virus (HBV) infection in a host cell 
and has demonstrated that proteomics could be used to map virus-host 
interactions. This gave rise to the creation of a hypothetical model containing 
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three major groups of the most varied proteins involved in retinol metabolism, 
calcium ion-binding, and protein-degradation pathways (217). Quantitative 
proteomics also played a vital role in obtaining host profile responses to the 
rabies virus (RBV). RBV affects the expression of proteins involved in ion 
homeostasis and also affects the movement of synaptic vesicles to merge with 
presynaptic membrane that leads to neuronal dysfunction (218).  
 
While 2D-DIGE provided a global insight of cellular changes in response to 
viral infection, there were limitations. These included the identification of highly 
abundant proteins and the selection of proteins that could be 
resolved/separated by 2D-DIGE. IAV causes whole system changes, including 
low-abundance proteins. Therefore, this technique is not sensitive enough to 
highlight these changes. For example, changes in the cellular proteome of 
IAV-infected A549 and MDCK cell lines were observed using 2D-DIGE 
coupled with mass spectrometry. This revealed a total of 16 differentially 
abundant proteins (219). The use of subcellular fractionation as an enrichment 
method of A549 cells infected with H3N2 swine influenza virus, followed by 
2D-DIGE and mass spectrometry, improved the number of proteins detected 
(220). Nuclear and cytoplasmic proteomic fractions were prepared and 
revealed a total of 47 differentially expressed proteins following IAV infection. 
Proteins involved in apoptosis, cell death, and the induction of the IFN pathway 
were differentially abundant. More proteins were recorded as differentially 
abundant when subcellular enrichment methods were used, thus improving 
the understanding of the cellular interactome. While it highlighted certain 
proteins, the limitations of the 2D-DIGE techniques can be observed, as only 
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proteins that registered a change in high abundance were identified (219). 
Subcellular fractionation, used to enhance 2D-DIGE, is time-consuming and 
can lead to the loss of proteins. 
 
1.9.2 Quantitative proteomics using label-based techniques – SILAC and 
label-free techniques 
Label-based techniques, including stable isotope labelling by amino acids in 
cell culture (SILAC) and label-free strategies coupled with mass spectrometry, 
also gained popularity in quantitative proteomics. Label-based methods entail 
metabolic, enzymatic, or chemical labelling, while label-free methods utilise 
spectral counting and ion intensity-based quantification (221). Despite having 
respective disadvantages, both methods are powerful tools to identify changes 
in the abundance of proteins (Table 1.6). Other limitations of label-based 
strategies include additional sample-processing steps, high cost of labelling 
reagents and human error, and variability in effective labelling (222). 
 
Label-free liquid chromatography Mass Spectrometry (LC-MS) is a novel 
approach used to identify qualitative and quantitative information for the 
characterisation of components in a protein mixture (223). Label-free 
approaches have gained popularity due to the decrease in the number of 
chemistries required for a run as well as a wider range of application (224). 
This approach was used to compare the proteome of Hep 2 cells infected and 
uninfected with the respiratory syncytial virus (RSV). The cells were lysed, 
separated, and prepared using off-gel fractionation. The LC-MS run following 
tryptic digestion revealed a total of 1,352 cellular and seven viral differentially 
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abundant proteins. Proteins involved in the synthesis of interferon-induced 
proteins with tetratricopeptide repeats 3 (IFIT3) and 5’-3’-exoribonuclease 2 
(XRN2) (225) were highlighted. Different proteomics methods were developed 
and used over the years. LC-MS has gained more popularity for high-
throughput quantitative proteomics due to its simple and straightforward 
processing steps and can be used for a large sample size. These are 
particularly useful for biomarker discovery in clinical samples.
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Table 1.6: Advantages and disadvantages of label-free LC MS/MS to 
identify novel biomarkers 
 
 Advantages Disadvantages 
Label free LC-
MS/MS 
Highly reproducible and stable 
analysis workflow 
Insufficient resolving power of 
previous generations of 
spectrometers 
 Flexible technique Uses two different quantification 
strategies – precursor-based and 
spectral counting. Spectral 
counting cannot resolve small 
abundance differences. 
 Deep coverage of investigated 
proteome 
Limited to samples undergoing 
active protein synthesis 
 Quantification strategies; does 
not impose requirements about 
reference sample 
 
 Outperform SILAC in terms of 
both proteome coverage and 
dynamic range 
 Scalable to number of samples 
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Reproducible samples and data are key elements to any successful biomarker 
study. Label-free approaches offer little or no technical variation, but may not 
automatically reduce systematic differences, such as bias.  
A label-free LC-MS platform was used throughout this thesis to analyse the 
IAV-host interaction in vitro and in vivo. This maintained consistency in the 
data analysis and allowed the results obtained in each chapter to be compared 
to one another. Chapter 3 focused on the use of label-free LC-MS to 
understand the IAV-host interaction in vitro (A549 cells), Chapter 4 focused on 
the use of label-free LC-MS to understand the IAV-host interaction in vivo 
(samples from macaques), and Chapter 5 focused on the use of label free LC-
MS to understand the IAV-host interaction in NAs from paediatric patients. 
This set the tone to evaluate IAV in different models and compare the data to 
that observed in human NAs.  
 
1.10 Interferon-Induced proteins  
The results detailed in this thesis from chapter 3 (in vitro), chapter 4 (in vivo) 
and chapter 5 in NAs from paediatric patients consistently highlighted proteins 
that form a major component of the antiviral host defense system; these are 
interferon induced proteins. The interferon-induced antiviral state is a powerful 
host’s response to viral infection to limit the replication and spread of the virus 
(226) (227). Amongst these proteins are Interferon Induced Proteins with 
Tetratricopeptide repeats (IFITs) consisting of four members in humans and 
three in mice (227), Interferon-induced transmembrane proteins (IFITMs) 
consisting of five members in humans (228), interferon-induced murine Mx1 
(229) and interferon-induced human MxA (226). 
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1.10.1 Interferon Induced Proteins with Tetratricopeptide repeats (IFITs) 
The human IFIT family comprises of IFIT1, IFIT2, IFIT3 and IFIT5. Upon 
bacterial and viral infection, IFITs are induced through type I IFNs (IFN-D/E). 
IFIT1s have the ability to bind to 5’-ppp-RNA whilst IFIT2 and IFIT3 enhance 
this biniding activity (227). Cells infected with IAV, showed restored replication 
with when IFIT1 was deficient. IFIT1 similarly to RIG-I and MDA5 recognise 
specific viral molecular patterns. IFIT1 specifically recognises and binds to 
viral mRNAs whose caps are deficient in 2’-O-methylation and subsequently 
blocks their translation (227). This goes on to inhibit the viral replication. 
 
1.10.2 Interferon-induced transmembrane proteins (IFITMs) 
IFITMs are small proteins located in plasma and endolysosomal membranes. 
IFITMs are part of the anti-viral innate response and prevent viral entry by 
halting the viral envelope and cellular membrane envelope fusion. In addition, 
they also reduce the number of infectious virions produced (228). A study in 
mice using a knockout model showed that IFITM3 was essential when 
defending the host against IAV. Mice that lack IFITM3 showed an explosive 
viral pneumonia and lung damage following IAV infection (230).  Several 
studies that have examined patients with seasonal and pandemic H1N1 and 
H7N9 have reported an IFITM3 SNP of rs 12252 is associated with 
susceptibility and severity to these viral infections(228). This is the most 
studied SNP associated with altering IAV infection outcomes. IFITM3 SNP of 
rs 12252 is a nonsynonymous variation occurring in the first exon of IFITM3 
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(230). The major T allele is subsequently substituted with a C allele giving a 
CC allele and altering the IFITM3 mRNA spicing. The product of this is an N-
terminally truncated variant of IFITM3 (21 amino acid residues deleted) (228).  
This has been a major difference between Europeans and East Asians.  A 
study in vitro set out to explore the effect of the CC allele and found that these 
variants were more susceptible to infection and had lower levels of IFITM3 
protein expression.  This study also found that the truncated N terminal (21 
amino acid residues deleted) were unable to restrict viral replication compared 
to wid type IFITM3 (230). This shows the importance of IFITM3 when 
restricting IAV infection.  
 
1.10.3 Interferon-Induced Human MXA 
The protein MxA is an Interferon Induced protein regulated by type I and type 
III interferon and frequently used as a biomarker for an Interferon Induced 
antiviral state in a host (226). In IAV infection, MxA specifically targets the 
nucleoprotein (NP) and is thought to be required to prevent the export of vRNP 
to the nucleus. Nonetheless, the exact mechanism of action has not been 
clearly defined (226). A similar effect was seen in mice cell line where human 
MxA was monitored and it blocked IAV replication after primary transcription 
(231).  
 
1.10.4 Interferon-Induced Murine MX1 
The Mx1 gene was discovered in the mouse over 50 years ago.  It was thought 
to potently restrict IAV.  Some studies in mice showed  mice carrying  
functional Mx1 locus were resistant to IAV whilst mice that  had a deletion of 
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Mx1 locus were susceptible to the virus  (229).   A study in mice showed that 
Mx1 inhibited the PB2-NP interaction and this correlated with a decrease in 
the virus’ polymerase activity. A direct interaction was observed between Mx1, 
PB2 and NP. Active Mx1 was required for the inhibition process of NP-PB2.   
This therefore showed the role Mx1 played when interacting with the IAV 
ribonucleoprotein complex and subsequently interferes with its  assembly by 
inhibiting the NP-PB2 interaction (229).  These Interferon Induced proteins 
have significant functional roles in response to IAV infection in vitro and in vivo 
in mice in the literature. These proteins have also been identified in all the 
results chapters of this thesis therefore giving confidence to the methodology, 
data analysis and the results. 
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1.11 Thesis aims, objectives, and findings 
My PhD aims were to investigate the interaction of IAV in hosts in vitro and in 
vivo as follows: 
1- Establishing IAV infection in vitro over a time frame; 
2- Establishing the potential of high-throughput techniques – label-free 
Mass Spectrometry and MinION sequencing to characterise IAV 
infection in vitro and in vivo and highlight potential biomarkers; 
3- Find out if the dataset obtained from in vitro host-viral interactions are 
comparable to dataset from in vivo host-viral interactions; 
4- Highlight the proteins connecting both in vitro and in vivo studies, 
ensuring proteins highlighted in vitro are of relevance and importance 
in vivo; and 
5- Use bioinformatics tools (IPA) to further understand the data and 
highlight potential host biomarkers for diagnosis or therapeutics. 
Chapter 3 formed the basis for IAV infection in vitro. It established IAV 
infection in A549 cells, quantified it using Avicel plaque assay, and validated 
by SDS-PAGE and immunofluorescence microscopy. It established the use of 
mass spectrometry for global proteome discovery and the use of MinION 
sequencing to obtain high-throughput data transcriptome, which validated the 
mass spectrometry data. The results from this chapter highlighted the 
importance of in vitro models to understand the cellular response to IAV 
infection and to highlight the proteins that contribute to the replication of the 
virus, its survival, and, therefore, its continuous pathogenesis within the host. 
Chapter 4 focused on the use of Mass Spectrometry to explore an in vivo 
model, a non-human primate (NHP) macaque. NHP macaque is a commonly 
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used animal model for the study of human-infecting pathogens, due to their 
genetic closeness and immune response to humans. The results from this 
chapter highlight the importance of in vivo models, especially to understand 
respiratory infections such as IAV, which cause an exacerbated immune 
response. 
Chapter 5 focused on the use of Mass Spectrometry to explore the global 
proteome of NA from IAV-infected paediatric patients, compared to IAV-
negative patients. This chapter provided a global overview of the host’s 
reaction to IAV: a combination of both cellular and immunological response. 
This chapter first validated the techniques used. Next, it highlighted the need 
for both in vivo and in vitro models, especially for the study of different aspects 
of the IAV pathogenesis. Finally, it highlighted potential protein biomarkers for 
the diagnosis of IAV in humans. The data in this chapter validated the data 
from chapter 3 – in vitro and that from Chapter 4 – in vivo.  
This thesis set out to understand IAV pathogenesis and subsequently find a 
biomarker that could be used, clinically, in humans. Following this, the premise 
is that in vitro and in vivo studies are only essential and relevant if the results 
obtained can be reflected back to humans for this purpose. This was certainly 
the case in this PhD thesis.  
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PhD thesis contribution: 
1- Several proteins were highlighted and associated with IAV infection, 
which have been published in the literature-confirming data; 
2- New proteins were highlighted as potential biomarkers for diagnosis;  
3- Different stages of IAV infection were observed and proteins that could 
be targets for different stages of infection were highlighted; 
4- Proteins were identified that are drug targets currently used for other 
diseases. These drugs could be repurposed and potentially developed 
for therapeutic use against IAV infection; and 
5- Use of new techniques – Mass spectrometry and MinION sequencing 
to identify these proteins and subsequent validation of the results in 
vitro and in vivo. 
 
 72 
CHAPTER 2:  
MATERIALS AND METHODS 
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2.1 Preparation of IAV strain 
The IAV strain used in this study was kindly provided by Professor Paul Digard, 
from the Roslin Institute, at the University of Edinburgh. IAV X-31 is a mouse-
adapted IAV H3N2. The X-31 strain undergoes productive infection in A549 
and MDCK cells. The virus was grown in eggs and MDCK cells.  
 
2.1.1 Growing IAV in MDCK cells and eggs 
IAV can be grown in tissue culture in cells that are permissive to the virus (232) 
or in nine to 11-day-old embryonated chicken eggs (233). Chicken eggs 
usually produce high virus titres over a shorter time frame. This gives them the 
advantage over tissue culture. Furthermore, virus stocks from chicken eggs 
are free of mammalian pathogens (234). However, growing the influenza virus 
in chicken eggs for other purposes, such as vaccine production, has its 
limitations. The production is unable to meet the volume of required doses in 
scenarios of widespread epidemics and pandemics (235). To circumvent this 
limitation, a cell culture has been developed for the production of a seasonal 
vaccine and any shortages that may occur in pandemic situations (235). 
MDCK cell line is the preferred cell line for influenza virus propagation for 
vaccine production. This is because MDCK cells have the most suitable 
surface for primary isolates of influenza viruses to latch onto (236-241). This 
could be because the interferon (IFN)-induced myxovirus resistance protein 1 
(MX1), produced by canine cells, cannot inhibit the IAV replication. In addition, 
trypsin is added to aid in virus entry during infection. This trypsin has an 
adverse effect on IFN-induced antiviral proteins (242-244). Therefore, the 
limited ability of the IFN system in the host allows viral replication and high 
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titres to be obtained (235). MDCK cells are, therefore, frequently used to grow 
IAV stocks in vitro.  
 
2.1.2 Growing IAV in MDCK cells  
MDCK cells were obtained from the Health Protection Agency Culture 
Collections (HPACC, UK) (232, 245). The cells were maintained according to 
the manufacturer’s instructions. All cells were seeded at a density of 1x106 
cells/flask in two 25cm2 flasks, 48h prior to infection following the World Health 
Organisation (WHO) protocol and maintained at 37qC with 5% CO2 (246). The 
Dulbecco’s Modified Eagle Medium (DMEM) (Sigma [D6429]) supplemented 
with 10% (v/v) foetal bovine serum (FBS) (Invitrogen [10270]) and 1% (v/v) 
penicillin-streptomycin to 80–100% confluency.  
For viral growth, DMEM was discarded from the flasks and cells were washed 
three times with Phosphate Buffered Saline (PBS). The X-31 strain (MOI 0.1) 
was diluted in 10ml serum-free DMEM media and TPCK trypsin in a 1/1000 
dilution of 1mg/ml stock (245); 400µl was applied per flask and incubated for 
1 hour at 37oC. The inoculum was then removed, and the cells were washed 
with PBS. DMEM media (supplemented with 0.14% BSA fraction V and TPCK 
Trypsin) was added to each flask (6 ml). Flasks were further incubated at 37oC. 
3 days post infection (p.i.) the supernatant was collected and aliquoted into 
1ml cryovials at 500µl/cryovial and stored at -80oC (246, 247). A 
hemagglutination test (described in section 2.2) was performed on the 
supernatant to test for the presence of the virus (248, 249). Following this, an 
avicel plaque assay was performed to quantify the virus and obtain a viral titre. 
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2.1.3 Growing IAV in eggs  
As mentioned above, the influenza virus can be propagated in cell culture as 
well as in embryonated chicken eggs. To continuously study influenza in vitro, 
reliable and cost-effective methods, which produce high viral titres, are 
necessary (250). To achieve this, fertilised chicken eggs are incubated for 10–
11 days at 37qC, 55–50% humidity. During this period, the embryo 
development is monitored using an egg candler. A needle is used to inject 
virus stock into the egg’s allantoic fluid cavity. After this time, the eggshell is 
removed and the membrane containing the allantoic fluid opens. The allantoic 
fluid, which contains the virus, is harvested carefully using a syringe. This fluid 
is centrifuged to clear any debris and subsequently aliquoted. A total of 5–10 
ml of allantoic is collected per egg (250). The eggs were infected following the 
WHO protocol (251) that has been widely used in the literature (250).  
 
i)  Candling of eggs 
Fertile eggs at 9–10 days old were kindly provided by colleagues based in the 
School of Veterinary Science, at the University of Liverpool. The eggs were 
set in egg incubators at 37oC, with a humidity of 61 and 0% CO2. The eggs 
were incubated for nine days. On the ninth day, the eggs and the candler were 
wiped with 70% ethanol. They were candled one at a time in a dark room to 
ensure viability (250). The margin of air space and embryo location was 
marked using a pencil. Eggs lacking blood vessels were classed as non-viable 
while eggs with mobile embryos and blood vessels were viable and kept for 
infection (250-252).  
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ii) Preparation of virus inoculum and inoculation of eggs 
The eggs were placed into egg trays with blunt end up, specifically labelled, 
and moved into a fume hood. The blunt end of each egg was wiped with 70% 
alcohol prior to injecting. Using an egg hole punch, a hole was drilled slightly 
above the airspace (following the pencil markings) slightly to the right or left of 
the embryo’s location. The virus was diluted in a 1/1000 dilution with PBS. A 
needle was inserted into the hole in the shell at a 45q angle using a short 
stabbing motion. The chloroallantoic membrane was pierced and inoculated 
with 200 Pl of the specimen. The hole was sealed using nail polish. The eggs 
were placed in an incubator at 35oC for 48 hours. At 48 hours post infection, 
the eggs were candled to ensure viability; 4 eggs were classed as non-viable 
and were discarded. The viable eggs were transferred to 4oC overnight (250-
252).  
 
iii) Harvesting virus from inoculated chicken eggs 
After 48 hours, the eggs were inspected and taken out to harvest the allantoic 
fluid containing the IAV. The infected blunt end of each egg was cleaned with 
70% ethanol and 15ml centrifuge tubes were labelled for each egg. Starting 
with the controls, the egg shells were broken over the air sac and the allantoic 
membrane was pushed to the side using sterile forceps. Using a 1ml pipette, 
the allantoic fluid was aspirated and placed in the corresponding 15ml 
centrifuge tubes. The tubes were centrifuged at 2000 rpm for 10 minutes to 
remove excess blood, tissue, and debris (Figure 2.1). A hemagglutination test 
was performed on the collected allantoic fluid (Figure 2.2) (249, 252).  
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Figure 2.1: Taken from Eisfield et al., 2014 (252) – The process of IAV 
inoculation in eggs and harvesting allantoic fluid. A) Representation of a 
fertilized egg’s interior B) an overview of the egg with the markings for 
candling and inoculation puncture hole. C) The egg piercing tool, 
puncturing the egg, and subsequent inoculation with IAV. D) 48 hours 
following inoculation, the eggs were removed to harvest the allantoic fluid 
containing the virus.  
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2.2 Identification of influenza isolates using hemagglutination inhibition 
(HAI) test 
The hemagglutination assay is an economical and rapid assay used to detect 
the presence of the virus. The assay is based on the virus’s ability to 
agglutinate and bind to red blood cells (RBCs). This occurs through the D2,3- 
linked and D2,6- linked sialic acid component present on the RBC surface. 
RBCs are mixed with virus-containing samples and the agglutination pattern 
is observed. The presence of the virus causes the RBCs to agglutinate and 
form a sheet, giving a cloudy appearance. Contrarily, the absence of the virus 
causes the RBCs to settle at the bottom of the well (252).  
Using a multichannel pipette, 50µl of PBS was aliquoted into eight rows (a 
row/egg) of a 96-well round-bottom tissue culture plate. Exactly 50 µl of the 
virus and 50µl chicken adult red blood cells in Alsever’s was added into the 
first column of each row. Using a multichannel pipette, the solution was mixed, 
and a serial dilution carried out by taking up 50µl, mixing three to five times 
and transferring it to the next well (A1 to A2; then A2 to A3; and continuously 
in the same order). The final 50µl after column 11 was discarded; column 12 
was maintained as the negative control. The assay was incubated at room 
temperature for 45 minutes. The results were recorded and interpreted. The 
absence of hemagglutination represents the inability to recover virus from the 
specimen (253).  
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Figure 2.2: Taken from www.microbeonline.com showing the interpretation of 
the hemagglutination assay. A) The presence of just RBCs and no virus leads 
to no interaction and therefore no reaction. This give a clear appearance with 
cells settled at the bottom of the plate. B) In the presence of the virus and 
RBCs, an interaction occurs and leads to a hemagglutination reaction. This 
gives a cloudy appearance. C) The presence of the virus, antibody, and RBCs 
lead to interaction between the antibody and the virus. This gives a similar 
appearance as in A, where the RBCs settle at the bottom of the plate. 
 
2.3 In vitro studies – maintaining continuous cell culture and preparing 
cells for different techniques 
2.3.1 Maintaining continuous cell culture 
Adenocarcinoma human alveolar basal epithelial cells (A549) and madin-
darby canine kidney cells (MDCK) were obtained from the Health Protection 
Agency Culture Collections (HPACC, UK). All cells were maintained according 
to the manufacturer’s recommendations. 
 
 80 
i) Cell culture (MDCK cells) and plating for avicel plaque assay 
The X-31 Strain titre was calculated using an avicel based plaque assay (254, 
255). MDCK cells were found to be more suitable for plaque assay purposes. 
MDCK Cells were grown in a T75 flask in Dulbecco's modified Eagle's medium 
(DMEM) (Sigma [D6429]) supplemented with 10% (v/v) foetal bovine serum 
(FBS) (Invitrogen [10270]) and 1% (v/v) penicillin-streptomycin to 80–100% 
confluency. Twenty-four hours prior to infection for the plaque assay, the cells 
were obtained and seeded at 5x105/mL suspension and 2mL added to each 
well of a six-well tissue culture plate (Table 3.1). This was to obtain 90–100% 
confluency when infecting cells.
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Table 2.0: Plaque assay cell types and conditions 
Viral strain Influenza A 
Cell type MDCK 
Infection period 1 hour 
Incubation time 3 days 
Plaque overlay Avicel 
 
ii) Cell culture (A549 cells) for immunofluorescence (IF) 
For immunofluorescence experiments, 19 mm glass coverslips were dipped in 
100% methanol, left to dry, and then washed in sterile PBS. These coverslips 
were transferred to six-well dishes, prior to seeding, using methanol sterilised 
forceps. Cells were grown in a six-well dish (1 x106/well). Cells were infected 
24 hours after seeding. IF was performed after the infection time point had 
elapsed. 
 
iii) Cell culture (A549 cells), plating for infection and preparation 
for SDS-PAGE 
For infection, cells were seeded in a six-well dish (1x106/ well), 24h prior to 
infection, to achieve 70–80% confluency. For infection experiments, using the 
H3N2 lab-adapted X-31strain, cell lines were grown in Dulbecco's modified 
Eagle's medium (DMEM) (Sigma [D6429]) supplemented with 10% (v/v) foetal 
bovine serum (FBS) (Invitrogen [10270]), 1% (v/v) penicillin-streptomycin, and 
Glutamax. The cells were scraped using cell scrapers, resuspended in PBS, 
and transferred in Eppendorfs. 
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iv) Cell culture (A549 cells) plating for infection and preparation 
for RNA extraction and subsequent MinION sequencing 
For infection and RNA extraction, cells were seeded in a six-well dish (1x106/ 
well) 24h prior to infection to achieve 70–80% confluency. For infection 
experiments using the H3N2 lab-adapted X-31strain, cell lines were grown in 
Dulbecco's modified Eagle's medium (DMEM) (Sigma [D6429]) supplemented 
with 10% (v/v) foetal bovine serum (FBS) (Invitrogen [10270]), 1% (v/v) 
penicillin-streptomycin, and Glutamax. RNA from the samples were extracted 
after the infection timepoint had elapsed. Total RNA was extracted from whole 
cell lysates using an RNeasy Mini Kit (Qiagen, Manchester, UK) following the 
manufacturer’s instructions (Cell pellets [5x105 -106 cells]). RNA samples were 
subjected to MinION sequencing.  
 
v) Cell culture and preparation of A549 samples for LC-MS/MS 
analysis 
T75 flasks were seeded with 2x106/ml A549 cells in 10ml of Dulbecco’s 
Modified Eagles Medium/High Glucose (DMEM). Twenty-four hours later, the 
cells were infected with IAV at MOI 1. The virus was diluted in 5ml of serum-
free media (SFM), 1% TPCK trypsin (1/1000 dilution of 1mg/ml stock), and 
10% (v/v) penicillin-streptomycin. At the point of infection, the media was taken 
up and 3ml of virus stock was used to inoculate infected cells. Mock-treated 
cells were inoculated with a similar stock, without the virus. The inoculum was 
left to adsorb for one hour, after which the viral inoculum was aspirated from 
the wells and the wells washed with PBS. A post-inoculum solution was made; 
SFM, 1% TPCK trypsin (1/1000 dilution of 1mg/ml stock), 10% (v/v) penicillin-
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streptomycin, and 0.14% BSA fraction V; 7ml of this solution was aliquoted 
into each flask and the flasks incubated at 37oC with 5% CO2 for 18 hours. 
After the incubation time had elapsed, the post-inoculum was aspirated, the 
cells were washed with PBS, and 2ml of PBS was aliquoted into both flasks. 
The cells were scraped using a cell scraper and transferred to an Eppendorf. 
The pellet samples were given to our colleagues for mass spectrometry 
analysis on the Q-Exactive.  
 
2.4 Determining IAV X31 strain titre using avicel plaque assay 
To determine the infectious virus titres, six-well tissue culture plates were 
seeded with 2x106/ml Madin-Darby Canine Kidney cells (MDCK) in 2ml 
Dulbecco’s Modified Eagles Medium/High Glucose (DMEM). DMEM was 
supplemented with 10% foetal bovine serum, 1% L-glutamine, and 1% 
penicillin-streptomycin. Plates were incubated at 37oC, 5% CO2 overnight 
using the CO2 incubator (SANYO, MCO175) to achieve 95–100% confluency. 
The next day, a 10-fold serial dilution of virus stock in ice-cold Dulbecco’s 
Modified Eagles Medium/High Glucose (DMEM) only supplemented with 
1µg/ml Tosylamido-Phenylethyl-Chloromethyl Ketone (TPCK)-trypsin 
(Worthington Biochemical Corporation, #3740) was carried out. A 
concentration of 1:1000 dilution of 1mg/ml stock was prepared in 7ml 
polystyrene Bijou containers. The dilutions 10-1 to 10-5 were used, and 1ml 
virus dilution from each dilution was used in duplicate (see Table 3.2).  
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Table 2.1: Viral dilutions for plaque assay (IAV) 
10-1 10 Pl virus + 90 Pl media (1:10) 
10-2 100 Pl virus + 900 Pl media (1:10) 
10-3 300 Pl +2700 Pl media 
10-4 300 Pl +2700 Pl media 
10-5 300 Pl +2700 Pl media 
10-6 300 Pl +2700 Pl media 
10-7 300 Pl +2700 Pl media 
 
Discard 300 Pl from last dilution. Add 1ml from each dilution to each well in 
duplicate. Plates were incubated for one hour at 37oC, 5% CO2 using virus 
CO2 incubator (SANYO, MCO-17AIC) and agitated every 10–15 minutes to 
ensure coverage. After one hour, the viral inoculums were removed and 2ml 
of overlay medium were added per well. The overlay medium was made up 
and contained immediately prior to overlaying cells (Table 3.3). 
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Table 2.2: Avicel overlay medium 
Component 
2.4% Avicel (FMC BioPolymer, RC-581) 
20% of Dulbecco’s Modified Eagles Medium 10% Low Glucose (Sigma 
D2429) 
4% 1M HEPES Solution (Sigma, H0887) 
2% L-glutamine 
2% penicillin-streptomycin (Sigma P4333) 
2% of 7.5% NaHCO3 (Sigma, S5761) 
70% of double-processed tissue culture water (Sigma, W3500) 
TPCK-treated trypsin (1:1000 dilution of 1 mg/ml stock) (Worthington 
Biochemical Corporation, #3740) 
 
The 2.4% Avicel and 20% of Dulbecco’s Modified Eagles Medium 10% Low 
Glucose were added in a 1:1 ratio. Plates were incubated for three days (72 
hours) and plaques were visible. The overlay was aspirated, and the wells 
were washed twice using PBS. Cells were fixed with ice-cold acetone: 
methanol (60:40) for 10 minutes at room temperature and left to completely 
air-dry. They were then stained with crystal violet for approximately 10 
minutes. Plaques were counted macroscopically using a light microscope 
(MOTIC ST-30 SERIES) to determine the plaque-forming units (PFU) per 
sample. The PFU was the average PFU obtained in five different dilutions of 
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sample, each performed in duplicate. The infectious titre was the average 
result of two separate titrations and the titre was calculated using the formula:  
 
Titre (PFU/ml) = No. of plaques x dilution 
                 1 ml inoculum 
 
 
2.5 Sodium-Dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
2.5.1 Preparation of whole cell lysate for SDS-PAGE  
Cell pellets were re-suspended in radioimmunoprecipitation assay (RIPA) 
buffer (50 mM Tris, [pH 7.5], 150 mM NaCl, 1% (v/v) NP40 alternative, 0.5% 
(w/v) sodium deoxycholate, 0.1% sodium dodecyl-sulphate [SDS], 
supplemented with one EDTA free complete protease inhibitor mixture [Roche 
Applied Science] per 50 ml buffer) and incubated for 30 minutes at 4°C. 
Alternatively, the RIPA buffer was applied directly to the washed cell 
monolayer and incubated for 20 minutes before cell scraping. Both methods 
of lysis were followed by three minutes of incubation in a sonicating water bath 
at 4°C to ensure complete lysis. The supernatant that contained total protein 
was collected after centrifugation at 13,000 x g for 20 minutes at 4°C and 
stored at -80°C. 
 
2.5.2 Determining protein concentration using a BCA Assay  
The cellular fractions were obtained as detailed above. The total protein 
concentration was determined using the Micro Bicinchoninic Acid (BCA) 
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protein assay system (Pierce [23227]) according to the manufacture’s 96-well 
plate protocol. Absorbance was measured at 570 nm on a F50 infinite plate 
reader (Tecan). 
 
2.5.3 Preparation of SDS-PAGE Gel  
Protein samples (8 μg) were resolved using a Bio-Rad Mini-Protein II minigel 
system. Resolving and stacking gels were made according to Sambrook and 
Russell (256). Acrylamide gels were made using 30% acrylamide. Standard 
gel recipes used are described in Table 2.0. Protein samples were prepared 
using 4 x LDS sample buffer (Invitrogen [NP0007]) supplemented with 50 mM 
DTT reducing agent and denatured at 70qC for 10 min. 7.5μl of Blue plus two 
pre-stained standard (Invitrogen: 250-4 kDa [LC5925]) or ColorPlus 
prestained protein ladder (NEB: 10-230 kDa [P7711S]) was loaded as a 
reference for molecular weight. SDS-PAGE gels were run at 150V in 1 x SDS-
PAGE running buffer or until optimum resolution of the marker was achieved. 
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Table 2.3: SD
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2.5.4 Immunoblot analysis  
Poly-vinylidine fluoride (PVDF) membranes (Millipore [IPVH00010]) were 
primed in 100% methanol and equilibrated in SDS-PAGE transfer buffer (25 
mM Tris-HCl [pH8.3], 192 mM glycine, 20% [v/v] methanol). Two thick pieces 
of filter paper were also soaked in the transfer buffer. Two pieces of thick filter 
paper soaked in Towbin and the PVDF membranes followed by the SDS-
PAGE gel were placed in the semi-dry transfer apparatus. Transfers were 
performed according to the manufacturer’s instructions, for 1h at 100 V. 
Following the transfer, the PVDF membranes were blocked in 10% (w/v) non-
fat skimmed milk powder (Sigma) prepared in Tris-buffered saline (50 mM 
Tris-HCl [pH 8.3], 150 mM NaCl) containing 0.5% (v/v) Tween-20 (TBS-T). 
Antibodies were diluted in 5% (w/v) milk-TBST and applied overnight at 4˚C 
with rocking. Proteins, including IAV protein NP, were detected with the 
antibodies listed in Table 2.4. The primary antibodies were detected with the 
secondary antibodies listed in Table 2.4. The secondary antibodies were 
diluted in 5% (w/v) non-fat skimmed milk-TBST and applied for 1h at room 
temperature with rocking. The secondary antibodies were detected using Bio-
Rad kit. Antibody-bound proteins were visualised on equipment (this is a 
Hiscox lab adapted protocol). 
 
 
 
 
 
 
 91 
Table 2.4 Table of primary and secondary antibodies used in the 
detection of cellular and IAV proteins in protein samples 
 Antigen Cat n˚ Manufacturer Species Dilution 
Primary GAPDH Ab8245 Abcam Mouse 
monoclonal 
1/5000 
 NP Ab20343 Abcam Mouse 
monoclonal 
1/1000 
 SPLUNC1 
(BPIFA1) 
Ab1897 R&D systems Mouse 
monoclonal 
1/1000 
 SCGB3A2 AF3545 R&D systems Goat 
monoclonal 
1/1000 
 IL6 Ab9324 Abcam Mouse 
monoclonal 
1/1000 
Secondary Rabbit Ab6741 Abcam Goat 1/1000 
 Mouse A4116 Sigma Goat 1/1000 
 
Not all the data from the use of antibodies in Table 2.4 were reported in this 
thesis.  
 
2.6 Immunofluorescence staining  
DMEM Media was aspirated from a six-well plate and filled with 1ml of PBS. 
PBS was used to wash the cells three times and 4% paraformaldehyde was 
used to fix the cells at room temperature. 1ml of PBS was used to wash the 
cells, which were permeabilised using 0.1% of Triton and incubated for 10 
minutes at room temperature. Cells were washed with PBS (and Tween 0.5%) 
 92 
three times. A blocking step was used to reduce non-specific binding. Blocking 
was done using PBS + 10% FBS at room temperature. The primary antibody 
master mix was prepared following the dilutions in Table 2.5. 
 
Table 2.5: Primary antibody master mix 
 Dilution Volume 
Primary Antibody 1/50 2 Pl 
Foetal Bovine Serum 
(FBS) 
1/50 2 Pl 
PBS with Tween 0.5% Complete volume to 
100 Pl 
96 Pl 
Final volume 100 Pl 100 Pl 
 
100 Pl of this master mix was placed on each coverslip and left in darkness for 
one hour at room temperature. These were washed three times with 1ml of 
PBS with Tween 0.5%. The second antibody master mix was prepared 
following the dilutions in Table 2.6. 
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Table 2.6: Secondary antibody master mix 
 Dilution Volume 
Secondary Antibody 1/200 0.5 Pl 
Foetal Bovine Serum 
(FBS) 
1/50 2 Pl 
PBS with Tween 0.5% Complete volume to 
100 Pl 
97.5 Pl 
Final volume 100 Pl 100 Pl 
 
100 Pl of this master mix was placed on each coverslip and left for one hour 
at room temperature in darkness. These were washed three times with 1ml of 
PBS with Tween 0.5%. The coverslips were dried and mounted on a slide 
using Prolong Gold® as a mounting media, with DAPI to stain the nucleus. 
 
2.7 Label-free Liquid Chromatography Mass Spectrometry analysis on 
A549 cells  
Sample preparation, mass spectrometry, and analysis were adapted from 
Dong et al., (2017) (257). 
2.7.1 Homogenisation and protein digestion 
Cell pellets were lysed in 1% w/v sodium deoxycholate (Sigma) in 50mM 
ammonium bicarbonate. This was followed by three cycles of sonication on ice 
(Vibra-cell 130PB sonicator, 20Hz, with microprobe, 10 seconds sonication 
alternating with 30 seconds incubation on ice). Samples were centrifuged at 
13,000 x g for 10 minutes at 4°C. The supernatant was removed and retained. 
Samples were stored at -80°C until use. Protein concentrations of the samples 
 94 
were determined using a Bradford protein assay (Thermo). Samples were 
heated at 80°C for 10 minutes followed by reduction with 3mM DTT (Sigma) 
at 60°C for 10 minutes, cooled, then alkylated with 9mM iodoacetamide 
(Sigma) at RT for 30 minutes in the dark; all steps were performed with 
intermittent vortex-mixing. Proteomic-grade trypsin (Sigma) was added at a 
protein-trypsin ratio of 50:1 and incubated at 37°C overnight. Sodium 
deoxycholate was removed by adding TFA to a final concentration of 0.5% 
(v/v). Peptide samples were centrifuged at 13,000 x g for 30 min to remove 
precipitate (258).  
 
2.7.2 NanoLC MS ESI MS/MS analysis 
Peptides were analysed by on-line nanoflow LC using the Ultimate 3000 nano 
system (Dionex/Thermo Fisher Scientific). Samples were loaded onto a trap 
column (Acclaim PepMap 100, 2 cm × 75 μm inner diameter, C18, 3 μm, 100 
Å) at 9μl /min with an aqueous solution containing 0.1 %(v/v) TFA and 2% (v/v) 
acetonitrile. After 3 min, the trap column was set in-line with an analytical 
column (Easy-Spray PepMap® RSLC 50 cm × 75 μm inner diameter, C18, 2 
μm, 100 Å) fused to a silica nano-electrospray emitter (Dionex). The column 
was operated at a constant temperature of 35°C and the LC system was 
coupled to a Q-Exactive mass spectrometer (Thermo Fisher Scientific). 
Chromatography was performed with a buffer system consisting of 0.1% 
formic acid (buffer A) and 80% acetonitrile in 0.1% formic acid (buffer B). The 
peptides were separated by a linear gradient of 3.8–50% buffer B over 90 
minutes at a flow rate of 300 nl/min. The Q-Exactive was operated in data-
dependent mode with survey scans acquired at a resolution of 70,000 at m/z 
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200. Scan range was 300 to 2000m/z. Up to the top 10 most abundant isotope 
patterns with charge states +2 to +5 from the survey scan were selected with 
an isolation window of 2.0Th and fragmented by higher energy collisional 
dissociation with normalised collision energies of 30. The maximum ion 
injection times for the survey scan and the MS/MS scans were 250 and 50ms, 
respectively, and the ion target value was set to 1E6 for survey scans and 1E4 
for the MS/MS scans. MS/MS events were acquired at a resolution of 17,500. 
Repetitive sequencing of peptides was minimised through dynamic exclusion 
of the sequenced peptides for 20s (259).  
 
2.7.3 Protein Identification and Quantification  
Thermo RAW files were imported into Progenesis LC–MS (version 4.1, 
Nonlinear Dynamics. Peaks were picked by the software using default settings 
and filtered to include only peaks with a charge state between +2 and +7. 
Peptide intensities were normalised against the reference run by Progenesis 
LC-MS and these intensities were used to highlight differences in protein 
expression between control and treated samples with supporting statistical 
analysis (ANOVA p-values) calculated by the Progenesis LC-MS software. 
Spectral data were converted into .mgf files with Progenesis LC–MS and 
exported for peptide identification using the Mascot (version 2.3.02, Matrix 
Science) search engine. Tandem MS data were searched against a combined 
database, including translated ORFs from the Human genome (Uniprot, Feb 
2017), Influenza H3N2 (Uniprot, Feb 2015) and a contaminant database 
(cRAP, GPMDB, 2012) (combined 25534 sequences; 13007852 residues). 
The search parameters were as follows: precursor mass tolerance was set to 
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10 ppm and fragment mass tolerance was set as 0.01 Da. Two missed tryptic 
cleavages were permitted. Carbamidomethylation (cysteine) was set as a 
fixed modification and oxidation (methionine) set as a variable modification. 
Mascot search results were further validated using the machine-learning 
algorithm Percolator, embedded within Mascot. The Mascot decoy database 
function was utilised, and the false discovery rate was <1%, while individual 
percolator ion scores >13 indicated identity or extensive homology (p <0.05). 
Mascot search results were imported into Progenesis LC–MS as XML files 
(260).  
 
2.8 The MinION sequencing protocol 
2.8.1 Quantification of RNA samples using Qubit®3.0 fluorometer 
RNA samples quantified using Qubit®3.0 fluorometer using the Qubit RNA HS 
Assay Kit (Thermo Fisher [Q328520]) following manufacturer’s instructions. 
260/280 and 260/230 ratios were established using NanoDrop One/OneC 
Microvolume UV-Vis Spectrophotometer (Thermo Scientific). The ideal ratios 
to be attained were 2.0. After that, each reaction concentration used was 
quantified on the Qubit®3.0 fluorometer. 
 
2.8.2 Agarose gel electrophoresis  
Agarose gel electrophoresis with cybersafe staining was used to visualise 
RNA. Electrophoresis grade agarose (AGTC Bioproducts) (1% [w/v]) was 
melted in TBE buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.0) by heating, 
and cybersafe was added to cooled molten agarose to a final concentration of 
0.5 μg/ml. Molten agarose was poured into a gel-casting tray containing a 
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comb and allowed to set. The tray was transferred to a gel running tank and 
submerged in 1X TBE buffer. 5Pl of samples was diluted in 2Pl DNA loading 
buffer (Bioline) and loaded in the wells of the gel alongside Hyperladder I DNA 
ladder (Bioline). RNA was analysed on a 1% agarose gel by electrophoresis 
at 120V. 400mA for one hour. This was to observe the distinct 28S and 18S 
rRNA bands (with a ratio of band intensity ~2:1) (data not shown). RNA 
samples were stored at -80oC. RNA samples were given to our colleagues at 
the centre for genomic research (CGR) to confirm the quality of RNA by 
visualising the 28S and 18S rRNA bands and RIN values.  
 
2.8.3 Reverse transcription and strand-switching 
200ng of total RNA was mixed with VN Primer (VNP) and 10mM dNTPs (NEB 
[N0447]) and incubated at 65qC for 5 minutes and snapped cooled. 
Superscript IV buffer and 100mM DTT (ThermoFisher Scientific [18090050]), 
RNaseOUT (Life technologies [10777019]) and SSP (ONT) were added to the 
reaction and incubated at 42qC for two minutes. 1Pl of Superscipt IV 
(ThermoFisher Scientific [18090050]) was added to the reaction and incubated 
following the protocol, (50qC, 10 mins), (42qC, 10 mins), (80qC, 10 mins). 
 
2.7.4 Selecting for full length transcripts by PCR 
Reverse transcribed RNA was split into four separate reactions with the 
addition of 2x LongAmp Taq (NEB [M0287]) and cDNA PRM (cPRM [ONT]). 
Reverse transcribed RNA was amplified using the following cycling conditions 
(Table 2.7).  The extension step was carried out for 10 minutes. 
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Table 2.7 Cycling conditions for full length transcripts by PCR 
Cycle step Temperature Time No. of cycles 
Initial denaturation 95qC 30 secs 1 
Denaturation 95qC 15 secs 11–18* 
Annealing 62qC 15 secs 11–18* 
Extension 65qC 50 secs per kb 11–18* 
Final extension 65qC 6 mins 1 
Hold 4qC f  
 
Exonucleases (NEB [M0293]) were added to each PCR reaction and were 
incubated at 37qC for 15 minutes, then 80qC for 15 minutes. The four separate 
reactions were then pooled before the addition of AMPure XP beads 
(Beckman Coulter [A63880]). The pooled reaction was then incubated for five 
minutes at room temperature on a Hula mixer. Reactions were then pelleted 
on a magnetic rack and washed twice with 70% ethanol. 21Pl of Rapid 
Annealing Buffer (RAB [ONT]) was added to the reaction and incubated on a 
hula mixer for 10 minutes at room temperature. Reactions were pelleted on 
the magnetic rack and the eluate was retained for Qubit analysis. 
 
2.8.5 Adapter ligation 
2Pl of cDNA Adapter Mix (cAMX [ONT]) was added to the amplified cDNA 
library and incubated on a Hula mixer for five minutes at room temperature. 
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2.8.6 AMPure XP bead binding 
20Pl of AMPure XP beads were added to the reaction and incubated on a hula 
mixer for five minutes at room temperature. Reactions were pelleted on the 
magnetic rack and supernatant was removed. AMPure XP beads were 
resuspended in 140Pl of Adapter Bead Binding Buffer (ABB [ONT]), 
supernatant was removed once pelleted on the magnetic rack before 
resuspending the beads in ABB once again. Beads were resuspended in 13Pl 
Elution Buffer (ELB [ONT]) and incubated on a hula mixer for 10 minutes at 
room temperature. Beads were pelleted on the magnetic rack and the eluate 
was transferred into a clean 1.5 ml Eppendorf DNA LoBind tube. 1Pl of eluate 
was quantified using a Qubit fluorometer.  
 
2.8.7 Priming and loading the flow cell 
Approximately 20 Pl of air was removed from the priming port of the flow cell 
800 Pl of priming mix containing Running Buffer with Fuel Mix (RBF [ONT]) 
and nuclease free water was added to the flow cell. After five minutes, the 
SpotON sample port cover was lifted and 200 Pl of priming mix was added to 
the priming port. 12 Pl of the cDNA library was mixed with 35 Pl RBF (ONT), 
25.5 Pl of library loading beads (LLB [ONT]) and 2.5 Pl of nuclease free water. 
75Pl of the prepared library was added, drop wise, to the flow cell via the 
SpotON sample port. 
 
2.8.8 Data acquisition, transfer and Bioinformatic analysis 
The specialist software MinKNOW was used for base calling and data 
acquisition. After the experiment was over (48 hours later), the data pass 
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FASTA files were downloaded on a 1TB external hard drive and transported 
for bioinformatic data analysis following the methods described in (261).  
 
2.9 Infection of Cynomolgus NHP Macaque (Macaca Fascicularis) with 
IAV  
All animal experiments in non-human primates (NHP) were conducted by our 
collaborators at Public Health England (PHE), at their facilities in Porton Down, 
UK. It was not possible for me to undertake the training and obtain a license 
to carry out the animal experiments for the duration of the project. The rest of 
the analysis and experiments were performed by me and my colleagues in the 
proteomics department at the University of Liverpool. 
 
Cynomolgus NHP Macaque (Macaca Fascicularis) were infected via the 
inhaled aerosol (i.a.) route at a dose of 105 pfu. This i.a. dose was used 
because it was the maximum dose technically achievable for the A/Cal/04/09. 
These animals were culled at day five and day seven (262). Broncho-alveolar 
lavage fluid (BALF) from naïve NHP and i.a. challenged NHP-infected, culled 
at day five and day seven, were received. BALF samples were analysed by 
mass spectrometry as described below.  
 
2.9.1 BALF sample preparation from NHP for Mass Spectrometry 
Protein from Broncho-alveolar lavage fluid (BALF) after spinning out and 
discarding cells was dispensed into low protein-binding microcentrifuge tubes 
(Sarstedt, Leicester, UK) and made up to 160 μl with the addition of 25 mM 
ammonium bicarbonate. The proteins were denatured using 10 μl of 1% (w/v) 
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RapiGestTM (Waters MS Technologies, Manchester, UK) in 25 mM 
ammonium bicarbonate, followed by two cycles of 10-minute sonication in a 
water bath. A sample was then incubated at 80°C for 10 minutes, reduced 
(addition of 10μl of 60 mM DTT and incubation at 65 °C for 10 min), and 
alkylated (addition of 10μl of 180 mM iodoacetamide and incubation at room 
temperature for 30 min in the dark). Trypsin (Sigma-Aldrich) was reconstituted 
in 50 mM acetic acid to a concentration of 0.2 μg/μl. Digestion was performed 
by the addition of 10μl of trypsin to the sample followed by incubation at 37°C 
overnight. The RapiGestTM was removed from the sample by acidification (1 
μl of trifluoroacetic acid and incubation at 37°C for 45 min) and centrifugation 
(15,000 × g for 15 min) (260). 
 
Digests (2µl) were analysed on a 50cm Easy-Spray column with an internal 
diameter of 75µm, packed with 2µm C18 particles, fused to a silica nano-
electrospray emitter (Thermo Fisher Scientific). Reversed phase liquid 
chromatography was performed using the Thermo EASY-nLC 1000 with a 
binary buffer system consisting of 0.1% formic acid (buffer A) and 80% 
acetonitrile in 0.1% formic acid (buffer B). The peptides were separated by a 
linear gradient of 5–40% buffer B over 110 min at a flow rate of 300nl/min. The 
column was operated at a constant temperature of 35°C and the LC system 
coupled to a Q-Exactive mass spectrometer (Thermo Fisher Scientific). The 
Q-Exactive was operated in data-dependent mode with survey scans acquired 
at a resolution of 70,000 at m/z 200. The top 10 most abundant isotope 
patterns with charge states +2, +3 and/or +4 from the survey scan were 
selected with an isolation window of 2.0Th and fragmented by higher energy 
 102 
collisional dissociation with normalised collision energies of 30. The maximum 
ion injection times for the survey scan and the MS/MS scans were 250 and 
100ms, respectively, and the ion target value was set to 1E6 for survey scans 
and 1E4 for the MS/MS scans. Repetitive sequencing of peptides was 
minimised through dynamic exclusion of the sequenced peptides for 20s 
(262). 
 
2.10 Obtaining Nasopharyngeal aspirates (NA) from patients in Alderhey 
Children’s Hospital (AHCH), Great Ormond Street Hospital (GOSH) and 
the Institute Pasteur, Dakar (IPD) 
NAs (due for discard after routine diagnostic work) were obtained from the 
diagnostic laboratories at AHCH, GOSH, and IPD (Table 2.9). Samples were 
made anonymous and supplied only with the following information: respiratory 
virus status, influenza status, gender, and age in years. All samples from the 
different cohorts were sampled from paediatric patients between the ages of 
two and 13 years old. Five samples from those testing IAV-H3N2-positive, 
along with six samples testing negative, for a defined suite of respiratory 
viruses, including IAV, were provided by AHCH. Six samples from those 
testing IAV-H3N2-positive along with six samples testing negative for a 
defined suite of respiratory viruses, including IAV, were provided by GOSH. 
Ten samples from those testing IAV-H3N2-positive, 10 samples from those 
testing IAV-H1N1 (pdm2009)-positive, along with 10 samples from those 
testing negative for a defined suite of respiratory viruses and IAV-negative 
were provided by IPD. Upon completion of the project, the NA samples were 
destroyed. 
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Table 2.9 P
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Table 2.10 Summary Characteristics of patient samples from Great 
Ormond Street Hospital, Institut Pasteur Dakar and Alder Hey 
Children’s Hospital 
 
 Total No. 
of 
patients 
No. of 
Males 
No. of 
Females 
Age bin 
(1-4) 
Age bin 
(5-13) 
GOSH (H3N2 Positive) 6 3 3 3 3 
GOSH (H3N2Negative 6 3 3 3 3 
IPD (H3N2 Positive) 10 9 1 4 6 
IPD (H1N1 Positive) 10 4 6 5 5 
IPD (H3N2 & H1N1 
negative) 
10 7 3 5 5 
AHCH (H3N2 Positive) 5 - - 3 2 
AHCH (H3N2 & H1N1 
Positive) 
- - - - - 
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2.10.1 Ethics Statement 
I used residual material that was from NHS diagnostic samples and was fully 
anonymised. These samples were held under the Human Tissue Authority 
(HTA) license. Similarly, residual material that was from diagnostic samples 
and was fully anonymised were obtained from Institut Pasteur Dakar, Senegal. 
 
2.10.2 Film array and qRT-PCR analysis of influenza virus 
The Film Array multiplex polymerase chain reaction (PCR) system respiratory 
panel by Biomerieux diagnostics was used to detect the presence of 
pathogens in the NA. This panel detects the 20 most common respiratory 
pathogens; adenovirus, coronavirus HKU1, coronavirus NL63, coronavirus 
OC43, human metapneumovirus, human rhinovirus/Enterovirus, influenza A, 
influenza A H1, influenza A H1-2009, influenza A/H3, influenza B, 
parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, 
parainfluenza virus 4, HRSV, Bordetella pertussis, Chlamydophila 
pneumoniae and Mycoplasma pneumoniae. IAV viral load was determined by 
qRT-PCR, where positive amplification controls were used with cDNA derived 
from plasmids that contained the amplicon sequences of each target. An 
internal positive control (IPC) of Phocine Distemper virus (PDV) was added to 
every sample. The PDV target was detected with a real-time RT-PCR assay 
that was run in a multiplex reaction with the IAV target. The targets for the IAV 
were HA, M1/M2, and NP segments. The limit of detection was 10 copies per 
reaction. 
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2.10.3 Sample preparation for proteomics 
Protein pellets from nasal wash precipitation were re-solubilised in 50mM 
ammonium bicarbonate, 0.1% Rapigest (Waters). Protein concentration was 
determined using the Pierce Coomassie Plus bicinchoninic acid protein assay 
(Thermo Scientific) as instructed in the manufacturer’s guide. Sample protein 
content and volume were normalised with 50mM ammonium bicarbonate. 
Samples were then heated at 80⁰C for 10 minutes, reduced with 3mM 
dithiothreitol (Sigma) at 60⁰C for 10 minutes, and then alkylated with 9mM 
iodoacetimde (Sigma) at room temperature for 30 minutes in darkness. 
Proteomic grade trypsin (Sigma) was added at a protein-trypsin ratio of 50:1 
and samples incubated at 37⁰C overnight. Rapigest was removed by adding 
TFA to a final concentration of 0.5% (v/v) and incubating at 37⁰C for 2 h before 
centrifugation at 12,000g for 60 minutes (4⁰C) to remove the precipitate (263) 
(257). 
 
2.10.4 NanoLC MS ESI MS/MS analysis 
Samples were re-analysed by on-line nanoflow LC using the Ultimate 3000 
nano system (Dionex/Thermo Fisher Scientific) coupled with Q-Exactive mass 
spectrometer (Thermo Fisher Scientific). Samples were loaded on a 50cm 
Easy-Spray column with an internal diameter of 75µm, packed with 2µm C18 
particles, fused to a silica nano-electrospray emitter (Thermo Fisher Scientific). 
The column was operated at a constant temperature of 35°C. Chromatography 
was performed with a buffer system consisting of 0.1% formic acid (buffer A) 
and 80% acetonitrile in 0.1% formic acid (buffer B). The peptides were 
separated by a linear gradient of 3.8–50% buffer B over 90 minutes at a flow 
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rate of 300nl/min. The Q-Exactive was operated in data-dependent mode with 
survey scans acquired at a resolution of 70,000. Up to the top 10 most 
abundant isotope patterns with charge states +2, +3 and/or +4 from the survey 
scan were selected with an isolation window of 2.0Th and fragmented by 
higher energy collisional dissociation with normalised collision energies of 30 
(258). MS/MS scans were acquired at a resolution of 17,500. The maximum 
ion injection times for the survey scan and the MS/MS scans were 250 and 50 
ms, respectively, and the ion target value was set to 1E6 for survey scans and 
1E5 for the MS/MS scans. Repetitive sequencing of peptides was minimised 
through dynamic exclusion of the sequenced peptides for 20s. 
 
2.10.5 Label-free analysis using Progenesis 
Thermo RAW files were imported into Progenesis LC–MS (version 4.1, 
Nonlinear Dynamics). Runs were time aligned using default settings and using 
an auto-selected run as reference. Peaks were picked by the software and 
filtered to include only peaks with a charge state of between +2 and +6 (257). 
Peptide intensities were normalised against the reference run by Progenesis 
LC-MS and these intensities were used to highlight differences in protein 
expression between control and treated samples with supporting statistical 
analysis (ANOVA p-values) calculated by the Progenesis LC-MS software. 
Spectral data were transformed to .mgf files with Progenesis LC–MS and 
exported for peptide identification using the Mascot (version 2.3.02, Matrix 
Science) search engine (260). Tandem MS data were searched against a 
combined database including translated ORFs from the Human genome 
(Uniprot, Feb 2014), and a combined human respiratory virus database 
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(including Influenza (A), HRSV (A, B), Human adenovirus 14, Human 
mastadenovirus (A, B, C, D), Human parainfluenza virus (1, 2, 3), Human 
metapneumovirus, Human coronavirus (OC43,NL63, 229E), Human 
bocavirus, Rhinovirus (A, B14, C) all from NCBI, Aug 2014) and a contaminant 
database (cRAP, GPMDB, 2012) (combined 20896 sequences; 11589421 
residues) (258). Mascot search parameters were as follows; precursor mass 
tolerance set to 10ppm and fragment mass tolerance set to 0.05 Da. One 
missed tryptic cleavage was permitted. Carbamidomethylation (cysteine) was 
set as a fixed modification and oxidation (methionine) set as a variable 
modification. Mascot search results were further processed using the machine-
learning algorithm Percolator. The false discovery rate was <1%. Individual ion 
scores >13 indicated identity or extensive homology (p<0.05). Protein 
identification results were imported into Progenesis LC–MS as .xml files (264). 
 
2.10.6 Label-free analysis using Progenesis 
Thermo RAW files were imported into Progenesis LC–MS (version 4.1, 
Nonlinear Dynamics). Runs were time aligned using default settings and using 
an auto-selected run as reference. Peaks were picked by the software and 
filtered to include only peaks with a charge state of between +2 and +6 (257). 
Peptide intensities were normalised against the reference run by Progenesis 
LC-MS and these intensities were used to highlight differences in protein 
expression between control and treated samples with supporting statistical 
analysis (ANOVA p-values) calculated by the Progenesis LC-MS software. 
Spectral data were transformed to .mgf files with Progenesis LC–MS and 
exported for peptide identification using the Mascot (version 2.3.02, Matrix 
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Science) search engine. Tandem MS data were searched against the human 
(60,806 sequences, NCBI RefSeq release-2014_09). Mascot search 
parameters were as follows; precursor mass tolerance set to 10ppm and 
fragment mass tolerance set to 0.5 Da. One missed tryptic cleavage was 
permitted. Carbamidomethylation (cysteine) was set as a fixed modification 
and oxidation (methionine) set as a variable modification. Mascot search 
results were further processed using the machine-learning algorithm 
Percolator. The false discovery rate was <1%. Individual ion scores >13 
indicated identity or extensive homology (p<0.05). Protein identification results 
were imported into Progenesis LC–MS as .xml files (259) (264). 
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CHAPTER 3: CHARACTERISING THE CELLULAR RESPONSE TO 
INFLUENZA A VIRUS INFECTION USING AN ALVEOLAR LUNG 
EPITHELIAL CELL LINE (A549 CELL LINE)
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3.1 INTRODUCTION 
The IAV possesses various mechanisms that enable it to enter, replicate, and 
exit host cells, as well as evade the host anti-viral response (117). The IAV 
has developed mechanisms for the production of more viruses, including ‘cap-
snatching’ and preventing the host from expressing its own genes (117). The 
IAV has gained the ability to ‘shut off the host’. This, in effect, means upon 
viral infection in infected cells, the virus has gained the capability to redirect 
cellular resources to enable viral gene expression. In addition, evading the 
host immune response. (265, 266). Some of the mechanisms used by the IAV 
to shut off the host, are described below. 
 
NS1 is an IAV viral protein that plays a key role in inhibiting type I interferon 
(IFN) responses. This is crucial in evading the host innate immune response 
(266). Viruses in which the NS1 protein has been deleted, are proven to 
induce high levels of IFN. These viruses also replicated more efficiently in the 
absence of IFN-D/E in vero cells than in the presence of type 1 IFNs in MDCK 
cells (266-268). As stated above, ‘cap-snatching’ is another mechanism that 
IAV uses to ‘shut off the host’. The RNA-dependent RNA polymerase RdRp 
complex from the IAV, binds to the host’s RNA pol II. RdRp cleaves new 
transcripts close to the 5’ end. These fragments are used as primers for viral 
mRNA transcription. The 5’ caps intended for host messages are used for viral 
messages (146, 266). The RdRp-pol II association also leads to the 
ubiquitination and degradation of Pol II. Pol II plays a role in the expression of 
IFN-stimulated genes such as ISG15 (269). Therefore, the degradation of Pol 
II allows IAV to circumvent host antiviral response (266, 270). PA-X is a viral 
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protein produced after amino acid 191 of PA (85, 271). PA-X degrades host 
RNA by reducing reporter and endogenous gene expression and plays a role 
in circumventing host innate immune response. (85, 266, 272, 273).  
 
Lung epithelial cells are the first line of the host defence from respiratory 
infections (2). Upon viral entry, the host interferon (IFN) response is one of 
the first barriers IAV overcomes to establish an infection (274, 275). Proteins 
from the IFN family play a major role in responding to the early stages of 
infections. Lung epithelial cells infected with respiratory viruses, and 
specifically IAV, produce IFN type I and III depending on the retinoic acid-
inducible-gene-I protein and mitochondrial antiviral signalling protein (RIG-
I/MAVS) pathway (276). Receptors that detect IAV affect the induction of IFN. 
The Toll-like receptor 7 (TLR7) on plasmacytoid dendritic cells (pDC) 
recognise the influenza virus, while RNA helicase retinoic acid-induced gene 
I (RIG-I) recognises RNA viral genomes (277). RNA binding to RIG-I caused 
interactions with mitochondrial adaptor protein MAVS. This leads to the 
activation of transcriptional factors, such as NFNB and expression of IFNE and 
IFND1 in humans and IFND4 in mice (277-279). After IFNE and IFND1/ IFND4 
are secreted, receptor-associated tyrosine kinases JAK1 and Tyk2 are 
activated alongside transcription factors STAT1 and STAT2 (277, 280). These 
activated STATs go on to form complexes called interferon stimulator gene 
factor 3 (ISGF3), which induce hundreds of IFN-stimulated genes (ISGs). 
ISGs play a crucial role in establishing the antiviral state in the cell after 
infection (277). Type III IFNs are a novel class of IFNs and have three 
members: IFNO1, IFNO2 and IFNO3, also called IL-29, IL-28A and IL-28B 
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respectively (281). IFN III are induced by similar mechanisms as IFN1 through 
RIG-I/MAVS/TBK1/IRF3 (277). IFN I and III therefore protect the host from 
IAV infection by upregulating interferon stimulated genes (ISGs) (277, 282).  
 
The aim of this thesis was to understand host responses in vitro and in vivo. 
The first aim (and the subject of this chapter) was to characterise IAV H3N2 
in a well-controlled in vitro cell culture system (A549 cells were used). This 
was established by infecting A549 cells with IAV and quantifying the virus at 
3h.p.i, 6h.p.i, 9h.p.i, 12h.p.i, 18h.p.i, 24h.p.i, 36h.p.i, and 48h.p.i. The 
technique used for this was the avicel plaque assay (2.4%) (254). This was to 
assess the most suitable time point of infection before the cells arrived at 
cytopathic effect (CPE). Following this, an informed decision was made when 
choosing a time point (18h.p.i) that would be used for subsequent 
experiments. Immunofluorescence microscopy and SDS-PAGE were used to 
validate the data and confirm the cells were IAV infected prior to further 
experiments. Once this time point (18h.p.i) was selected, mass spectrometry 
was used to characterise the proteome of A549 cells infected with IAV 
compared to mock infected cells. MinION sequencing was further used to 
characterise the transcriptome of A549 cells infected with IAV compared to 
mock infected cells. The results from the in vitro experiment provided a high 
degree of confidence and allowed for a direct comparison between in vitro 
(chapter 3) and in vivo (Chapters 4 and 5) systems. 
 
A549 cells used in this chapter are a model cell line derived from alveolar 
epithelial cells. These cells have been used extensively in the analysis of the 
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cellular response in other respiratory pathogens. Some of these respiratory 
pathogens include; respiratory syncytial virus (RSV) (283-286) and the 
measles virus (287). A comparison of the host cell proteome after infection of 
A549 cells with negative stranded viruses, such as HRSV, parainfluenza virus, 
measles virus, and HMPV was done. The results obtained revealed an 
induction of apoptosis upon infection. A two-dimensional gel electrophoresis 
(2D-DIGE) approach was used to identify the host proteome changes that are 
in concordance with these findings (287).  
 
 IAV, just like RSV and Porcine Reproductive and Respiratory Syndrome Virus 
(PRRSV) (288), is known to have a tropism for respiratory epithelial cells. 
Therefore, this cell line was selected as an appropriate model (289, 290). 
A549 cells have been used to understand the dynamics and complexity of 
virus-host cell interactions (219). A549 cells have been used for in vitro 
analysis of human surfactant synthesis (291). The cell line provides a robust 
IFN response as seen in humans during respiratory infection (226, 274). The 
IFN response has the potential to be used as a treatment against pandemic 
influenza virus infections (292, 293). The antiviral actions of type I and type III 
IFN were effective in suppressing the pandemic 2009 (H1N1) influenza virus 
infection (294). 
 
However, there are caveats in using A549 cells. The A549 cell line is derived 
from a human alveolar cell carcinoma and has a modal chromosome number 
of 66 (295, 296). Consequently, the genes (and ultimately proteins) are maybe 
over or under represented compared to normal cells. Nonetheless, A549 cells 
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at both low and high passage numbers have properties typical of type II 
alveolar epithelial cells based on histochemical, electron microscopic, and 
biochemical data (297, 298).  
 
In addition to A549 cells, MDCK cells are used in the study of influenza virus 
strains due to their high susceptibility to infection. As an alternative to egg-
based vaccine production, MDCK cells have been used widely for these 
purposes (242). MDCK cell culture-derived influenza vaccine production has 
been approved by the European Medicines Agency (242, 299). MDCK cells 
are known to be more susceptible and robust to various strains of IAV and 
are, therefore, frequently used for viral growth in vitro and in the development 
of vaccines (300, 301). MDCK cells are used for the avicel plaque assay to 
quantify the virus over time. This is due to the MDCK cells robust nature and 
their ability to withstand being coated with 1Pg/ml of trypsin over long periods 
of time. A549 cells do not have this ability.  
 
To investigate the host response and identify biomarkers of viral infection, in 
this chapter, two independent approaches were used to investigate changes 
in protein and transcript abundance. A combination of these methods would 
give an insight into host changes. Quantitative proteomics was used to gain a 
global quantitative and qualitative overview of the cellular proteome changes. 
Label-free mass spectrometry was used because of its simpler biochemical 
workflows and the ability to use it in biomarker discovery in clinical samples. 
This was essential to ensure that all the data is collected and analysed from 
the same platform. This reduces technical variation and data comparison 
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between in vitro (chapter 3) and in vivo (Chapters 4 and 5). MinION 
sequencing was used to obtain a global transcriptome by sequencing samples 
from IAV-infected A549 cells and A549 mock-infected cells. Data from Mass 
Spectrometry and MinION revealed host proteome and transcriptome data 
that are comparable to further characterise IAV and identify potential 
biomarkers. 
 
3.2 Next Generation Sequencing (NGS)  
The benefits of having the ability to determine the order of nucleic acid 
residues in biological samples are numerous. This order gives information on 
biochemical and hereditary properties of a biological sample. Researchers 
have applied themselves over the last fifty years in the search of techniques 
and technologies to enable this. Sequencing has therefore encompassed 
sequencing DNA molecules, sequencing RNA molecules over increasingly 
shorter time frames (Figure 3.1) (302). Next Generation sequencing is the 
ability to use technologies to sequence DNA or RNA for high-throughput 
production of sequencing data. This is in comparison to the traditional 
sequencing method – Sanger first-generation sequencing. NGS is frequently 
used today to determine how an organism survives independently and within 
a host (Figure 3.1) (Table 3.1) (303).  
 
NGS is a culmination of deep, high-throughput and in-parallel DNA 
sequencing technologies developed three decades after Sanger DNA 
sequencing. NGS technologies produce high-throughput data at a much-
reduced cost, while undertaking parallel DNA analysis (303-306). First-
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generation Sanger sequencing focused on the use of fragment-cloning 
methods to sequence DNA nucleotides (307). Second-generation sequencing 
focused on amplifying sequence libraries prior to sequencing amplified DNA 
clones (308). Third generation sequencing, on the other hand, can be 
completed without creating amplification libraries. This saves time and cost 
(309). 
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Figure 3.1: A
 brief history D
N
A
 sequencing adapted from
 Eurofins G
ATC
 B
iotech G
m
bH
 (w
w
w
.eurofinsgenom
ics.eu) (310). It 
highlights the various w
ell-know
n sequencing m
ethods developed since the structure of the D
N
A
 double helix, w
hich w
as published 
in 1953. The developm
ent of D
N
A
 sequencing m
ethods from
 Sanger sequencing to pyrosequencing and the illum
ina buying S
olexa. 
It highlights the start of Third-G
eneration S
equencing in 2009, the first P
acB
io com
m
ercialised in 2011m
 and the com
m
ercialisation 
of O
xford N
anopore Technologies in 2012. Finally, it highlights the era of bioinform
atics analysis, w
hich started in 2017.  
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Table 3.1: Features and perform
ance of N
G
S platform
s – First G
eneration Sequencing, Second G
eneration Sequencing 
and Third G
eneration Sequencing. For a better understanding of the N
G
S outputs, the hum
an genom
e has 3x10
9 bp or 3 
G
b. (adapted from
 (303, 307, 311-313) 
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3.3 MinION Sequencing (Oxford Nanopore technologies) 
The MinION is the first commercial sequencer form Oxford Nanopore 
Technologies (ONT). The MinION has provided another leap in the revolution 
of genome sequencing. MinION sequencing uses electrical conductivity, 
which is generated as a DNA strand that passes through a biological pore to 
identify DNA bases. This is the first portable, affordable technology that can 
be used to produce real-time data (314). The MinION combats the caveat of 
short reads from previous genome sequencing technologies, by producing 
longer reads. This was a Sanger Generation Sequencing (SGS) shortfall as 
de novo genome assembly was relatively poor (314).  
 
The MinION is a small sequencing device (Figure 3.2). It can be plugged into 
a standard USB3 port on a computer. The MinION produces a lot of data 
therefore devices with more than 128 GB of hard disk space are 
recommended. Software called MinKNOW is used to carry out data 
acquisition, real-time analysis and feedback, data streaming, sample 
identification, and tracking. This ensures the platform processes the samples 
correctly (314).  
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Figure 3.2: The MinION sequencing device taken from (314). The sample is 
added to the flow cell. Sequencing commences as the DNA molecules pass 
through the nanopore, a change in the magnitude of the current in the 
nanopore is measured and registered by the sensor. The data is collected by 
the software (MinKNOW) and processes it into two categories: ‘pass’ and ‘fail’. 
 
Once the sample was added to the flow cell, DNA sequencing began. When 
a DNA molecule passes through a nanopore, there is a change in magnitude 
of the current. This change in magnitude is measured by a sensor several 
thousand times a second (314). These data streams are passed to the 
MinKNOW, which generates the signal-level data, acquires the data, and 
conducts the analysis (314). The experiment runs for 48 – 72 hours. 
MinKNOW generates FASTA files while the experiment is running, and they 
are sorted into ‘PASS’ and ‘FAIL’. For a file to ‘PASS’, the read had a mean 
Q-value !9. FASTA files that passed were downloaded to a hard drive and 
subjected to bioinformatics. A Q-value is described as minimum false 
discovery rate (FDR) (315). A Q-value is an adjusted P-value that uses the 
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FDR approach. Whilst the P-value takes into account all samples when 
discovering which are false prostives, Q-values take into account only tests 
with Q-values less than a specific threshold (in the case of this thesis Q-value 
of 0.05). This gives a far more accurate indication of the level of false 
positives (315).  
 
The potential of the MinION sequencing was tested during the biggest Ebola 
outbreak in West Africa, which was responsible for over 28,599 cases and 
over 11,000 deaths (316). During an epidemic, genome sequencing is crucial 
as it provides information on the evolution of the pathogen and provides 
information to implement public health guide control measures (316). During 
an epidemic, genome surveillance has not been easily attained due to cost 
and practicality of the setting and equipment. The MinION sequencer provided 
a platform from which real-time genomic surveillance was implemented during 
an outbreak. Over one hundred positive Ebola samples were sequenced, and 
results were generated less than 24 hours after receipt of the positive sample. 
This showed the innovative potential of the MinION sequencer in resource-
limited settings to monitor outbreaks. It was used to understand viral evolution, 
track and investigate transmission chains, and validate other diagnostic 
assays (314, 316-319). 
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3.4 RESULTS 
As previously stated, the aim of this chapter was to characterise IAV H3N2 in 
a well-controlled in vitro cell culture system (A549 cells were used). Two 
independent approaches were used to investigate changes in protein and 
transcript abundance. A combination of these methods would give an 
overarching insight into host changes. Mass spectrometry was used to 
characterise the proteome of A549 cells infected with IAV compared to mock 
infected cells. MinION sequencing was used to characterise the global 
transcriptome. Finally, other techniques (immunofluorescence and SDS-
PAGE) were used to validate the data and add to the findings from mass 
spectrometry and MinION sequencing. A549 cells were infected with IAV and 
the supernatant collected at the time points 3h.p.i, 6h.p.i, 9h.p.i, 12h.p.i, 
18h.p.i, 24h.p.i, 36h.p.i, and 48h.p.i. The virus in the supernatant was 
quantified using avicel plaque assay (2.4%) (254). Following this, an informed 
decision was made when choosing a time point that would be used for 
subsequent proteomics and transcriptomics experiments. 18h.p.i was 
selected as the most suitable time point.  
 
3.5 Characterisation and quantification of IAV in MDCK cells at time 
points post infection; 3h.p.i, 6h.p.i, 9h.p.i, 12h.p.i, 18h.p.i, 24h.p.i, 
36h.p.i, 48h.p.i, and non-infected (mock) 
Avicel plaque assay was used to characterise and quantify IAV at different 
time points. A549 cells were infected with IAV at MOI 1 and observed following 
figure 3.3. After the specified time points, the supernatants were collected and 
stored at -80qC. MDCK cells were then set up to quantify the IAV in these 
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supernatants using the avicel plaque assay. Two biological replicates were 
conducted, following the protocol described in the material and methods in 
Chapter 2 and following the workflow in Figure 3.3. After 72 hours, the plates 
were fixed with ice-cold acetone – methanol – and then stained with crystal 
violet (Figure 3.4). SDS-PAGE (Figure 3.5) and immunofluorescence staining 
(Figure 3.6) were used to confirm the presence of IAV in A549 cells at 6h.p.i, 
12h.p.i, 18h.p.i, and 24h.p.i.
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Figure 3.3: Progression of workflow from obtaining IAV supernatant from A549 
cells in six-well plates after infection 3h.p.i, 6h.p.i, 9h.p.i, 12h.p.i, 18h.p.i, 
24h.p.i, 36h.p.i, 48h.p.i, and non-infected (mock). The virus in these 
supernatants were quantified via avicel plaque assay. MDCK cells were used 
for the avicel plaque assay and inoculated with the respective viral 
supernatants. This inoculum was adsorbed after one hour and the cells were 
covered with an avicel overlay for 72 hours.  
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Figure 3.4: Avicel plaque assay of MDCK cells mock infected and infected 
with viral supernatant at 3h.p.i, 6h.p.i, 9h.p.i, 12h.p.i, 18h.p.i, 24h.p.i, 36h.p.i, 
and 48h.p.i. A virus dilution of 10-1 was used to infect the cells. After 72 hours, 
the cells were fixed with acetone – methanol – and stained with crystal violet. 
The plaques formed by the infectious viral particle are clearly visible at 
different time points in comparison to the mock-infected samples. This 
experiment was repeated twice for biological repeats.  
 
3.6 Confirming and validating IAV in A549 cells infected at MOI 1 at 
6h.p.i, 12h.p.i, 18h.p.i and 24h.p.i, compared to mock infected cells via 
SDS-PAGE 
To assess virus-host cell interactions post infection, A549 cells were infected 
with the IAV X31 strain. The time points post infection 6h.p.i, 12h.p.i, 18h.p.i, 
and 24h.p.i were selected and compared to the mock-infected (M) cells, 
following the results from the plaque assay in Figure 3.4 and based on 
previous H3N2 swine influenza proteomics studies (219, 320). This allowed 
the viral infection process to be monitored by observing the NP viral protein 
and comparing it to the mock infected cells. MOI 1 was used to infect cells. 
 
Proteins from these samples were extracted and the protein concentration 
was obtained using a BCA assay. The proteins extracted from the cells at 
different time points were separated by SDS-PAGE. Equal volumes and 
concentrations (8 Pg/Pl) of protein were loaded in each well. This allowed for 
visual comparison of relative abundance between these samples. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a 
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loading control. The influenza NP antibody, which is an IAV viral protein, is 
located within the nucleus of cells and used as a marker of infection (226) 
(Figure 3.5). The NP antibody (Chapter 2, Table 2.4) marker showed the NP 
protein abundance changed over the time post-infection. No viral protein was 
detected in the mock-infected cells. Cells collected at 24h.p.i showed a higher 
abundance of NP antibody markers compared to cells collected at 6h.p.i. 
There was a progressive increase in abundance of the viral protein NP from 
the times 6h.p.i, 12h.p.i, 18h.p.i, and 24h.p.i (Figure 3.6). Cells from which the 
cell lysate was collected 48 hours post infection showed visible signs of cell 
death and cytopathic effect (CPE) (data not shown).  
 
 
 
Figure 3.5: A549 cells were mock-treated (M) and infected with IAV X-31 at 
MOI 1. The cell lysates were strategically prepared and collected at 6h.p.i, 
12h.p.i, 18h.p.i, 24h.p.i and compared to mock (M) infected cells. The NP 
antibody marker was used as an IAV marker and GAPDH antibody marker 
was used as a loading control.  
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3.7 Visualising IAV infection in A549 cells and mock-treated cells at 
MOI 1 and at 6 hours, 12 hours, 18 hours and 24 hours post infection 
via immunofluorescence staining 
Immunofluorescence analysis was used to monitor the viral infection in A549 
cells over the time frame – 6h.p.i, 12h.p.i, 18h.p.i, and 24h.p.i, and compared 
it to mock infected cells (Figure 3.6). The NP antibody was used as the marker 
of IAV infection in the immunofluorescence protocol. This protocol was 
elaborated in the materials and methods (Chapter 2). 
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Figure 3.6: A549 cells mock-treated and IAV X-31 infected at MOI 1 at 6h.p.i, 
12h.p.i, 18h.p.i, and 24h.p.i post infection. Cells were stained with the 
Influenza NP antibody (Table 2.4, Chapter 2), a marker protein located within 
the nucleus of the cells. The nucleus was stained blue with DAPI. The NP 
protein was stained red with Rhodamine. Both channels were merged and the 
NP in the nucleus was visible. The images of cells were taken from two 
different viewpoints providing; a far view (scale bar – 100Pm) and a magnified 
view (scale bar – 20Pm).  
 
The results from these experiments outline IAV infection over time through the 
avicel plaque assay (Figure 3.4), validation via SDS-PAGE (Figure 3.5) and 
immunofluorescence staining (Figure 3.6) points towards 18h.p.i as the 
preferred time point for further analysis by label-free mass spectrometry and 
MinION sequencing.  
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3.8 Label-free mass spectrometry analysis and MinION sequencing on 
A549 cells infected with IAV X31 at MOI 1 and analysed 18 hours post 
infection 
Label-free mass spectrometry was used to gain a global overview of the 
cellular proteome changes post IAV infection. The A549 cell line was mock-
infected and IAV X31 infected at MOI 1 and analysed at 18h.p.i following the 
workflow in Figure 3.7. The results from these experiments were compared to 
understand the difference in cellular proteome between infected and non-
infected cells. This dataset was further analysed by bioinformatics using the 
software, Ingenuity Pathway Analysis (IPA). To validate the data from these 
experiments, another technique was used. This was the MinION sequencing. 
A549 cells were mock infected and IAV X31 infected at MOI 1 and collected 
at 18h.p.i. The RNA was extracted from these samples and subjected to 
MinION sequencing. The data from the MinION sequencing was analysed 
using a differential gene expression analysis. The transcripts that were found 
to be differentially expressed in infected, compared to non-infected, cells 
confirmed the data from the label-free mass spectrometry. These datasets 
were further analysed using ingenuity pathway analysis (IPA). This analysis 
teased out and connected the proteins according to function and linked them 
to already identified proteins in the literature. These datasets gave high 
confidence to findings from mass spectrometry and when comparing them to 
similar studies in the literature and in vivo studies (Chapters 4 and 5). 
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Figure 3.7: Progression of workflow and techniques for the processing of 
proteins and RNA from mock-infected and IAV X31-infected A549 samples at 
MOI 1 at 18h.p.i. Protein samples were subjected to the mass spectrometry 
platform; Q-Exactive for label-free proteomics and further data analysis was 
done via Bioinformatics – Ingenuity Pathway Analysis (IPA). RNA was 
extracted from cells and the concentration obtained via nanodrop and Qubit. 
RNA samples ran on an agarose gel to check for integrity by visualising 18S 
and 28S bands. These samples were then subjected to the Bioanalyser for 
further validation. After this, RNA samples were subjected to the MinION for 
sequencing.  
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3.9 Identification of cellular proteome of IAV infected A549 cells at 
MOI 1 and 18h.p.i via label-free mass spectrometry 
Label-free proteomics was used to obtain an unbiased global view of the 
changes that occur in a host cell proteome after IAV X31 infection. The A549 
cell line was mock-infected and IAV X31 infected at MOI 1, collected at 18h.p.i. 
The whole cell lysates were collected and subjected to the Q-Exactive LC-MS 
platform. This experiment was repeated twice (biological replicates). Data 
from biological replicates could be compared and also provide high 
confidence in this dataset. The dataset obtained from the first run produced 
over a thousand cellular and viral proteins that were detected and quantified. 
In the dataset from the second run, over three thousand cellular and viral 
proteins were detected and quantified.  
 
3.10 Identification and quantification of cellular and viral proteins in 
host-viral interaction 
The analysis of the dataset included several processing steps to increase 
confidence in the identified proteins. These processing steps included 
proteins with two or more peptides, proteins with a log two-fold change of +/- 
one or two and above, proteins with a p-value of 0.05 and proteins with a q-
value of 0.05. A combination of these data-processing steps was used to 
process the data from the two biological repeats from the Q-Exactive. This 
increases the probability of correctly identifying proteins. These data-
processing steps are widely used in the study of virus host interactions. 
However, many of the proteins identified by single peptides were also of 
interest and are included in the full data tables present in the appendices (321-
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324).  
 
In the first biological repeat, proteins identified with two or more peptides, 
proteins with a log two-fold change of +/- 2 and above and proteins with a p-
value 0.05 were selected to be significantly different (325). In the second 
biological repeat, proteins identified with two or more peptides, proteins with 
a log two-fold change of +/- one and above and proteins with a q-value  0.05 
were selected to be significantly different. It is worth noting that these 
biological repeats were carried out three years apart. Similar proteins and the 
pathways involved were identified between the datasets from the two 
biological repeats. Nonetheless, slightly different data processing tools were 
utilised. This is as a result of advances in the data analysis processes when 
using high throughput techniques, such as mass spectrometry. 
 
The quantitative proteomic analysis of the first biological repeat identified up 
to 1283 cellular and viral proteins. These proteins were obtained by comparing 
mock-infected samples to IAV X31 infected samples. This data set was 
quantified, analysed and provided the protein abundance changes which 
occurred following IAV X31 infection. The degree of change in abundance was 
represented by log two-fold change per protein. To increase confidence in the 
datasets, the data processing steps highlighted above were implemented. To 
reiterate, these steps were: proteins identified with two or more peptides, 
proteins with a log 2-fold change of +/- 2 and above, proteins with a p-value  
0.05. The results after these data processing steps are detailed in Tables 3.2 
and 3.3. 
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The quantitative proteomic analysis of the second biological repeat identified 
up to 3,361 cellular and viral proteins. These proteins were obtained by 
comparing mock-infected samples to IAV X31-infected samples. This data set 
was quantified, analysed and provided the protein abundance changes, which 
occurred following IAV X31 infection. The degree of change in abundance was 
represented by log two-fold change per protein. To increase confidence in the 
datasets, the data processing steps highlighted above were implemented. To 
reiterate, these steps were: proteins identified with two or more peptides, 
proteins with a log two-fold change of +/- 1 and above, and proteins with a q-
value  0.05 to be significantly different. The results after these data 
processing steps are detailed in Tables 3.4 and 3.5. 
 
3.11 Identification and quantification of proteins that were differentially 
abundant in the first biological repeat 
The dataset was analysed on MaxQuant software and the data processing 
steps described above were used to increase confidence in the highlighted 
data. Proteins were grouped based on their increase or decrease in 
abundance when comparing the mock-infected to the IAV X31-infected cells. 
The dataset revealed 33 proteins, which significantly increased in abundance 
and 58 proteins, which significantly decreased in abundance. These proteins 
are presented in Table 3.2 and 3.3. 
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Table 3.2: 33 proteins identified in the first biological replicate by Q-
Exactive Mass Spectrometry, followed by data processing steps, have 
significantly increased in abundance when comparing mock-infected 
cells to IAV X31-infected cells. The log two-fold change, the number of 
peptides (Pep.), and the proteins biological process are shown below 
using GO via uniprot: http://www.uniprot.org and (326).  
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33 proteins that significantly increased in abundance w
hen com
paring IA
V X31 infected cells to m
ock-infected cells 
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Peptide 
C
ount 
 
O
14879 
IFIT3_H
U
M
AN
 
Interferon- induced protein w
ith 
tetratricopeptide repeats 3 
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9 
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Arginase 
Arginase Activity 
2 
2.9 
2 
P29590 
PM
L_H
U
M
AN
 
Prom
yelocytic leukaem
ia 
protein 
Functions in tum
our suppression, 
transcription regulation, apoptosis, 
2 
2.9 
3 
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senescence, D
N
A dam
age response 
and viral m
echanism
 
P31689 
D
N
JA1_H
U
M
AN
 
D
naJ-like protein subfam
ily A 
m
em
ber 1 
Interacts w
ith H
sp70. Stim
ulate 
ATPase activity. 
2 
2.7 
3 
Q
01130 
SR
SF2_H
U
M
A
N
 
Serine/arginine-rich splicing 
factor 2 
N
ecessary for splicing of pre-m
R
N
A 
3 
2.5 
3 
Q
9BR
L6 
SR
SF8_H
U
M
A
N
 
Serine/arginine-rich splicing 
factor 8 
Involved in pre-m
R
N
A
 alternative 
splicing 
3 
2.5 
3 
P84103 
SR
SF3_H
U
M
A
N
 
Serine/arginine-rich splicing 
factor 3 
Splicing factor 
4 
2.5 
5 
P49773 
H
IN
T1_H
U
M
A
N
 
H
istidine triad nucleotide-
binding protein 1 
M
odulates p53/TP53 levels 
2 
2.5 
2 
P63167 
D
YL1_H
U
M
AN
 
D
ynein light chain 1, 
cytoplasm
ic 
Plays a role in the nuclear localisation 
of ESR
1 
2 
2.3 
2 
Q
02413 
D
SG
1_H
U
M
AN
 
D
esm
oglein-1 
C
om
ponent of intercellular 
desm
osom
e junctions 
2 
2.3 
2 
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Q
07000 
1C
15_H
U
M
AN
 
H
LA class I histocom
patibility 
antigen, cw
-15 alpha chain 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
P01892 
1A02_H
U
M
A
N
 
H
LA class 1 histocom
patibility 
antigen, A-2 alpha chain 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
P01893 
H
LAH
_H
U
M
AN
 
Putative H
LA
 class I 
histocom
patibility antigen, alpha 
chain H
 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
P05534 
1A24_H
U
M
A
N
 
H
LA class I histocom
patibility 
antigen, A-24 alpha chain 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
P10321 
1C
07_H
U
M
AN
 
H
LA class I histocom
patibility 
antigen, C
w
-7 alpha chain 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
P13746 
1A11_H
U
M
A
N
 
H
LA class I histocom
patibility 
antigen, A-11 alpha chain 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
P18463 
1B37_H
U
M
A
N
 
H
LA class I histocom
patibility 
antigen, B-37 alpha chain 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
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P30447 
1A23_H
U
M
A
N
 
H
LA class I histocom
patibility 
antigen, A-23 alpha chain 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
P30460 
1B08_H
U
M
A
N
 
H
LA class I histocom
patibility 
antigen, B-8 alpha chain 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
P30499 
1C
01_H
U
M
AN
 
H
LA class I histocom
patibility 
antigen, C
w
-1 alpha chain 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
Q
29718 
1B82_H
U
M
A
N
 
H
LA class I histocom
patibility 
antigen, B-82 alpha chain 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
Q
29940 
1B59_H
U
M
A
N
 
H
LA class I histocom
patibility 
antigen, B-59 alpha chain 
Involved in the presentation of foreign 
antigens to the im
m
une system
 
3 
2.2 
3 
P30046 
D
O
PD
_H
U
M
AN
 
D
-dopachrom
e decarboxylase 
Tautom
erization of D
-dopachrom
e 
w
ith decarboxylation to give 5,6-
dihydroxyindole 
2 
2.1 
2 
P18124 
R
L7_H
U
M
AN
 
60S ribosom
al protein L7 
Binds to G
-rich structures in 28S 
rR
N
A
 and in m
R
N
A
s 
9 
2.1 
9 
P81605 
D
C
D
_H
U
M
AN
 
D
erm
cidin 
D
isplays antim
icrobial activity 
2 
2.0 
2 
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Q
86V
P6 
C
AN
D
1_H
U
M
AN
 
C
ullin-associated N
ED
D
8-
dissociated protein 1 
C
ell differentiation 
2 
2.0 
2 
O
75874 
ID
H
C
_H
U
M
A
N
 
Isocitrate dehydrogenase 
(N
AD
P) cytoplasm
ic 
R
esponse to oxidative stress 
2 
2.0 
2 
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Table 3.3: 58 proteins identified in the first biological replicate by Q
-Exactive M
ass Spectrom
etry, follow
ed by data 
processing steps have significantly decreased in abundance w
hen com
paring m
ock-infected cells to IAV X31-infected cells. 
The log tw
o-fold change, the num
ber of peptides (P
ep.), and the proteins’ biological process are show
n below
 using G
O
 via 
uniprot: http://w
w
w
.uniprot.org and (326).  
 
58 proteins that significantly decreased in abundance w
hen com
paring IA
V X31 infected cells to m
ock-infected cells 
U
niprot 
accession 
ID
  
G
ene ID
 
 
Protein N
am
e 
 
Function 
 
Peptides for 
Q
uantification 
 
Fold C
hange 
(Log 2) 
 
Peptide C
ount 
 
P16144 
ITB4_H
U
M
AN
 
Integrin Beta 4 
C
ritical structural role in the 
hem
idesm
osom
e of epithelial 
cells 
2 
8.3 
3 
Q
14116 
IL18_H
U
M
AN
 
Interleukin 18 
Increases natural killer cell 
activity in spleen cells. 
Stim
ulates interferon gam
m
a 
2 
5.5 
2 
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production in T-helper type 
cells 
Q
96P
K6 
R
BM
14_H
U
M
AN
 
R
N
A
 binding m
otif protein 
14 
N
uclear receptor coactivator 
and enhancing transcription 
2 
5.3 
2 
Q
13740 
C
D
166_H
U
M
AN
 
C
D
166 antigen hom
olog 
C
ell adhesion m
olecule that 
binds to C
D
6 
7 
3.7 
7 
O
00468 
AG
R
IN
_H
U
M
AN
 
Agrin 
Basal lam
ina glycoprotein 
plays a central role in 
form
ation and m
aintenance of 
neurom
uscular junction (N
M
J) 
2 
3.6 
2 
Q
43570 
C
AH
12_H
U
M
A
N
 
C
arbonic anhydrase 12 
H
ydration of carbon dioxide 
(R
eversible) 
2 
3.2 
2 
Q
8N
FJ5 
R
AI3_H
U
M
AN
 
R
etinoic acid induced 3 
M
odulating differentiation and 
m
aintaining hom
eostasis in 
epithelial cells 
3 
3.2 
3 
Q
00341 
VIG
LN
_H
U
M
AN
 
Vigilin 
C
ell protection from
 over-
accum
ulation of cholesterol 
2 
3.1 
2 
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Q
12860 
C
N
TN
1_H
U
M
Q
N
 
C
ontactin 1 
M
ediate cell surface 
interactions during nervous 
system
 developm
ent 
11 
2.9 
11 
Q
15056 
IF4H
_H
U
M
A
N
 
Eukaryotic translation 
initiation factor 4H
 
Stim
ulates the R
N
A helicase 
activity of EIF4A in the 
translation initiation com
plex 
4 
2.9 
4 
Q
8N
BJ4 
G
O
LM
1_H
U
M
AN
 
G
olgi m
em
brane protein 1 
C
ellular response protein to 
viral infection 
5 
2.9 
5 
P98179 
R
BM
3_H
U
M
AN
 
R
N
A
-binding protein 3 
R
educes the relative 
abundance of m
icroR
N
As 
4 
2.9 
4 
Q
9C
005 
D
P
Y30_H
U
M
AN
 
Protein dpy-30 hom
olog 
M
ay play som
e role in histone 
H
3 acetylation 
2 
2.8 
2 
Q
9H
C
84 
M
U
C
5B_H
U
M
A
N
 
M
ucin – 5B
 
G
el form
ing m
ucin rich, 
contributes to lubricating and 
viscoelastic properties of saliva 
and cervical m
ucus 
16 
2.8 
18 
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O
15230 
LAM
A5_H
U
M
AN
 
Lam
inin subunit alpha - 5 
Binding to cells via high affinity 
receptor, m
ediates attachm
ent, 
m
igration and organisation of 
cells 
3 
2.7 
3 
P62633 
C
N
B
P_H
U
M
AN
 
C
ellular nucleic acid-
binding protein 
Single-stranded D
N
A binding 
protein 
4 
2.7 
4 
P04844 
R
PN
2_H
U
M
AN
 
D
olichyl-
diphosphooligosaccharide-
protein glycosyltransferase 
subunit 2 
Essential subunit of the N
-
oligosaccharyl transferase 
(O
ST) com
plex 
4 
2.6 
6 
P49756 
R
BM
25_H
U
M
AN
 
R
N
A-binding protein 25 
R
N
A
 – binding protein that 
acts as a regulator of 
alternative pre-m
R
N
A
 splicing 
2 
2.5 
2 
Q
71D
I3 
H
32_H
U
M
AN
 
H
istone H
3.2 
C
ore com
ponent of 
nucleosom
e 
2 
2.5 
5 
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Q
96PD
2 
D
C
B
D
2_H
U
M
AN
 
D
iscoidin, C
U
B
 and LC
C
L 
dom
ain-containing protein 
2 
Intracellular receptor signalling 
pathw
ay 
3 
2.5 
3 
Q
9BW
F3 
R
BM
4_H
U
M
AN
 
R
N
A
-binding protein 4 
R
N
A-binding factor involved in 
m
ultiple aspects of cellular 
processes like alternative 
splicing of pre-m
R
N
A
 and 
translation regulation 
3 
2.4 
3 
Q
9BVJ6 
U
T14A_H
U
M
AN
 
U
3 sm
all nucleolar R
N
A
-
associated protein 14 
hom
olog A
 
M
ay be required for ribosom
e 
biogenesis 
6 
2.4 
6 
Q
5TAP6 
U
T14C
_H
U
M
AN
 
U
3 sm
all nucleolar R
N
a-
associated protein 14 
hom
olog C
 
Essential for sperm
atogenesis 
6 
2.4 
6 
P30049 
ATPD
_H
U
M
AN
 
ATP synthase subunit 
delta, m
itochondrial 
Proton-transporting ATP 
synthase activity, rotational 
m
echanism
 
2 
2.4 
2 
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Q
68C
Z2 
TEN
S3_H
U
M
A
N
 
Tensin-3 
M
ay play a role in actin 
rem
odelling 
3 
2.4 
4 
P23246 
SFPQ
_H
U
M
AN
 
Splicing factor, proline and 
glutam
ine rich 
D
N
A
 and R
N
A binding protein 
involved in several nuclear 
processes 
9 
2.4 
10 
O
60763 
U
SO
1_H
U
M
AN
 
G
eneral vesicular 
transport factor p115 
Act as a vesicular anchor 
4 
2.3 
5 
Q
5JTJ3 
C
O
A6_H
U
M
AN
 
C
ytochrom
e C
 oxidase 
assem
bly factor 6 
hom
olog 
Involved in the m
aturation of 
the m
itochondrial respiratory 
chain com
plex IV subunit 
5 
2.3 
5 
P98088 
M
U
C
5A_H
U
M
A
N
 
M
ucin 5A
C
 
G
el form
ing glycoprotein of 
gastric and respiratory tract 
epithelia that protects the 
m
ucosa from
 infection 
9 
2.3 
9 
P20290 
BTF3_H
U
M
A
N
 
Transcription factor BTF3 
W
hen associated w
ith N
AC
A 
prevents inappropriate 
targeting of non-secretory 
4 
2.3 
5 
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polypeptides to the 
endoplasm
ic reticulum
 (ER
) 
Q
13242 
SR
SF9_H
U
M
A
N
 
Serine/arginine-rich 
splicing factor 9 
Plays a role in constitutive 
splicing and can m
odulate the 
selection of alternative splice 
sites 
3 
2.3 
3 
Q
00325 
M
PC
P_H
U
M
AN
 
Phosphate carrier protein, 
m
itochondrial 
Transport of phosphate groups 
from
 the cytosol to the 
m
itochondrial m
atrix 
2 
2.3 
2 
Q
9Y2W
2 
W
BP11_H
U
M
AN
 
W
W
 dom
ain-binding 
protein 11 
Activates pre-m
R
N
A
 splicing 
3 
2.3 
3 
Q
03701 
C
EB
PZ_H
U
M
AN
 
C
C
A
AT/enhancer-binding 
protein zeta 
Stim
ulates transcription from
 
the H
SP
70 prom
oter 
3 
2.3 
3 
O
60869 
ED
F1_H
U
M
AN
 
Endothelial differentiation-
related factor 1 
R
egulates nitric oxid synthase 
activity 
2 
2.3 
2 
P60866 
R
S20_H
U
M
AN
 
40S ribosom
al protein S
20 
Poly (A) R
N
A
 binding 
2 
2.2 
2 
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P28799 
G
R
N
_H
U
M
AN
 
G
ranulins 
G
ranulins have possible 
cytokine-like activity 
7 
2.2 
8 
Q
14247 
SR
C
8_H
U
M
AN
 
Src substrate cortactin 
C
ontributes to the organization 
of the actin cytoskeleton and 
cell shape 
10 
2.2 
11 
Q
9U
K
V3 
AC
IN
U
_H
U
M
AN
 
Apoptotic chrom
atin 
condensation inducer in 
the nucleus 
Auxiliary com
ponent of the 
splicing-dependent 
m
ultiprotein exon junction 
com
plex (EJC
) 
7 
2.1 
8 
Q
14061 
C
O
X
17_H
U
M
AN
 
C
ytochrom
e c oxidase 
copper chaperone 
C
opper chaperone for 
cytochrom
e c oxidase (C
O
X
) 
2 
2.1 
2 
Q
9U
LD
2 
M
TU
S1_H
U
M
AN
 
M
icrotubule-associated 
tum
our suppressor 1 
C
ooperates w
ith AG
TR
2 to 
inhibit E
R
K
2 activation and cell 
proliferation 
3 
2.1 
3 
P05067 
A4_H
U
M
AN
 
Am
yloid beta A4 protein 
C
ell surface receptor 
6 
2.1 
6 
Q
9P0K7 
R
AI14_H
U
M
A
N
 
Ankycorbin 
Actin cytoskeleton 
3 
2.0 
6 
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Q
15233 
N
O
N
O
_H
U
M
AN
 
N
on-P
ou dom
ain-
containing octam
er-
binding protein 
D
N
A
 and R
N
A
 binding protein 
involved in several nuclear 
processes 
5 
2.0 
6 
Q
6U
N
15 
FIP1_H
U
M
AN
 
Pre-m
R
N
A
 3’ end 
processing factor FIP
1 
C
om
ponent of the cleavage 
and polyadenylation specificity 
factor (C
PSF) 
3 
2.0 
4 
Q
16891 
IM
M
T_H
U
M
AN
 
M
IC
O
S
 com
plex subunit 
M
IC
60 
Plays an im
portant role in the 
m
aintenance of the M
IC
O
S
 
com
plex 
21 
2.0 
22 
Q
9H
C
35 
EM
AL4_H
U
M
AN
 
Echinoderm
 m
icrotubule-
associated protein-like 4 
M
ay m
odify the assem
bly 
dynam
ics of m
icrotubules 
2 
2.0 
2 
P46976 
G
LYG
_H
U
M
A
N
 
G
lycogenin-1 
Self-glucosylates 
3 
2.0 
3 
O
75976 
C
BP
D
_H
U
M
AN
 
C
arboxypeptidase D
 
M
etallocarboxypeptidase 
activity 
9 
2.0 
9 
Q
9G
ZU
8 
F192A_H
U
M
AN
 
Protein FAM
192A
 
Post translation m
odification 
2 
2.0 
2 
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P16070 
C
D
44_H
U
M
AN
 
C
D
44 antigen 
R
eceptor for hyaluronic acid 
(H
A) 
7 
2.0 
7 
P68431 
H
31_H
U
M
AN
 
H
istone H
3.1 
C
ore com
ponent of 
nucleosom
e 
2 
2.0 
5 
P11940 
PA
BP
1_H
U
M
A
N
 
Polyadenylate-binding 
protein 1 
Binds the poly (A) tail of m
R
N
A
 
6 
2.0 
7 
Q
13310 
PA
BP
4_H
U
M
A
N
 
Polyadenylate-binding 
protein 4 
Binds the poly (A) tail of m
R
N
A
 
6 
2.0 
7 
Q
9H
361 
PA
BP
3_H
U
M
A
N
 
Polyadenylate-binding 
protein 3 
Binds the poly (A) tail of m
R
N
A
 
6 
2.0 
7 
P20073 
AN
X
A7_H
U
M
AN
 
Annexin A7 
C
alcium
/phospholipid binding 
protein w
hich prom
otes 
m
em
brane fusion and is 
involved in exocytosis 
3 
2.0 
3 
P33240 
C
STF2_H
U
M
AN
 
C
leavage stim
ulation 
factor subunit 2 
O
ne of the m
ultiple factors 
required for polyadenylation 
4 
2.0 
4 
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and 3’end cleavage of 
m
am
m
alian pre-m
R
N
A
 
Q
9H
0L4 
C
STFT_H
U
M
AN
 
C
leavage stim
ulation 
factor subunit 2 tau variant 
Significant role in A
AU
AA
A
-
independent m
R
N
A
 
polyadenylation in germ
 cells 
4 
2.0 
4 
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3.12 Identification and quantification of viral and host proteins that 
were differentially abundant in the second biological repeat 
 
 
Table 3.4: 2 Influenza A viral proteins identified in the second biological 
replicate by Q-Exactive Mass Spectrometry followed by data processing 
steps, have significantly increased in abundance when comparing 
mock-infected cells to IAV X31-infected cells. The log two-fold change, 
the number of peptides (Pep.), and the proteins’ biological function are 
shown below using GO via uniprot http://www.uniprot.org and (326).  
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2 Influenza A
 viral proteins identified by M
ass Spectrom
etry w
hen com
paring IA
V X31 infected cells to m
ock-infected cells 
U
niprot accession 
ID
  
G
ene ID
 
 
Protein N
am
e 
 
Function 
 
Peptides for 
Q
uantification 
 
Fold C
hange (Log 
2)  
Peptide C
ount 
 
Q
91U
L1 
Q
91U
L1_I000X 
N
ucleoprotein – 
Influenza A virus 
(strain A/X
31 
H
3N
2) 
R
N
A
 binding and 
essential in viral 
penetration into host 
nucleus 
3 
9.7 
3 
Q
0PD
M
0 
N
S1_I000X 
N
on-structural 
protein 1 (N
S1A) – 
Influenza A virus 
(strain A/X
31 
H
3N
2) 
Prevents establishm
ent 
of the cellular antiviral 
state by inhibiting 
TR
IM
25-m
ediated 
D
D
X
58 (innate im
m
une 
receptor sensing viral 
infection) ubiquitination 
2 
2.6 
2 
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Table 3.5: Nine cellular proteins identified in the second biological 
replicate by Q-Exactive Mass Spectrometry, followed by data processing 
steps, have significantly increased and decreased in abundance when 
comparing mock-infected cells to IAV X31-infected cells. The log 2-fold 
change, the number of peptides (Pep.), and the proteins’ biological 
function are shown below using GO via uniprot http://www.uniprot.org 
and (326).  
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9 cellular proteins that significantly increased and decreased in abundance w
hen com
paring IA
V X31 infected cells to m
ock-infected cells 
U
niprot 
accession 
ID
  
G
ene ID
 
 
Protein N
am
e 
 
Function 
 
Peptides for 
Q
uantification 
 
Fold C
hange 
(Log 2) 
 
Peptide C
ount 
 
P20591 
M
X
1_H
U
M
AN
 
Interferon-induced G
TP
-
binding protein M
x1 
Antiviral activity against som
e 
R
N
A
 and D
N
A
 viruses. 
Targets negative-stranded 
R
N
A
 viruses through binding 
and inactivation of their 
ribonucleocapsid 
3 
3.1 
3 
Q
9Y6D
9 
M
D
1L1_H
U
M
A
N
 
M
itotic spindle assem
bly 
checkpoint protein M
AD
1 
Part of the spindle-assem
bly 
checkpoint that prevents onset 
of anaphase until 
2 
1.8 
2 
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chrom
osom
es are aligned at 
m
etaphase 
P29317 
EPH
A2_H
U
M
AN
 
Ephrin type-A receptor 2 
R
egulates m
igration, integrin-
m
ediated adhesion, 
proliferation and differentiation 
of cells. A
lso acts as a 
receptor for hepatitis C
 virus 
(H
C
V
) and facilitates its entry 
into cells5 
4 
3.3 
5 
P23229 
ITG
A6_H
U
M
AN
 
Integrin alpha-6 
Integrin alpha-6/beta-1 is a 
receptor for lam
inin on 
platelets 
9 
1.6 
10 
Q
13740 
C
D
166_H
U
M
AN
 
C
D
166 antigen 
C
ontributes to form
ation and 
m
aturation of im
m
unological 
synapse through interaction 
w
ith C
D
6 
7 
1.4 
7 
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P54289 
C
A2D
1_H
U
M
A
N
 
Voltage-dependent 
calcium
 channel subunit 
alpha-2/delta-1 
M
etal ion binding and voltage-
gated calcium
 channel activity 
4 
1.4 
4 
P49916 
D
N
LI3_H
U
M
AN
 
D
N
A
 ligase 3 
Isoform
 3 – heterodim
er w
ith 
D
N
A-repair protein X
R
C
C
1 in 
nucleus. Isoform
 1 –functions 
as D
N
A ligase in m
itochondrial 
base-excision D
N
A repair 
2 
1.1 
2 
P26006 
ITA3_H
U
M
AN
 
Integrin alpha-3 
R
eceptor for fibronectin, 
lam
inin, collagen, epiligrin 
participate in adhesion, m
atrix 
degradation processes, 
prom
oting cell invasion 
14 
1.1 
14 
Q
53EL6 
PD
C
D
4_H
U
M
AN
 
Program
m
ed cell death 
protein 4 
Inhibits translation initiation 
and cap-dependent translation. 
D
ow
n regulates expression of 
4 
-1 
4 
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M
A
P4K1, inhibiting events that 
drive invasion 
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3.13 Bioinformatics Analysis- Ingenuity Pathway Analysis (IPA) 
The datasets obtained from the Q-Exactive platform were analysed using 
Ingenuity Pathway Analysis (IPA) (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis). 
The proteins highlighted were connected and categorised based on function. 
Different expression networks were generated using IPA. The data sets 
contained accession gene identifiers, corresponding maximum fold change 
values, P-values, and q-values, which were uploaded into the application. This 
analysis provided a deeper understanding of the dataset. Proteins were 
visualised from a perspective of their function in the host in response to IAV 
infection. Through this analysis, all proteins, which were involved in the 
‘replication of IAV’, were highlighted (Table 3.6). Among these proteins in 
Table 3.6, the proteins in bold are those that were also highlighted when the 
data from MinION sequencing was subjected to IPA.  
 
Table. 3.6: 131 proteins identified by Q – Exactive Mass Spectrometry 
and highlighted by the IPA in the category – Replication of IAV (the 
proteins in bold are those that were highlighted when data from MinION 
sequencing was subjected to IPA) 
 
 
179 
U
niprot 
accession ID
 
G
ene ID
 
Protein nam
e 
Function 
Log-2-fold 
change 
P05161 
ISG
15_H
U
M
AN
 
U
biquitin-like protein ISG
15 
Key role in innate im
m
une response to viral infection 
6.046 
P20591 
M
X
1_H
U
M
AN
 
Interferon-induced G
TP
-binding protein 
M
x1  
Antiviral activity against som
e R
N
A and D
N
A viruses. Targets 
negative-stranded R
N
A
 viruses through binding and 
inactivation of their ribonucleocapsid 
3.051 
P26006 
ITG
A3_H
U
M
AN
 
Integrin alpha-3 
R
eceptor for fibronectin, lam
inin, collagen, epiligrin, 
throm
bospondin and C
SPG
4 
1.099 
P17612 
PR
K
AC
A_H
U
M
A
N
 
cAM
P-dependent protein kinase catalytic 
subunit alpha 
Phosphorylates a large substrate in the cytoplasm
 and 
nucleus 
1.011 
Q
9H
269 
VP
S16_H
U
M
AN
 
Vacuolar protein sorting-associated 
protein 16 hom
olog 
R
ole in vesicle-m
ediated protein trafficking to the lysosom
al 
com
partm
ents 
0.833 
Q
9Y6K5 
O
AS3_H
U
M
AN
 
2’-5’-oligoadenylate synthase 3 
Activated by dsR
N
A and plays a role in innate antiviral 
response (Interferon-induced)  
0.808 
P42224 
STAT1_H
U
M
AN
 
Signal transducer and activator of 
transcription 1-alpha/beta 
M
ediates cellular responses to interferons (IFN
) 
0.704 
Q
13287 
N
M
I_H
U
M
A
N
 
N
-m
yc-interactor 
Augm
ents cytokine-m
ediated STAT transcription 
0.498 
 
180 
Q
8W
U
K0 
PTPM
T1_H
U
M
A
N
 
Phosphatidylglycerophosphatase and 
protein-tyrosine phosphatase 1 
Lipid phosphatase 
0.484 
P55265 
AD
A
R
_H
U
M
AN
 
D
ouble-stranded R
N
A
-specific adenosine 
deam
inase 
C
atalyzes hydrolytic deam
ination of adenosine to inosine 
0.464 
Q
13190 
STX
5_H
U
M
AN
 
S
yntaxin-5 
M
ediates endoplasm
ic reticulum
 to G
olgi transport 
0.449 
Q
9U
BU
9 
N
X
F1_H
U
M
AN
 
N
uclear R
N
A
 export factor 1 
N
uclear export of m
R
N
A
 species from
 nucleus to cytoplasm
 
0.421 
P19525 
EIF2AK
2_H
U
M
AN
 
Interferon-induced, double stranded R
N
A
-
activated protein kinase 
Key role in innate im
m
une response to viral infection 
0.384 
Q
9U
LT8 
H
EC
TD
1_H
U
M
AN
 
E3 ubiquitin-protein ligase H
EC
TD
1 
E3 ubiquitin-protein ligase 
0.332 
P62875 
PO
LR
2L_H
U
M
A
N
 
D
N
A
-directed R
N
A
 polym
erases I, II and 
III subunit R
P
AB
C
5 
C
atalyses the transcription of D
N
A into R
N
A
 
0.314 
P14324 
FD
PS
_H
U
M
AN
 
 
 
0.312 
Q
12788 
TBL3_H
U
M
AN
 
Transducin beta-like protein 3 
R
N
A
 binding 
0.25 
P08865 
R
PS
A_H
U
M
AN
 
40S ribosom
al protein S
A
 
Assem
bly and/or stability of the 40S
 ribosom
al subunit 
0.249 
P52434 
PO
LR
2H
_H
U
M
AN
 
D
N
A
-directed R
N
A
 polym
erases I, II and 
III subunit R
P
AB
C
3 
C
atalyses transcription of D
N
A to R
N
A
 
0.234 
P62263 
R
PS
14_H
U
M
AN
 
40S ribosom
al protein S
14 
m
R
N
A
 5’-U
TR
 binding 
0.228 
 
181 
P49790 
N
U
P
153_H
U
M
AN
 
N
uclear pore com
plex protein N
up153 
R
equired for trafficking across the nuclear envelope 
0.214 
Q
14152 
EIF3A_H
U
M
A
N
 
Eukaryotic translation initiation factor 3 
subunit A
 
R
N
A-binding com
ponent of eukaryotic translation initiation 
factor 3 and required for initiation of protein synthesis 
0.214 
Q
96C
W
1 
AP
2M
1_H
U
M
AN
 
AP-2 com
plex subunit m
u 
Protein transport via transport vesicles 
0.213 
P07437 
TU
BB_H
U
M
AN
 
Tubulin beta chain 
M
ajor constituent of m
icrotubules 
0.204 
O
75821 
EIF3G
_H
U
M
AN
 
Eukaryotic translation initiation factor 3 
subunit G
 
R
N
A-binding com
ponent of eukaryotic translation initiation 
factor 3 (eIF-3) com
plex 
0.201 
Q
7Z3B
4 
N
U
P54_H
U
M
A
N
 
N
ucleoporin p54 
C
om
ponent of nuclear pore com
plex needed for 
trafficking across the nuclear m
em
brane 
0.19 
P31749 
AKT1_H
U
M
AN
 
R
AC
-alpha serine/threonine-protein 
kinase 
R
egulates processes including; m
etabolism
, proliferation cell 
survival, grow
th, and angiogenesis 
0.186 
Q
9B
TD
8 
R
B
M
42_H
U
M
AN
 
R
N
A-binding protein 42 
B
inds 3’-untranslated region (U
TR
) of C
D
K
N
1A
 m
R
N
A
 
0.182 
Q
9Y3B4 
SF3B
6_H
U
M
AN
 
Splicing factor 3B subunit 6 
Involved in pre-m
R
N
A
 splicing 
0.181 
P68104 
EEF1A1_H
U
M
AN
 
Elongation factor 1-alpha 1 
G
TPase activity  
0.171 
O
95470 
SG
PL1_H
U
M
A
N
 
Sphingosine-1-phosphate lyase 1 
Involved in the pathw
ay sphingolipid m
etabolism
 
0.162 
Q
2TAY7 
SM
U
1_H
U
M
AN
 
W
D
40 repeat-containing protein S
M
U
1 
Involved in pre-m
R
N
A
 splicing 
0.149 
Q
9Y224 
R
TR
AF_H
U
M
AN
 
R
N
A
 transcription, translation and 
R
N
A
 binding protein involved in m
R
N
A
 transcription by 
0.146 
 
182 
transport factor protein 
Polym
erase II 
P62979 
R
PS
27A_H
U
M
A
N
 
U
biquitin-40S ribosom
al protein S
27a 
U
biquitin – covalently bound to another protein or free 
0.145 
Q
99720 
SIG
M
AR
1_H
U
M
AN
 
Sigm
a non-opioid intracellular receptor 1 
Lipid transport from
 the endoplasm
ic reticulum
 
0.138 
O
75153 
C
LU
H
_H
U
M
AN
 
C
lustered m
itochondria protein hom
olog 
R
egulates transport or translation of transcripts close to 
m
itochondria  
0.136 
P15428 
H
PG
D
_H
U
M
AN
 
15-hydroxyprostaglandin 
dehydrogenase 
Prostaglandin inactivation 
0.135 
P07900 
H
SP
90AA
1_H
U
M
AN
 
H
eat shock protein H
SP
 90-alpha 
M
olecular chaperone prom
oting m
aturation of specific target 
proteins 
0.134 
Q
13200 
PS
M
D
2_H
U
M
AN
 
26S proteasom
e non-ATPase regulatory 
subunit 2 
R
ole in m
aintaining protein hom
eostasis 
0.132 
Q
14974 
KPN
B1_H
U
M
AN
 
Im
portin subunit beta-1 
Function in nuclear protein im
port 
0.131 
Q
9U
H
Y1 
N
R
B
P1_H
U
M
AN
 
N
uclear receptor-binding protein 
R
ole in subcellular trafficking betw
een endoplasm
ic reticulum
 
and G
olgi apparatus 
0.129 
P49841 
G
SK3B_H
U
M
AN
 
G
lycogen synthase kinase-3 beta 
ATP binding 
0.128 
P53621 
C
O
PA
_H
U
M
AN
 
C
oatom
er subunit alpha 
H
orm
one activity 
0.125 
Q
15424 
SAFB_H
U
M
A
N
 
Scaffold attachm
ent factor B1 
Allow
s form
ation of ‘transcriptional’ com
plex containing SR
 
0.119 
 
183 
proteins and R
N
A polym
erase II 
P27708 
C
AD
_H
U
M
AN
 
C
AD
 protein 
Fusion protein  
0.119 
Q
9Y678 
C
O
PG
1_H
U
M
AN
 
C
oatom
er subunit gam
m
a-1 
M
ediates biosynthetic protein transport form
 the ER
 
0.108 
Q
12906 
ILF3_H
U
M
A
N
 
Interleukin enhancer-binding factor 3 
Essential role in biogenesis of circular R
N
As 
0.107 
Q
9U
Q
35 
SR
R
M
2_H
U
M
A
N
 
Serine/arginine repetitive m
atrix protein 2 
Involved in pre-m
R
N
A
 splicing 
0.105 
Q
16658 
FSC
N
1_H
U
M
AN
 
Fascin 
R
ole in organization of actin filam
ent 
0.093 
Q
6P2Q
9 
PR
PF8_H
U
M
A
N
 
Pre-m
R
N
A
-processing splicing factor 8 
R
N
A
 binding 
0.092 
P60953 
C
D
C
42_H
U
M
AN
 
C
ell division control protein 42 hom
olog 
Apolipoprotein A
-I receptor binding 
0.091 
Q
15907 
R
AB
11B_H
U
M
A
N
 
R
as-related protein R
ab-11B
 
Key regulators of intracellular m
em
brane trafficking 
0.09 
O
95747 
O
X
SR
1_H
U
M
AN
 
Serine/threonine-protein kinase O
S
R
1 
ATP binding 
0.09 
 
R
PS
5_H
U
M
A
N
 
40S ribosom
al protein S
5 
m
R
N
A
 binding 
0.087 
P18583 
SO
N
_H
U
M
A
N
 
Protein SO
N
 
R
N
A-binding protein 
0.087 
P35658 
N
U
P
214_H
U
M
AN
 
N
uclear pore com
plex protein N
up214 
Serves as a docking site for substrates in nuclear pore 
com
plex 
0.086 
P48444 
AR
C
N
1_H
U
M
AN
 
C
oatom
er subunit delta 
R
N
A
 binding 
0.082 
P36507 
M
A
P2K2_H
U
M
AN
 
D
ual specificity m
itogen-activated protein 
kinase kinase 2 
Activates ER
K1 and ER
K2 M
A
P K
inases 
0.072 
 
184 
O
75533 
SF3B
1_H
U
M
AN
 
Splicing factor 3B subunit 1 
Involved in pre-m
R
N
A
 splicing as a com
ponent of splicing 
factor SF3B com
plex 
0.067 
P62249 
R
PS
16_H
U
M
AN
 
40S ribosom
al protein S
16 
R
N
A
 binding 
0.064 
P48506 
G
C
LC
_H
U
M
A
N
 
G
lutam
ate cysteine ligase catalytic 
subunit 
A
D
P binding 
0.06 
Q
01628 
IFITM
3_H
U
M
AN
 
Interferon-induced transm
em
brane 
protein 3 
IFN
-induced antiviral protein 
0.06 
Q
99613 
EIF3C
_H
U
M
AN
 
Eukaryotic translation initiation factor 3 
subunit C
 
C
om
ponent of eukaryotic translation initiation factor 3 
com
plex 
0.059 
Q
96K
B5 
PB
K_H
U
M
A
N
 
Lym
phokine-activated killer T-cell-
originated protein kinase 
Phosphorylates M
AP kinase p38 
0.056 
P23246 
SFPQ
_H
U
M
AN
 
Splicing factor, proline and glutam
ine rich 
D
N
A
 and R
N
A
 binding protein 
0.041 
Q
9U
N
H
7 
SN
X
6_H
U
M
A
N
 
Sorting nexin-6 
Involved in intracellular trafficking 
0.038 
O
00487 
PS
M
D
14_H
U
M
AN
 
26S proteasom
e non-ATPase regulatory 
subunit 14 
C
om
ponent of 26S proteasom
e 
0.038 
P08133 
AN
X
A6_H
U
M
AN
 
Annexin A6 
R
egulates release of C
a
2+ from
 intracellular stores 
0.038 
P55060 
C
SE
1L_H
U
M
AN
 
Exportin-2 
Export receptor for im
portin-alpha 
0.033 
 
185 
P53618 
C
O
PB
1_H
U
M
AN
 
C
oatom
er subunit beta 
Vesicle m
ediated transport from
 endoplasm
ic reticulum
 to 
G
olgi apparatus 
0.029 
Q
9U
B
E0 
SA
E1_H
U
M
AN
 
SU
M
O
-activating enzym
e subunit 1 
Involved in the pathw
ay for protein sum
oylation 
0.029 
P15144 
A
N
PEP_H
U
M
A
N
 
A
m
inopeptidase N
 
A
m
inopeptidase activity  
0.022 
Q
13526 
PIN
1_H
U
M
AN
 
Peptidyl-prolyl cis-trans isom
erase N
IM
A
-
interacting 1 
Involved in cell cycle and beta-catenin binding 
0.019 
Q
9U
EW
8 
STK39_H
U
M
AN
 
STE20/SP
S1-related proline-alanine-rich 
protein kinase 
M
ediator of stress-activated signals 
0.018 
P60033 
C
D
81_H
U
M
AN
 
C
D
81 antigen 
Involved in integrin binding and have a role in activation of 
M
A
PK activity 
0.007 
Q
12802 
A
K
A
P13_H
U
M
AN
 
A
-kinase anchor protein 13 
cAM
P-dependent protein kinase activity 
0.005 
Q
0JR
Z9 
FC
H
O
2_H
U
M
AN
 
F-BAR
 dom
ain only protein 2 
H
as a role in early step clathrin-m
ediated endocytosis 
0.005 
Q
9N
Q
W
7 
X
PN
P
EP1_H
U
M
AN
 
X
aa-Pro am
inopeptidase 1 
H
as a role in degradation of bradykinin 
0.004 
P25786 
PS
M
A
1_H
U
M
AN
 
Proteasom
e subunit alpha type-1 
C
om
ponent of the 20S core proteasom
e com
plex 
-0.003 
P21281 
ATP6V1B2_H
U
M
AN
 
V-type proton ATPase subunit B
 
ATP binding 
-0.015 
P61956 
SU
M
O
2_H
U
M
AN
 
Sm
all ubiquitin-related m
odifier 2 
U
biquitin like protein– covalently bound to another protein or 
free 
-0.016 
 
186 
Q
6R
W
13 
AG
TR
AP_H
U
M
A
N
 
Type-1 angiotensin II receptor-associated 
protein 
Angiotensin type II receptor activity 
-0.02 
P38919 
EIF4A3_H
U
M
AN
 
Eukaryotic initiation factor 4A
-III 
ATP-dependent R
N
A helicase 
-0.021 
Q
96FX
7 
TR
M
T61A_H
U
M
A
N
 
tR
N
A
-m
ethyltransferase catalytic subunit 
TR
M
T61A
 
m
R
N
A
-m
ethyltransferase activity 
-0.028 
Q
9Y696 
C
LIC
4_H
U
M
AN
 
C
hloride intracellular channel protein 4 
C
hloride channel activity 
-0.029 
Q
9Y230 
R
U
V
BL2_H
U
M
AN
 
R
uvB-like 2 
AD
P
 binding 
-0.031 
P10809 
H
SP
D
1_H
U
M
AN
 
60 kD
a heat shock protein 
Apolipoprotein A
-I binding 
-0.031 
P36776 
LO
N
P1_H
U
M
AN
 
Lon protease hom
olog 
AD
P
 binding 
-0.032 
P38606 
ATP6V1A_H
U
M
AN
 
V
-type proton ATPase catalytic subunit A
 
C
atalytic subunit of peripheral V
1 com
plex of vacuolar 
ATPase 
-0.059 
Q
6PKG
0 
LAR
P1_H
U
M
AN
 
La-related protein 1 
R
N
A-binding protein that prom
otes translation of m
R
N
A
s 
dow
nstream
 of the m
TO
R
C
1 com
plex 
-0.062 
P46783 
R
PS
10_H
U
M
AN
 
40S ribosom
al protein S
10 
C
om
ponent of 40S ribosom
al subunit 
-0.078 
Q
13573 
SN
W
1_H
U
M
AN
 
SN
W
 dom
ain-containing protein 1 
Involved in pre-m
R
N
A
 splicing 
-0.078 
Q
9Y5S2 
C
D
C
42BP
B_H
U
M
AN
 
Serine/threonine-protein kinase M
R
C
K 
Im
portant com
ponent of C
D
C
42 and role in cell m
igration 
-0.081 
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beta 
O
14980 
X
PO
1_H
U
M
AN
 
Exportin-1 
M
ediates nuclear export of cellular proteins 
-0.083 
Q
15459 
SF3A
1_H
U
M
AN
 
Splicing factor 3A subunit 1 
R
N
A
 binding 
-0.086 
Q
7KZ85 
SU
PT6H
_H
U
M
AN
 
Transcription elongation factor SPT6 
Transcription elongation factor 
-0.089 
P62306 
SN
R
PF_H
U
M
AN
 
Sm
all nuclear ribonucleoprotein F 
H
as a role in pre-m
R
N
A
 splicing 
-0.089 
Q
9Y5X
1 
SN
X
9_H
U
M
A
N
 
Sorting nexin-9 
Involved in endocytosis and intracellular vesicle trafficking 
-0.09 
P24928 
PO
LR
2A_H
U
M
AN
 
D
N
A
-directed R
N
A
 polym
erase II subunit 
R
PB
1 
D
N
A
 binding 
-0.093 
P60891 
PR
P
S1_H
U
M
AN
 
R
ibose-phosphate pyrophosphokinase 1 
C
atalyses the synthesis of phosphoribosyl pyrophosphate 
(PR
P
P) needed for nucleotide synthesis 
-0.1 
Q
92905 
C
O
PS
5_H
U
M
AN
 
C
O
P9 signalosom
e com
plex subunit 5 
Part of the C
S
N
 com
plex w
hich is essential in ubiquitin 
conjugation pathw
ay 
-0.101 
P51452 
D
U
S
P3_H
U
M
AN
 
D
ual specificity protein phosphatase 3 
C
ytoskeletal protein binding 
-0.102 
P40429 
R
PL13A
_H
U
M
AN
 
60S ribosom
al protein L13a 
m
R
N
A
 binding 
-0.103 
Q
9H
0H
5 
R
A
C
G
A
P1_H
U
M
A
N
 
R
ac G
TPase-activating protein 1 
A
lpha-tubulin binding 
-0.105 
P16220 
C
R
EB
1_H
U
M
A
N
 
C
yclic AM
P-responsive elem
ent-
binding protein 1 
Phosphorylation-dependent transcription that stim
ulates 
transcription 
-0.105 
 
188 
P78406 
R
AE
1_H
U
M
A
N
 
m
R
N
A
 export factor 
Binds m
R
N
A
, and has a role in m
itotic bipolar spindle 
form
ation  
-0.106 
P61421 
ATP6V0D
1_H
U
M
AN
 
V-type proton ATPase subunit d 1 
Protein-containing com
plex binding 
-0.108 
O
75348 
ATP6V1G
1_H
U
M
AN
 
V-type proton ATPase subunit G
1 
ATPase binding 
-0.109 
Q
04206 
R
ELA_H
U
M
A
N
 
Transcription factor p65 
Involved in the N
F-kappa-B
 com
plex such as inflam
m
ation, 
im
m
unity, differentiation, cell grow
th 
-0.11 
O
43865 
AH
C
YL1_H
U
M
AN
 
S
-adenosylhom
ocysteine hydrolase-like 
protein 1 
R
N
A
 binding and identical protein binding 
-0.127 
P08621 
SN
R
N
P70_H
U
M
AN
 
U
1 sm
all nuclear ribonucleoprotein 70 
kD
a 
m
R
N
A
 binding 
-0.134 
Q
7L7X
3 
TAO
K1_H
U
M
AN
 
Serine/threonine-protein kinase TAO
1 
Involved in p38/M
AP
K14 stress-activated M
A
PK cascade 
-0.144 
P11182 
D
BT_H
U
M
A
N
 
Lipoam
ide acyltransferase com
ponent of 
branched-chain alpha-keto acid 
dehydrogenase com
plex 
Acetyltransferase activity 
-0.161 
P42766 
R
PL35_H
U
M
AN
 
60S ribosom
al protein L35 
C
om
ponent of large ribosom
al subunit 
-0.161 
P28482 
M
A
PK
1_H
U
M
AN
 
M
itogen-activated protein kinase 1 
Essential com
ponent of the M
A
P kinase signal transduction 
pathw
ay 
-0.165 
 
189 
P68032 
AC
TC
1_H
U
M
AN
 
Actin, alpha cardiac m
uscle 1 
Involved in cell m
otility 
-0.165 
O
00754 
M
AN
2B
1_H
U
M
A
N
 
Lysosom
al alpha-m
annosidase 
A
lpha-m
annosidase activity 
-0.169 
P62861 
FAU
_H
U
M
A
N
 
40S ribosom
al protein S
30 
R
N
A
 binding 
-0.171 
P35606 
C
O
PB
2_H
U
M
AN
 
C
oatom
er subunit beta 
M
ediates biosynthetic protein transport from
 endoplasm
ic 
reticulum
 
-0.198 
Q
9N
R
R
5 
U
BQ
LN
4_H
U
M
AN
 
U
biquilin-4 
R
ole in regulation of protein degradation 
-0.208 
Q
13177 
PA
K2_H
U
M
AN
 
Serine/threonine-protein kinase P
A
K 2 
R
ole in signalling pathw
ays including cytoskeleton regulation, 
cell m
otility cell cycle progression, apoptosis or proliferation 
-0.225 
P41743 
PR
K
C
I_H
U
M
A
N
 
Protein kinase C
 iota type 
R
ole in protective role against apoptotic stim
uli involved 
in N
F-K
appa-B
 
-0.24 
P98194 
ATP2C
1_H
U
M
AN
 
C
alcium
-transporting ATPase type 2C
 
m
em
ber 1 
Transport of calcium
 
-0.253 
P63165 
SU
M
O
1_H
U
M
AN
 
Sm
all ubiquitin-related m
odifier 1 
U
biquitin – covalently bound to another protein or free 
-0.334 
P61769 
B2M
_H
U
M
AN
 
Beta-2-m
icroglobulin 
It’s a com
ponent of class I m
ajor histocom
patibility com
plex 
(M
H
C
) 
-0.363 
Q
8TD
19 
N
EK
9_H
U
M
A
N
 
Serine/threonine-protein kinase N
ek9 
R
egulates m
itotic progression 
-0.413 
Q
8N
BM
4 
U
BA
C
2_H
U
M
AN
 
U
biquitin-associated dom
ain-containing 
R
estricts trafficking of FA
F2 from
 endoplasm
ic reticulum
 to 
-0.445 
 
190 
protein 2 
lipid droplets 
Q
92621 
N
U
P
205_H
U
M
AN
 
N
uclear pore com
plex protein N
up205 
R
ole in nuclear pore com
plex (N
PC
) assem
bly 
-0.525 
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The IAV proteins highlighted in Table 3.4 and the IAV transcripts in Table 3.6 
confirm the presence of IAV infection in the cells and the ongoing process of 
viral replication in vitro. The host proteins highlighted in Tables 3.5, 3.6, and 
3.8 show the potential of the Q-Exactive Mass Spectrometry in combination 
with bioinformatic analysis to categorise and highlight host proteins involved 
in IAV pathogenesis. The IPA further connects the proteins identified into 
networks based on their function. These pathways are a visual representation 
of the changes occurring in the host cell after IAV infection. The pathways 
below (Figure 3.8) highlight the proteins involved in the immune response and 
activation of proteins known to exacerbate the IAV pathogenesis.  
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Figure 3.8: Network pathway analysis of proteins identified in A549 cells 
infected with IAV compared to mock-infected cells. The network highlights 
proteins increased or decreased in protein abundance. Proteins in red 
highlight a two-fold or more increase in abundance, while proteins in green 
highlight a two-fold or more decrease in abundance when comparing the IAV 
infected samples to mock-infected samples. The lines with solid arrows 
represent a direct molecular interaction with one protein initiating the other 
and the dashed arrows an indirect molecular interaction with one protein 
potentially initiating the other. Strong lines without an arrow show a 
relationship between two protein molecules and dashed lines without an arrow 
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show an assumed relationship between two protein molecules. Strong lines 
or dashed lines with a dash at the end are inhibitory to that protein. The 
proteins that were not highlighted were not identified in the dataset but are 
indirectly involved in these pathways. 
 
3.14 Identification of the transcriptome in IAV infected A549 cells 
compared to mock-infected cells at MOI 1 at 18h.p.i by MinION 
sequencing  
A549 cells were infected with IAV X31 and compared to mock-infected cells. 
The RNA was extracted and subjected to the MinION for sequencing (Chapter 
2, section 2.8). Differential gene expression (DEG) analysis was used to 
process the data obtained from these experiments. To the best of our 
knowledge, this is the first study to explore the viral (IAV) host (A549 cells – 
in vitro) interaction using MinION sequencing and analysed for DEG. To the 
best of our knowledge, DEG following MinION sequencing has been 
conducted in only one published paper. The same data analysis method was 
used in this chapter (261). 139 IAV transcripts pertaining to five segments of 
the IAV genome were identified (Table 3.7). The presence of these transcripts 
from IAV segments confirm the cells were infected with IAV.  
 
Table 3.7: 139 Influenza A viral transcripts from five segments 
identified by MinION sequencing (327) 
 
194 
 
Influenza A
 viral transcripts 
1 
Influenza A virus (A/reassortant/N
YM
C
 X
-203A
 (A/Puerto R
ico/8/1934 x A/M
innesota/11/2010) (H
3N
2)) segm
ent 1 polym
erase P
B2 (P
B
2) gene 
2 
Influenza A virus (A/Tehran/Sm
03/2015[H
1N
1]) segm
ent 1 polym
erase PB
2 (P
B2) gene, com
plete cds 
3 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
4 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
5 
Influenza A virus (A/N
etherlands/M
1/1957[H
2N
2]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
6 
Influenza A virus (A/reassortant/X
-139[X
-31B x N
ew
 C
aledonia/20/1999] [H
1N
1]) segm
ent 1 polym
erase PB
2 (P
B
2) gene, com
plete cds 
7 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012(H
6N
1)) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
8 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
9 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
10 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
03_S
21 segm
ent 1 polym
erase PB
2 (P
B2) gene, 
com
plete cds 
11 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
12 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
13 
Influenza A virus (A/P
uerto R
ico/8/1934(H
1N
1)) R
N
A, segm
ent 1, com
plete sequence 
14 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
15 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
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16 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
17 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
18 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
19 
Influenza A virus (A/P
uerto R
ico/8/1934[H
1N
1]) R
N
A, segm
ent 1, com
plete sequence 
20 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
21 
Influenza A virus (A/P
R
/8/34[H
1N
1]) m
R
N
A
 for hypothetical protein, strain A
/PR
/8/34 
22 
Influenza A virus (A/P
uerto R
ico/8/1934[H
1N
1]) polym
erase P
B2 (PB
2) gene, com
plete cds 
23 
Influenza A virus (A/reassortant/X
-139[X
-31B x N
ew
 C
aledonia/20/1999] [H
1N
1]) segm
ent 1 polym
erase PB
2 (P
B
2) gene, com
plete cds 
24 
Influenza A virus (A/P
uerto R
ico/8-SV
7/1934[H
1N
1]) polym
erase P
B2 (PB
2) gene, com
plete cds 
25 
Influenza A virus (A/lvPR
8/34[H
1N
1]) segm
ent 1, com
plete sequence 
26 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
03_S
21 segm
ent 1 polym
erase PB
2 (P
B2) gene, 
com
plete cds 
27 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
03_S
21 segm
ent 1 polym
erase PB
2 (P
B2) gene, 
com
plete cds 
28 
Influenza A virus (A/reassortant/X
-175C
 (U
ruguay/716/2007 x Puerto R
ico/8/1934) [H
3N
2]) segm
ent 1 polym
erase P
B2 (PB
2) gene, com
plete cds 
29 
Influenza A virus (A/lvPR
8/34[H
1N
1]) segm
ent 1, com
plete sequence 
30 
Influenza A virus (A/sw
ine/IL/00685/2005[H
1N
1]) segm
ent 1 polym
erase P
B2 (P
B2) gene, com
plete cds 
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31 
Influenza A virus (A/Tehran/Sm
03/2015[H
1N
1]) segm
ent 1 polym
erase PB
2 (P
B2) gene, com
plete cds 
32 
Influenza A virus (A/Tehran/Sm
03/2015[H
1N
1]) segm
ent 1 polym
erase PB
2 (P
B2) gene, com
plete cds 
33 
Influenza A virus (A/P
uerto R
ico/8/34[H
1N
1]) segm
ent 1, com
plete sequence 
34 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
03_S
21 segm
ent 1 polym
erase PB
2 (P
B2) gene, 
com
plete cds 
35 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
36 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
37 
Influenza A virus (A/chicken/H
enan/nd/1998[H
9N
2]) non-functional polym
erase basic protein 2 (P
B2) gene, partial sequence 
38 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone A
O
03_S
21 segm
ent 1 polym
erase PB
2 (P
B2) gene, 
com
plete cds 
39 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
03_S
21 segm
ent 1 polym
erase PB
2 (P
B2) gene, 
com
plete cds 
40 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A
 4 (from
 seg 1), in defective interfering virus 
41 
Influenza A virus (A/Tehran/Sm
03/2015[H
1N
1]) segm
ent 1 polym
erase PB
2 (P
B2) gene, com
plete cds 
42 
Influenza A Virus (A/Fiji/15899/83[H
1N
1]) m
R
N
A
 for P
B2 protein 
43 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
03_S
21 segm
ent 1 polym
erase PB
2 (P
B2) gene, 
com
plete cds 
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44 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
03_S
21 segm
ent 1 polym
erase PB
2 (P
B2) gene, 
com
plete cds 
45 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
03_S
21 segm
ent 1 polym
erase PB
2 (P
B2) gene, 
com
plete cds 
46 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
47 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
48 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
49 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
50 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
51 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
52 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
53 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
54 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
55 
Influenza A/Puerto R
ico/8/34 (H
1N
1), subgenom
ic R
N
A 4 (from
 seg 1), in defective interfering virus 
56 
Influenza A virus (A/reassortant/N
YM
C
 X
-211B
 (N
YM
C
 X
-157 x St. P
etersburg/100/2011)[H
1N
1]) polym
erase PB
2 (P
B2) gene, com
plete cds 
57 
Influenza A virus (A/sw
ine/Q
C
/382/2009[H
3N
2]) segm
ent 1 polym
erase P
B2 (P
B
2) gene, com
plete cds 
58 
Influenza A virus (A/m
ink/Shandong/F10/2013[H
9N
2]) segm
ent 1 polym
erase PB
2 (P
B
2) gene, com
plete cds 
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59 
Influenza A virus (A/m
allard/W
isconsin/1107/1982[H
11N
9]) polym
erase P
B2 (PB2) gene, com
plete cds 
60 
Influenza A virus (A/lvPR
8/34[H
1N
1]) segm
ent 1, com
plete sequence 
61 
Influenza A virus (A/Tehran/Sm
03/2015[H
1N
1]) segm
ent 1 polym
erase PB
2 (P
B2) gene, com
plete cds 
62 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 2 polym
erase P
B1 (P
B1) gene, com
plete cds 
63 
Influenza A virus (A/P
uerto R
ico/8H
Y/1934[H
1N
1]) segm
ent 2 polym
erase P
B1 (P
B1) gene, com
plete cds 
64 
Influenza A virus (A/N
YM
C
 X
-157B (P
uerto R
ico/8/1934-N
ew
 York/55/2004) [H
3N
2]) segm
ent 2, com
plete sequence 
65 
Influenza A virus (A/P
uerto R
ico/8/1934[H
1N
1]) R
N
A, segm
ent 2, com
plete sequence 
66 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
09_S
3 segm
ent 2 polym
erase P
B1 (PB
1) gene, 
com
plete cds 
67 
Influenza A virus (A/reassortant/N
YM
C
 X
-153A
 (Texas/40/2003 x Puerto R
ico/8/1934) [H
3N
2]) polym
erase P
B1 (P
B1) and P
B1-F2 protein (P
B1-
F2) genes, com
plete cds 
68 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
09_S
3 segm
ent 2 polym
erase P
B1 (PB
1) gene, 
com
plete cds 
69 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
09_S
3 segm
ent 2 polym
erase P
B1 (PB
1) gene, 
com
plete cds 
70 
Influenza A virus (A
/turkey/O
H
/313053_C
IP046_R
G
JS
71/2004[H
3N
2]) clone JS
71_S
17 segm
ent 3 polym
erase PA
 (PA) and P
A
-X
 protein (P
A
-X
) 
genes, com
plete cds 
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71 
Influenza A virus (A/P
uerto R
ico/8-C
V9/1934[H
1N
1]) polym
erase P
A (P
A) gene, com
plete cds 
72 
Influenza A virus (A/B
eijing/1/1968[H
3N
2]) hem
agglutinin (H
A) gene, com
plete cds 
73 
Influenza A virus (A/B
ilthoven/908/1969[H
3N
2]) hem
agglutinin (H
A) gene, com
plete cds 
74 
Influenza A virus (A/P
uerto R
ico/8/1934[H
1N
1]) gene for nucleoprotein, genom
ic R
N
A
 
75 
Influenza A virus (A/P
uerto R
ico/8/1934[H
1N
1]) gene for nucleoprotein, genom
ic R
N
A
 
76 
Influenza A virus (A/P
uerto R
ico/8/1934[H
1N
1]) gene for nucleoprotein, genom
ic R
N
A
 
77 
Influenza A virus (A/P
uerto R
ico/8-1-M
A/1934[H
1N
1]) segm
ent 5, com
plete sequence 
78 
Influenza A virus (A/B
el/1942[H
1N
1]) segm
ent 5, com
plete sequence 
79 
Influenza A virus (X
-31[H
3N
2]) R
N
A segm
ent 5 for N
P, com
plete sequence 
80 
Influenza A virus (X
-31[H
3N
2]) R
N
A segm
ent 5 for N
P, com
plete sequence 
81 
Influenza A virus (X
-31[H
3N
2]) R
N
A segm
ent 5 for N
P, com
plete sequence 
82 
Influenza A virus (A/reassortant/X
-139(X
-31B x N
ew
 C
aledonia/20/1999) [H
1N
1]) segm
ent 5 nucleocapsid protein (N
P
) gene, com
plete cds 
83 
Influenza A virus (X
-31[H
3N
2]) R
N
A segm
ent 5 for N
P, com
plete sequence 
84 
Influenza A virus (A/P
uerto R
ico/8/1934[H
1N
1]) gene for nucleoprotein, genom
ic R
N
A
 
85 
Influenza A virus (A/P
uerto R
ico/8H
Y/1934[H
1N
1]) segm
ent 5 nucleoprotein (N
P) gene, com
plete cds 
86 
Influenza A virus (A/guineafow
l/H
ong K
ong/W
F10_C
IP
046_R
G
AO
032/1999[H
9N
1]) clone AO
09_S
3 segm
ent 5 nucleocapsid protein (N
P) gene, 
com
plete cds 
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87 
Influenza A virus (X
-31[H
3N
2]) R
N
A segm
ent 5 for N
P, com
plete sequence 
88 
Influenza A virus (A/P
uerto R
ico/8/1934[H
1N
1]) nucleocapsid protein (N
P) gene, com
plete cds 
89 
Influenza A virus (X
-31[H
3N
2]) R
N
A segm
ent 5 for N
P, com
plete sequence 
90 
Influenza A virus (A/reassortant/N
YM
C
 X
-223(A
/Puerto R
ico/8/1934 x A/Texas/50/2012) [H
3N
2]) segm
ent 5 nucleocapsid protein (N
P
) gene, 
com
plete cds 
91 
Influenza A virus (A/P
uerto R
ico/8-1-M
A/1934[H
1N
1]) segm
ent 5, com
plete sequence 
92 
Influenza A virus (A/w
hite-rum
ped sandpiper/Lagoa do Peixe/R
S1167/2012[H
6N
1]) segm
ent 7 m
atrix protein 2 (M
2) and m
atrix protein 1 (M
1) 
genes, com
plete cds 
93 
Influenza A virus (A/N
anC
hang/08/2010[H
1N
1]) segm
ent 7 m
atrix protein 2 (M
2) and m
atrix protein 1 (M
1) genes, com
plete cds 
94 
Influenza A virus (A/P
uerto R
ico/8/34/M
ount Sinai/W
i[H
1N
1]) m
atrix protein 2 m
R
N
A
, partial cds 
95 
Influenza A virus (A/P
uerto R
ico/8/34/M
ount Sinai/W
i-M
2-P10L[H
1N
1]) m
atrix protein 2 m
R
N
A
, partial cds 
96 
Influenza A virus (A/P
uerto R
ico/8/34/M
ount Sinai/W
i[H
1N
1]) m
atrix protein 2 m
R
N
A
, partial cds 
97 
Influenza A virus (A/P
uerto R
ico/8/34/M
ount Sinai/W
i[H
1N
1]) m
atrix protein 2 m
R
N
A
, partial cds 
98 
Influenza A virus (A/S
ofia/1250/2006[H
3N
2]) m
atrix protein 2 (M
2) gene, partial cds; and m
atrix protein 1 (M
1) gene, com
plete cds 
100 
Influenza A virus (A/reassortant/X
-139(X
-31B x N
ew
 C
aledonia/20/1999) [H
1N
1]) segm
ent 8 nuclear export protein (N
E
P) and non-structural 
protein 1 (N
S1) genes, com
plete cds 
101 
Influenza A virus (A/Leningrad/1954/1[H
1N
1]) gene for non-structural protein, genom
ic R
N
A
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102 
Influenza A virus (A/Leningrad/1954/1[H
1N
1]) gene for non-structural protein, genom
ic R
N
A
 
103 
Influenza A virus (A/P
uerto R
ico/8H
Y/1934[H
1N
1]) segm
ent 8 nuclear export protein (N
EP) and non-structural protein (N
S1) genes, com
plete cds 
104 
Influenza A virus (A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934)[H
3N
2]) segm
ent 8 sequence 
105 
Influenza A virus (A/P
uerto R
ico/8H
Y/1934[H
1N
1]) segm
ent 8 nuclear export protein (N
EP) and non-structural protein (N
S1) genes, com
plete cds 
106 
Influenza A virus (A/P
uerto R
ico/8H
Y/1934[H
1N
1]) segm
ent 8 nuclear export protein (N
EP) and non-structural protein (N
S1) genes, com
plete cds 
107 
Influenza A virus (A/Brevig_M
ission/1/18[H
1N
1]) non-structural protein N
S1 and non-structural protein N
S
2 genes, com
plete cds 
108 
Influenza A virus (A/P
uerto R
ico/8H
Y/1934(H
1N
1)) segm
ent 8 nuclear export protein (N
EP) and non-structural protein (N
S1) genes, com
plete cds 
109 
Influenza A virus (A/reassortant/X
147[W
yom
ing/3/2003 x Puerto R
ico/8/1934] [H
3N
2]) segm
ent 8 sequence 
110 
Influenza A virus (A/reassortant/X
147[W
yom
ing/3/2003 x Puerto R
ico/8/1934][H
3N
2]) segm
ent 8 sequence 
111 
Influenza A virus (A/turkey/O
H
/313053_C
IP046_R
G
JS
71/2004[H
3N
2]) clone JS
71_S
17 segm
ent 8 nuclear export protein (N
E
P) and non-structural 
protein 1 (N
S1) genes, com
plete cds 
112 
Influenza A virus (A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934) [H
3N
2]) segm
ent 8 sequence 
113 
Influenza A virus (A/reassortant/N
YM
C
 X
-197(B
risbane/11/2010 x P
uerto R
ico/8/1934) [H
3N
2]) segm
ent 8 nuclear export protein (N
E
P) and non-
structural protein 1 (N
S1) genes, com
plete cds 
114 
Influenza A virus (A/P
uerto R
ico/8H
Y/1934[H
1N
1]) segm
ent 8 nuclear export protein (N
EP) and non-structural protein (N
S1) genes, com
plete cds 
115 
Influenza A virus (A/P
uerto R
ico/8/1934[H
1N
1]) R
N
A, segm
ent 8, com
plete sequence 
116 
Influenza A virus (A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934) [H
3N
2]) segm
ent 8 sequence 
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117 
Influenza A virus (A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934) [H
3N
2]) segm
ent 8 sequence 
118 
Influenza A virus (A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934) [H
3N
2]) segm
ent 8 sequence 
119 
Influenza A virus (A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934) [H
3N
2]) segm
ent 8 sequence 
120 
Influenza A virus (A/P
uerto R
ico/8H
Y/1934[H
1N
1]) segm
ent 8 nuclear export protein (N
EP) and non-structural protein (N
S1) genes, com
plete cds 
121 
Influenza A virus (A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934) [H
3N
2]) segm
ent 8 sequence 
122 
Influenza A virus (A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934) [H
3N
2]) segm
ent 8 sequence 
123 
Influenza A virus (A/P
uerto R
ico/8/1934[H
1N
1]) non-structural protein 2 (N
S
2) and non-structural protein 1 (N
S1) genes, com
plete cds 
124 
Influenza A virus [A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934] [H
3N
2]) segm
ent 8 sequence 
125 
Influenza A virus (A/lvPR
8/34[H
1N
1]) segm
ent 8, com
plete sequence 
126 
Influenza A virus (A/H
enry/1936[H
1N
1]) segm
ent 8, com
plete sequence 
127 
Influenza A virus (A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934) [H
3N
2]) segm
ent 8 sequence 
128 
Influenza A virus (A/P
uerto R
ico/8H
Y/1934(H
1N
1)) segm
ent 8 nuclear export protein (N
EP) and non-structural protein (N
S1) genes, com
plete cds 
129 
Influenza A virus (A/lvPR
8/34[H
1N
1]) segm
ent 8, com
plete sequence 
130 
Influenza A virus (A/reassortant/N
YM
C
 X
-197(B
risbane/11/2010 x P
uerto R
ico/8/1934) [H
3N
2]) segm
ent 8 nuclear export protein (N
E
P) and non-
structural protein 1 (N
S1) genes, com
plete cds 
131 
Influenza A virus (A/N
anC
hang/08/2010[H
1N
1]) segm
ent 8 nuclear export protein (N
EP) and non-structural protein 1 (N
S1) genes, com
plete cds 
132 
Influenza A virus (A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934) [H
3N
2]) segm
ent 8 sequence 
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133 
Influenza A virus (A/reassortant/X
147(W
yom
ing/3/2003 x Puerto R
ico/8/1934) [H
3N
2]) segm
ent 8 sequence 
134 
Influenza A virus (A/N
anC
hang/08/2010[H
1N
1]) segm
ent 8 nuclear export protein (N
EP) and non-structural protein 1 (N
S1) genes, com
plete cds 
135 
Influenza A virus (A/P
uerto R
ico/8H
Y/1934[H
1N
1]) segm
ent 8 nuclear export protein (N
EP) and non-structural protein (N
S1) genes, com
plete cds 
136 
Influenza A virus (A/reassortant/N
YM
C
 X
-197[Brisbane/11/2010 x P
uerto R
ico/8/1934] [H
3N
2]) segm
ent 8 nuclear export protein (N
E
P) and non-
structural protein 1 (N
S1) genes, com
plete cds 
137 
Influenza A virus (A/reassortant/X
147[W
yom
ing/3/2003 x Puerto R
ico/8/1934] [H
3N
2]) segm
ent 8 sequence 
138 
Influenza A virus (A/reassortant/X
147[W
yom
ing/3/2003 x Puerto R
ico/8/1934] [H
3N
2]) segm
ent 8 sequence 
139 
Influenza A virus (A/P
uerto R
ico/8H
Y/1934[H
1N
1]) segm
ent 8 nuclear export protein (N
EP) and non-structural protein (N
S1) genes, com
plete cds 
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In addition to the IAV transcripts, a total of 1,878 host transcripts were 
identified to be differentially expressed when comparing IAV infected cells to 
mock-infected cells (data not shown). Amongst the transcripts highlighted 
were interferon stimulated genes, such as IFI27, IFI44, and genes from the 
integrin family. These datasets were subjected to bioinformatic analysis – IPA 
for further analysis. 
 
3.15 Bioinformatics Analysis - Ingenuity Pathway Analysis (IPA) 
The datasets obtained from MinION sequencing were analysed using 
Ingenuity Pathway Analysis (IPA) (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis). 
The highlighted transcripts were connected and categorised based on 
function, and different expression networks were generated using IPA. The 
data sets used contained accession gene identifiers, corresponding maximum 
fold change, and p-values and q-values were uploaded into the application. 
This analysis provided a deeper understanding of the dataset. This was to 
visualise the transcripts from the perspective of their function in the host, in 
response to the viral infection. 
 
IPA analysis of the datasets from MinION sequencing revealed 18 transcripts 
that have direct interactions with IAV replication (Table 3.8). Ten of these 18 
transcripts had their complementary protein identified by Mass Spectrometry 
(Table 3.9). These proteins were highlighted in bold.  These results are 
consistent between both techniques (MinION sequencing and Mass 
Spectrometry). Therefore, this increases confidence in the experiments and 
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techniques. Of these 10 transcripts, five transcripts were identified in a study 
using genome-wide RNA interference screening to identify cellular factors that 
play functional roles in the early replication of IAV in A549 cells infected with 
IAV (328). In addition, RABEP1, CBLL1, and MDM2 were identified by MinION 
sequencing, but not by Mass Spectrometry, and were grouped under the 
functional category – replication of IAV by IPA. These transcripts were also 
identified in a study using genome-wide RNA interference screening to identify 
cellular factors that play functional roles in the early replication of IAV in A549 
cells infected with IAV (328). This shows consistency and reliability in the 
experiments, techniques, and the results obtained in this chapter. 
 
 
Table 3.8: 18 transcriptomes highlighted by the MinION sequencing 
and connected through Ingenuity Pathway Analysis were in the 
category – Replication of Influenza A virus (the proteins in bold are those 
that were also highlighted when the data from Mass Spectrometry was 
subjected to IPA) 
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EN
SEM
B
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G
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G
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N
S
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Transcription factor E
3 
D
N
A
-binding transcription factor 
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E
N
S
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A
TN
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M
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ole of extracellular filam
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netw
orks 
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A
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E
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G
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R
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TPase-activating 
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E
N
S
T00000492398 
P
LK
3 
S
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K
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A
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M
P-dependent protein kinase 
9.087 
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13 
activity 
E
N
S
T00000494092 
D
M
A
P
1 
D
N
A
 m
ethyltransferase 1-
associated protein 1 
Involved in transcription repression and 
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E
N
S
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C
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K
appa-B
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ST00000422112 
H
PG
D
 
15-hydroxyprostaglandin 
dehydrogenase 
Prostaglandin inactivation 
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E
N
S
T00000544561 
M
D
M
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E
3 ubiquitin-protein ligase 
M
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M
ediates ubiquitination of p53/TP
53 
follow
ing degradation by proteasom
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EN
ST00000592202 
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B
M
42 
R
N
A
-binding protein 42 
B
inds 3’-untranslated region (U
TR
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of C
D
K
N
1A
 m
R
N
A
 
9.079 
EN
ST00000515460 
N
U
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N
ucleoporin p54 
C
om
ponent of nuclear pore com
plex 
needed for trafficking across the 
nuclear m
em
brane 
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EN
ST00000596591 
M
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N
2B
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Lysosom
al alpha-
m
annosidase 
A
lpha-m
annosidase activity 
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To analyse the datasets further, IPA was used to identify pathways that are 
affected by IAV infection in the host. This has a potential of highlighting 
pathways that are triggered to respond to IAV infection. IPA connects the 
transcripts identified into networks based on their function. These pathways 
are a visual representation of the changes occurring in the host cell. Two 
pathways were highlighted as the transcripts identified were involved in the 
immune response (Figure 3.8) and the activation of other transcripts known to 
have anti-viral roles in the host following IAV infection (Figure 3.9).  
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Figure 3.9: Network pathway analysis of transcripts identified in A549 cells 
infected with IAV compared to mock-infected cells. The network highlights 
transcripts with an increase in Log two-fold change involved in the immune 
response. Transcripts in red highlight a two-fold or more increase in transcript 
abundance when comparing the IAV infected samples to mock-infected 
samples. The lines with solid arrows represent a direct molecular interaction 
with one transcript initiating the other and the dashed arrows an indirect 
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molecular interaction with one transcript potentially initiating the other. Strong 
lines without an arrow show a relationship between two transcripts and 
dashed lines without an arrow show an assumed relationship between two 
transcripts molecules. Strong lines or dashed lines with a dash at the end are 
inhibitory to that transcript. The transcripts that were not highlighted were not 
identified in the dataset but are indirectly involved in these pathways. 
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Figure 3.10: Network pathway analysis of transcripts identified in A549 cells 
infected with IAV compared to mock-infected cells. The network highlights 
transcripts with an increase in Log two-fold change and directly or indirectly 
affect, or are affected by, Trim25. Trim 25 is known to have a crucial anti-viral 
role in IAV infection. Transcripts in red highlight a two-fold or more increase in 
abundance when comparing the IAV infected samples with mock-infected 
samples.  
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The lines with solid arrows represent a direct molecular interaction with one 
transcript initiating the other and the dashed arrows an indirect molecular 
interaction with one transcript potentially initiating the other. Strong lines 
without an arrow show a relationship between two transcripts and dashed 
lines without an arrow show an assumed relationship between two transcripts 
molecules. Strong lines or dashed lines with a dash at the end are inhibitory 
to that transcript. The transcripts that were not highlighted were not identified 
in the dataset but are indirectly involved in these pathways. 
3.16 Transcripts and proteins identified by Mass Spectrometry and 
MinION sequencing, respectively, when comparing IAV infected A549 
cells with mock-infected cells  
As mentioned above, after the data was obtained from the Mass 
Spectrometry, they were analysed through IPA. Through this analysis, the 
data were categorised into proteins and transcripts involved in the ‘replication 
of IAV’. The comparison of these datasets revealed 10 proteins identified by 
Mass Spectrometry also identified in the transcripts from the MinION 
sequencing data. These are highlighted in Table 3.9. 
 
 
Table 3.9: 10 proteins highlighted by Mass Spectrometry and 10 
transcripts highlighted by the MinION sequencing categorised by IPA 
under ‘replication of IAV’
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3.17 DISCUSSION 
The study of viruses has moved beyond the need to understand their 
pathology and association to disease, but more ultimately to identify important 
cellular, regulatory proteins, transcripts, and pathways involved in the 
elucidation, survival, and transmission of viruses in the host. The era of 
proteomics and transcriptomics has revolutionised the understanding of the 
host-viral pathogenesis, by providing important insights into the interaction 
between host cellular and viral proteins. This chapter focused on 
understanding host-viral interaction, in vitro by using two independent 
approaches: proteomics by Mass Spectrometry and transcriptomics by 
MinION sequencing after using other techniques – avicel plaque assay, 
immunofluorescence staining, and SDS-PAGE to confirm IAV infection and 
select the most appropriate time point for infection. Figures 3.4, 3.5, and 3.6 
show IAV infected cells (stained with NP) in comparison with mock-infected 
cells at different time points. Based on this data, 18h.p.i was selected for the 
proteomics and transcriptomics experiments. Samples were run on the Q-
Exactive in two biological replicates three years apart. Samples were run on 
the MinION sequencer in two biological replicates two weeks apart. 
 
Proteomic approaches, specifically label-free methodologies, has allowed the 
exploration of changes in the cellular proteome during IAV infection. The use 
of label-free Liquid Chromatography Mass Spectrometry (LC – MS) is not 
restricted to cells in vitro, but can be replicated in a wider range of samples, 
including clinical samples. Similarly, MinION sequencing has provided the 
ability to sequence RNA from samples in vitro and obtain a host transcriptome, 
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while comparing mock-infected samples to IAV-infected samples. A 
combination of the two-independent approaches provides information on a 
cell’s transcriptome and proteome. This provides another dimension in the 
understanding of the host following infection. MinION sequencing has eased 
the process of observing the transcriptomics of host-viral interaction efficiently 
with high reliability and at a lower cost. This is the first study that has used the 
MinION Sequencer to observe differential gene expressions of the global 
transcriptome to compare IAV-infected with mock-infected A549 cells.  
 
The experiments in this chapter followed an assumption of a correlation 
(positive or negative) between transcriptomics and proteomics data. The 
results in this chapter showed a positive correlation as can be seen in Table 
3.9 with 10 proteins identified by Mass Spectrometry and their corresponding 
transcripts identified by MinION sequencing. However, the change in 
expression by the log two-fold change, identified by these techniques, are 
significantly different. Although they both registered an increase in expression, 
MinION sequencing identified about a 300-fold increase in Log two-fold 
change compared to Mass Spectrometry. This suggests that the changes 
identified in the transcripts have reduced, in translation to proteins. This could 
be a result of post-transcription machinery and different half-lives (329). These 
include ubiquitination, phosphorylation, and localisation of proteins post-
transcriptionally. In addition to this, mRNA transcripts in eukaryotic cells have 
a reported half-life of 10–20h, while proteins’ half-life are 48–72h. The 
degradation of different proteins affects their half-lives and expression levels 
albeit their correlation to the mRNA transcript (329). In addition to this, external 
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factors, such as experimental and technical differences in the process of 
sample collection and data extraction could affect these expression 
differences. 
 
3.17.1 Analysing proteomic data from the Q-Exactive platform and 
bioinformatic analysis via IPA 
Data from the first biological run of samples on the Q-Exactive revealed a data 
set of 1,283 cellular and viral proteins. These proteins were differentially 
abundant when comparing mock-infected A549 cells to IAV X31 infected A549 
cells. This data set was analysed by focusing on proteins represented by two 
or more peptides to increase reliability in the dataset. Identified proteins 
without a maximum fold change, as well as keratins, were removed from the 
dataset. Keratins are considered common contaminants of LC-MS 
experiments (330). The differentially abundant proteins were segregated into 
proteins with increased abundance and proteins with decreased abundance. 
The dataset revealed a total of 33 proteins showing an increase in abundance 
(Table 3.2) and 58 proteins showing a decrease in abundance (Table 3.3).  
 
To increase accuracy and focus on the proteins showing the maximum fold 
change, the top 10 proteins significantly increase or decrease in abundance 
will be discussed. Myxovirus resistance host proteins (MX1 and MX2) had an 
increase in expression by Log two-fold change of 7.8. Interferon-induced 
protein with tetratricopeptide repeats three (IFIT3) and interferon-induced 
protein with tetratricopeptide repeats two (IFIT2) had an increase in 
expression by log two-fold change of 10.1 and 7.1 respectively. These 
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proteins are all part of the interferon (IFN)-induced pathway; this pathway is 
stimulated as a response to pathogen (bacteria or viral) entry (331, 332). The 
IFN-induced pathway serves as a means of communication between cells, 
thereby triggering protective defences of the immune system. Promyelocytic 
leukaemia (PML) had an increase in expression by Log two-fold change of 
2.9. PML located in the nucleoplasm and matrix-associated protein complexes 
responds to IAV infection by inhibiting viral replication (320, 333). The direct 
pathway by which PML acts is not known but it is thought to occur indirectly 
by modifying other cellular proteins (333). Other proteins present within this 
dataset are immunoglobulins (Ig), this suggests the activation of the immune 
system to combat foreign bodies – viruses.  
 
Contrarily, Interleukin-18 (IL18) had a decrease in expression by a Log two-
fold change of 5.5 and Integrin Beta 4 (ITB4) had a decrease in expression by 
Log two-fold change of 8.3. IL18 acts as a pro-inflammatory cytokine, induces 
IFN-gamma, and activates natural killer cells, as well as proliferates T 
lymphocytes. This is a main role in protective immunity (334). Mice, deficient 
in IL-18, produced a poor immune response (335). The decrease in 
abundance of IL-18 following IAV infection cannot be confirmed without further 
independent assays to validate the results.  
 
The quantitative proteomic analysis of the second biological repeat identified 
up to 3361 cellular and viral proteins. These proteins were obtained by 
comparing mock-infected A549 cells to IAV X31-infected A549 cells. This data 
set was quantified, analysed, and provided the protein abundance changes 
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which occurred following IAV X31 infection. The degree of change in 
abundance was represented by Log two-fold change per protein. Two IAV 
proteins were identified; NP and NS1A. NP had an increase in expression log 
two-fold change of 9.7 and NS1 had an increase in expression log two-fold 
change of 2.6. This proves that the A549 cells were infected and shows the 
high abundance viral proteins reach in host cells. Nine host cellular proteins 
were identified with differentially significant abundances. Similar to the first 
biological run, the Myxovirus resistance host protein (MX1) was highlighted 
and had an increase expression log two-fold change of 3.1. Integrin subunit 
alpha 6 (ITGA6) had an increase in expression log two-fold change of 1.6. IAV 
infection increases ITGA6 leading to epithelial cell apoptosis and an increase 
in collagen deposition (336, 337). These changes go on to cause pulmonary 
fibrosis and lead a host to acute lung injury and emphysema (338). 
 
Bioinformatics analysis was performed on these datasets using the software 
IPA. IPA further categorised these proteins based on function; 131 proteins 
highlighted were involved in the ‘replication of IAV’ (Table 3.6). Some of these 
proteins were highlighted on a transcript level by MinION sequencing. These 
were highlighted in bold in Table 3.8 and also reported in Table 3.9. The 
concordance of the dataset identified in both Q-Exactive and MinION 
sequencing brings confidence in the techniques and experiments used in this 
chapter. Further network analysis highlighted proteins, such as galectin 3 
(LGALS3) and galectin 1 (LGALS1) (Figure 3.8). Galectin 1 inhibits viral 
infectivity by binding to IAV. Galectin 1 has been used as a potential treatment 
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for IAV (H7N9) and experiments in mice showed a decrease in viral load, 
reduced lung inflammation, and increased mouse survival (339).  
 
3.17.2 Analysing transcriptomic data from the MinION sequencing 
platform and bioinformatic analysis via IPA 
MinION sequencing was used as an independent approach alongside 
proteomics to obtain the transcriptome of the host and observe transcriptomic 
changes in the host following IAV infection. This was also to explore whether 
the transcriptomic data compliments the proteomics data from Mass 
spectrometry, thus giving a deeper understanding of the host changes. This 
established the first in vitro study exploring the transcriptome of IAV-infected 
A549 cells compared with mock-infected cells using DEG analysis to discover 
quantitative changes in expression levels of identified transcripts. This dataset 
only contained transcripts that increased in log two-fold change when 
comparing IAV infected samples to mock-infected samples; 139 IAV 
transcripts pertaining to five IAV segments were identified (Table 3.7). The 
five IAV segments identified were 2, 3, 5, 7, and 8. A total of 1,878 host cellular 
transcripts were identified to have significantly different expression levels 
(Data not shown). Of these 1,878 transcripts, 18 of them were classified by 
IPA to be involved in replication of IAV and 10 of these 18 transcripts had their 
complementary protein identified by Mass Spectrometry (Table 3.9). Five of 
the 10 transcripts were identified in a study using genome-wide RNA 
interference screening, to identify cellular factors that play functional roles in 
the early replication of IAV in A549 cells infected with IAV (328, 340). The 
 223 
functional role of these transcripts identified by genome-wide RNA 
interference in IAV replication were as follows:  
ANPEP with a role in actin organisation and functions in intracellular transport 
and implicated in NP functions, such as transcription, replication, and 
genome-trafficking; AKAP13, RACGAP1, PRKCI with signalling roles in the 
IP3-PKC pathway; the binding and the presence of IAV HA protein to the cell 
is thought to activate the PKC pathway (340); PKC is thought to play a crucial 
role in the IAV entry into the cell; the use of a PKC inhibitor has shown an 
inhibition of the IAV entry into the cell (340); CREB1 has a signalling role in 
the MAPK pathway; the MAPK family has four subgroups that have been well 
studied; extracellular signal regulated kinases (ERKs), the p38 MAPK, c-jun 
N-terminal (JNK/SAPK) and ERK5/Big MAP kinase (BMK1) (340); influenza 
infection has been shown to activate all of these four subgroups – this 
promotes viral production and vRNP traffic; the activation of p38, JNK, and 
ERK lead to increased expression of inflammatory response (340-342). The 
activation of JNK goes further to activate the transcription factor activator 
protein -1 (AP1); AP1 is essential for the expression of IFNE and other antiviral 
cytokines; through its different subgroups, the MAPK pathway plays a crucial 
role in viral survival as well as inflammatory response to IAV infection (328, 
340); CREB1 plays a role in calcium regulation and signalling (328). This is 
essential in the entry of IAV into the cells via clathrin-mediated and clathrin-
independent pathways and the calcium levels have a role to play in the 
regulation of these pathways (343); NUP54 is another protein that was 
identified by Mass Spectrometry and the corresponding transcript identified by 
MinION sequencing (Table 3.9). NUP54 has a role in nuclear transport and is 
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also an influenza polymerase interacting protein. These proteins are essential 
for the viral replication and subsequently survival in the host (344). 
Some of the transcripts identified by MinION sequencing (Table 3.8) without 
complementary proteins highlighted by Mass Spectrometry have been 
identified to have roles in influenza replication in the host. RABEP1, CBLL1, 
and MDM3 were identified in genome-wide RNA interference screening to 
identify cellular factors that play functional roles in the early replication of IAV 
in A549 cells infected with IAV (328). TFE3, MATN3, PLK3, and DMAP1 were 
also identified in another genome-wide study, which focused on host cell 
factors needed for IAV infection (345). MDM2 was identified by MinION 
sequencing and is involved in the PI3-AKT pathway (328). IAV activates the 
PI3-AKT pathway through NS1 protein to maintain efficient viral replication 
(340). Out of the other 1,360 host transcripts, identified by MinION 
sequencing, some of them have known crucial roles in IAV infection in the 
host. Interferon stimulated transcripts, such as IFI27, IFI44 were highlighted 
with an increase in expression of log two-fold change of 9.1. Transcripts from 
the Integrin family: ITGB4, ITGB1, and ITGB7, were also highlighted with an 
increase in expression of log two-fold change of 9.1. The role ITGBA6 plays 
in IAV infection was highlighted above. Integrins are a large family primarily 
known to maintain cell adhesion and tissue integrity. However, they are also 
known to have essential roles in cell survival, differentiation, proliferation, and 
migration, and are potential therapeutic targets for respiratory diseases (338).  
 
Figure 3.8 highlights several immunoglobulins present with an increase in log 
two-fold change in IAV infected cells compared to mock-infected cells in the 
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MinION sequencing data. This confirms data observed from the Mass 
Spectrometry (Table 3.2). Figure 3.10 highlights various transcripts with an 
increase in log two-fold change, which form a network and directly or indirectly 
affect TRIM25. TRIM25 induces ubiquitination of RIG-I that leads to increased 
signalling of RIG-I (346, 347). In addition, TRIM25 is essential for RIG-I 
mediated IFNE production and therefore anti-viral response to RNA viral 
infection (346). TRIM25 binds to influenza ribonucleoproteins, inhibits viral 
RNA chain elongation, and stops the RNA’s movement into the polymerase. 
The Influenza NS1 protein avidly acts against TRIM25 activity (347). Although 
TRIM25 was not highlighted in the MinION data, the data highlighted directly 
or indirectly affects it. TRIM25 was highlighted in the data from the first 
biological replicate on the Mass Spectrometry platform (data not shown). 
TRIM28 was highlighted in the MinION sequencing data (data not shown) with 
an increase in expression log two-fold change of 8.9. TRIM28 negatively 
regulates interferons (348). Excessive IFN-induced response could negatively 
affect the host, so this is regulated by interferon regulatory factor 7 (IRF7). 
IRF7 is essential in the regulation of Type 1 IFN-dependent response to viral 
infection. Overexpression of TRIM28 inhibits IRF7 and knockdown of TRIM28, 
enhances IFN production as well as antiviral responses (349). The TRIM 
family have roles in regulating innate immunity. These are induced by type I 
and II interferons, necessary for the host resistance to pathogen infection 
(350, 351). 
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3.18 Conclusion 
This chapter forms the basis of the study of IAV in host in vitro. The results 
from this chapter established the reliability of quantitative label-free LC-MS 
Mass Spectrometry and MinION sequencing in the study of IAV in vitro. These 
results are concordant with the results seen by other studies and highlight 
proteins and transcripts that are observed in vivo and have the potential for 
biomarker studies. This is essential, as it gives room for high throughput, and 
rapid, controlled, and reliable research in vitro. The results in this chapter are 
phenomenal and reliable as they identify proteins and transcripts involved in 
the activation of four out of five well-known cell signalling pathways (MAPK 
pathway, PI3/AKT pathway, RIG-I/TLR pathway, and the IP3/PKC pathway) 
triggered by IAV infection (340). This highlights their importance for the 
continuous pathogenesis of the virus in vitro. Furthermore, these results give 
confidence in the techniques used. However, the bioinformatic analysis 
performed on these datasets were based on already existing data in the 
literature. Whilst this further validates the results in this chapter, to find novel 
biomarkers, targets that have not been highlighted need to be further explored 
using independent assays. 
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RESULTS CHAPTER 4: 
ELUCIDATING THE HOST RESPONSE TO INFLUENZA A VIRUS 
INFECTION IN VIVO in Non-Human Primates (NHP)  
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4.1 INTRODUCTION 
The aim of this thesis was to use proteomics to characterise IAV in three 
different hosts; in vitro – cell culture model (Chapter 3), in vivo – animal model 
(macaques - non-human primates [NHP]) (Chapter 4) and in vivo – humans 
through nasopharyngeal aspirates (NAs) (Chapter 5). This current chapter 
focused on examining the host response to IAV in macaques using NHP as a 
model. This chapter first reviewed studies in which in vivo models were 
infected with IAV and analysed using high-throughput methods. Focus was 
placed on studies that used proteomics as a high-throughput method. 
However, exceptions were made and some studies that used transcriptomics 
as a high-throughput method were also reviewed. This was to provide a 
literature review aligning with the high throughput methods used throughout 
this thesis.  
 
IAV infection can be distinguished into three forms: zoonotic, pandemic, and 
seasonal influenza. Each of these bear a differing severity of disease in 
humans: mild to severe morbidity and mortality burdens (352). The IAV is 
classed as a zoonotic infection, due to the ability of IAV in animals to infect 
humans. The zoonotic IAVs are generally not transmissible among humans 
via air droplets (352). If the IAV gains this ability, this could lead to a novel 
influenza pandemic (353). Examples of other viruses with these properties 
include Ebola and hanta viruses). IAV has the ability to reside in avian and 
swine, which poses the threat of a potential pandemic in humans. Using death 
toll as a criterion, the four major IAV pandemics that have occurred include: 
1918 (30–50 million deaths worldwide), 1957 ‘Asian Flu’ (0.3–2 million 
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deaths), 1968 ‘Hong Kong Flu’ (0.3–2 million deaths), and the 2009 ‘Mexican 
flu’ (0.3–2 million deaths) (352). Through several waves of circulation globally, 
IAV pandemics eventually became seasonal IAV epidemics leading to 3–5 
million severe cases and 290,000–650,000 deaths yearly (64, 352, 354, 355). 
Consequently, influenza viruses that have the potential to cause pandemics 
are thought to be zoonotic influenza viruses that have gained the ability 
through mutation, re-assortment, or both to be effectively air-borne 
transmissible (352). Understanding and characterising of IAV in vivo is 
therefore essential to anticipate potential changes in IAV-host interactions, 
which may lead to a pandemic. This is also important in the search of potential 
biomarkers to increase the efficiency of diagnostics. This may provide a 
blueprint towards what may be expected to occur in humans.  
 
1) IAV infection in birds 
Proteomic analysis was carried out on chickens infected with avian influenza 
virus H9 subtype. This virus caused major economic losses and severe 
respiratory tract diseases (356). The tracheal epitheliums of chickens, which 
was the primary target organ of avian influenza viruses, was infected with 
influenza virus H9 subtype. These samples were subjected to 2D-DIGE 
analyses followed by MALDI-TOF/TOF MS and bioinformatics analyses. In 
comparison to the control, 48 proteins were identified to be differentially 
expressed. Most of these proteins had roles in oxidative stress response as 
well as activating secretion of pro-inflammatory cytokines by interactions with 
other proteins such as TLR4. These proteins include ANXA1, PRDX1, ANXA2, 
and HSPB1 (356). These proteins provide insight into the host – viral 
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interactions and may serve as targets for further work – therapeutics and viral 
pathogenesis. Another study focused on understanding the central nervous 
system dysfunction in poultry caused by the H5N1 avian influenza virus (AIV). 
Proteomics – 2D-DIGE coupled with MALDI-TOF MS/MS was used to analyse 
the infection in chicken brain tissue. Eighteen proteins that increased in 
abundance and were differentially expressed were identified. In addition, 13 
proteins that decreased in abundance and were differentially expressed were 
also identified. These proteins gave insight into viral-host interaction in the 
brain tissue (357). The proteomic approaches provided insight into viral-host 
interaction and highlighted proteins of interest. However, this method is still 
fairly new, and, as a result, there are limited studies using this methodology.  
 
Sun et al. (2014) used proteomics – 2D-DIGE followed by MALDI-TOF/TOF-
MS to better understand the molecular pathogenesis and replication features 
of the AIV with H9 subtype in chickens (356). A total of 48 proteins, which had 
significantly changed in abundance, were identified. Following bioinformatics, 
protein expression changes associated with biosynthetic, immune and 
inflammatory response, signal transduction, and cell death were highlighted. 
ANXA1 is an example of a protein that was differentially expressed and 
involved in the inflammatory process. ANXA1 was reduced in abundance in 
AIV H9 infected groups. This may suggest its association with the 
inflammatory phenotype. The ubiquitin-proteasome pathway (UPP) was 
highlighted and it has been reported to influence the replication of several 
viruses, IAV included. Inhibition of the UPP affects viral replication (356, 358). 
In AIV infected group, proteasomel subunit alpha type six was upregulated. 
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This suggests a mechanism via which the virus facilitates replication and 
infection through distinct proteasomal subunits (356). 
 
2) IAV infection in ferrets 
The domestic ferret (Mustela putorius furo) has frequently been utilised as a 
model to study the pathogenesis and transmission of influenza. This is mainly 
due to its natural susceptibility to the human influenza virus and its ability to 
portray clinical symptoms in a similar manner to humans. LC/MS analysis was 
used to analyse samples from the lung and trachea of ferrets infected with 
either 1918 or 2009 human pandemic H1N1 influenza viruses; 4811 and 4060 
proteins were respectively identified. Proteins associated with innate immune 
and antiviral responses were highlighted. These proteins included Trim25, 
Stat1, and Mx1. Trim25 is part of the TRIM superfamily, which regulates viral 
RNA sensing pathways through the activation of RIG-I (359, 360). 
  
3) IAV infection in mice  
To understand the pathogenesis of IAV, several in vivo models have been 
used. To analyse the samples, high throughput methods, including, but not 
limited to, proteomics were used. Some studies have used the mouse (Mus 
musculus) as an in vivo model. This is mainly due to practical reasons: cost, 
size, husbandry requirements, species specific reagents, and ability to 
manipulate mice genetically (361). Tchitchek et al. (2013) used proteomics 
and transcriptomics (both high-throughput methodologies) to analyse mice 
infected with A/California/04/2009 (H1N1) (362). A total of 230 transcriptomic 
and 198 proteomic profiles were collected. Following analysis, the data profiles 
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revealed specific biological functions that were over represented in the 
infected cohort. These included the role of pattern recognition receptors in 
recognition of bacteria and viruses, death receptor signalling, and a protein 
ubiquitination pathway (363). There were 29 signalling pathways that 
overlapped and were highlighted in both transcript and protein sets. This 
dataset showed and confirmed that the transcriptomic and proteomic profiles 
complement each other (362).  
 
Still, in a bid to understand the pathogenesis of IAV in mice further, Shen et 
al. (2016) (364) used shot-gun proteomic profiling to analyse samples from 
mice infected with IAV H3N2 A/Hong Kong/X31 at four and 10 days. The 
results from this study were concurrent with various studies in the literature 
and highlighted within this thesis. For example, proteins with significant 
change in abundance included interferon stimulate genes (ISGs) ISG15, 
proteins relevant to interferon signalling, members of the IFIT family (IFIT1, 
IFIT2, IFIT3). These proteins play vital roles in inhibiting translation of 
uncapped viral RNA, thus suggesting the activation and stimulation of the 
antiviral pathway. IFITM3 is another protein that increased in abundance. 
IFITM3 plays a specific role in inhibiting IAV (364).  
 
 
 
4) IAV infection in macaques  
Rodent (mice and ferrets) model systems have frequently been used to study 
IAV, as seen above (365). However, the genetic and physiological differences 
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when comparing the datasets to humans have led to the use of more 
physiologically relevant models (366). Therefore, research has turned to 
several macaque species to study IAV. This includes Macaca mulatta, Macaca 
nemestrina, and Macaca fascicularis. These macaque species are currently 
used to study other viruses, such as HIV, Ebola, variola major, and IAV (367, 
368). Understanding the pathogenesis of IAV, and the host response to IAV, 
is important, especially if the virus has the potential to cause a pandemic. Baas 
et al. (2006) combined both high-throughput methods – proteomic and 
genomics – to analyse Macaca nemestrina infected with H1N1 A/New 
Cal/20/99, H3N2 A/Panama/2007/99 and H3N2 A/New Mexico/17/2003. 
Samples were collected at two, four, and seven days (367). The proteins that 
were differentially abundant in infected samples included GBP1, HMOX1, 
IFI44, IFIT1, IFIT2, IFIT3, LAMB1, MX1, SFTPD, and STAT1. Most of these 
proteins, especially those from the interferon family – IFIT1, IFIT2 and IFIT3 –
have antiviral roles (367). These proteins may be potential biomarkers and 
indicators of IAV. The data obtained from this study concurred with data from 
human studies challenged with IAV. For example, IL-6 and TNF-D were 
highlighted in this study and have an increased abundance in nasal lavage 
fluid. IL-6 and IFN-J also increased in abundance in volunteers infected with 
influenza A/Texas/36/91/virus (369, 370). A subset of the proteome results 
overlapped with parallel transcriptomic results (371), especially when focusing 
on interferon-mediated and anti-virus responsive factors (367). 
 
Brown et al. (2010) (372) built on the findings of Baas et al. (2006) (367) 
described above, and further analysed the in vivo host proteome response to 
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IAV infection (372). Cynomolgus macaque (Macaca fascicularis) were infected 
with high pathogen avian influenza (HPAI) and observed over seven days; 
35,239 peptides (about 4,250 proteins) were identified, while Baas et al. 
(2006) identified 15,322 peptides (3,098 proteins). 10,156 peptides (2,287 
proteins) were found in both studies (372). Data analysis by ingenuity pathway 
analysis identified the following biological processes: inflammatory response, 
complement system, role of pattern receptors in recognition of bacteria and 
viruses, replication of virus, and immune response (372). Extensive datasets 
have been obtained in previous studies that used high-throughput methods to 
evaluate IAV-host interaction.  
 
The findings presented in this chapter used high throughput proteomic 
methods on clinical left-over material of NHP macaques infected with IAV. 
Samples were collected at two and seven days, post infection. These samples 
were kindly provided by our collaborators at Public Health England (PHE) 
(studies headed by Prof Miles Carroll and Dr Catherine Whittaker). Table 4.0 
highlights the different samples, location, personnel in charge, and techniques 
used.  
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Table 4.0 Compilation of the samples used in this study, their 
location, personnel in charge, routes of infection, MOI of infection and 
the techniques used for analysis 
Samples  Location Personnel 
in charge 
Routes of 
Infection 
Plaque 
Forming 
Units 
(Measure 
of the 
number 
of 
infectious 
particles)  
Techniques 
Cynomolgus 
NHP 
Macaque 
(Macaca 
Fascicularis) 
– Broncho 
alveolar fluid 
(BALF) 
Public 
Health 
England 
(PHE) 
Prof Miles 
Carroll 
 
Dr. Tony 
Marriott 
Inhaled 
aerosol 
(i.a), 
intra-
nasal (i.n) 
and intra-
tracheal 
(i.t) 
Inhaled 
aerosol – 
105 pfu  
Infection then 
mass 
spectrometry 
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Only animals infected via inhaled aerosol (i.a) showed signs of disease 
throughout the body. For this reason, samples from NHP infected via i.a were 
used in this study; other routes of infection showed a confinement of the 
disease within a section of the body. The infected and non-infected (mock) 
samples were used for the analysis presented in this chapter. 
 
The samples obtained from the NHP macaques were subjected to proteomic 
analysis on the label-free mass spectrometry Q-Exactive platform. 
 
Data from this chapter contributed towards the following publication: 
 
Marriott AC, Dennis M, Kane JA, Gooch KE, Hatch G, Sharpe S, Prevosto C, 
Leeming G, Zekeng EG, Staples KJ, Hall G, Ryan KA, Bate S, Moyo N, 
Whittaker CJ, Hallis B, Silman NJ, Lalvani A, Wilkinson TM, Hiscox JA, Stewart 
JP, Carroll MW. 2016. Influenza A Virus Challenge Models in Cynomolgus 
Macaques Using the Authentic Inhaled Aerosol and Intra-Nasal Routes of 
Infection. PLoS One. 11(6): e0157887. doi: 10.1371/journal.pone.0157887. 
 
The general bioinformatics approaches developed were also used in the 
following publication: 
 
Liu X, Speranza E, Muñoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival 
I, Fang Y, Hall Y, Zekeng EG, Lüdtke A, Xia D, Kerber R, Krumkamp R, 
Duraffour S, Sissoko D, Kenny J, Rockliffe N, Williamson ED, Laws TR, N'Faly 
M, Matthews DA, Günther S, Cossins AR, Sprecher A, Connor JH, Carroll MW, 
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Hiscox JA. 2017. Transcriptomic signatures differentiate survival from fatal 
outcomes in humans infected with Ebola virus. Genome Biology. 18(1):4. doi: 
10.1186/s13059-016-1137-3. 
 
 
 
 
 
 
4.2 RESULTS 
4.2.1 Host – viral cellular overview from BALF from NHP cynomolgus 
macaques infected with influenza A H1N1 pandemic virus via an i.a 
challenged route 
To obtain an overview of the cellular interactome upon infection with IAV, 
BALF from NHP cynomolgus macaques was collected and analysed by label-
free mass spectrometry. NHPs were i.a challenged with IAV H1N1 2009 
pandemic virus at a dose of 105 pfu. The proteins from these samples, 
alongside proteins from BALF of naïve NHP cynomolgus macaques, were 
extracted and subjected to proteomic analysis using label-free mass 
spectrometry and the results were compared. Figure 4.1 illustrates the work 
flow from infection to analysis.  
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Figure 4.1: Schematic workflow for the processing of broncho-alveolar fluid 
(BALF) samples from NHP cynomolgus macaques infected with IAV 2009 
pandemic infection. Protein concentration was measured via the BCA assay 
and proteins were extracted from the samples. The samples were subjected 
to Coomassie staining followed by analysis on the mass spectrometry 
platform: Q-Exactive for label-free proteomics and subsequent data analysis. 
The data from the samples were analysed via Progenesis and Maxquant 
software. Further data analysis was done via bio-informatic python, Gene E, 
and Ingenuity pathway analysis (IPA).  
 
Proteins from BALF obtained from cynomolgus macaques, naïve and infected, 
were extracted and subjected to Coomassie staining as described in Figure 
4.1. This was to ensure the presence of protein in all samples prior to the 
proteomic analysis on the label-free mass spectrometry platform (Q-Exactive) 
(Figure 4.3).  
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Figure 4.2: Coomassie staining of proteins obtained from BALF from naïve 
cynomolgus macaques and cynomolgus macaques infected with IAV H1N1 
2009 pandemic via inhaled aerosol at a dose of 105 pfu culled five days post 
infection and seven days post infection. Equal protein concentration of each 
sample was loaded onto each well and stained to confirm the visual presence 
of protein in each sample. This figure confirms the presence of protein in each 
sample. The unequal band size seen shows the protein variation in each 
sample. 
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4.2.2 Defining the proteome of BALF taken from naïve and influenza A 
2009 pandemic cynomolgus NHP at day five and day seven post-
infection. 
To carry out this study, BALF samples were obtained from naïve NHPs, NHPs 
infected and culled at five days post infection and NHPs infected and culled at 
seven days post infection. The BALF proteome from three naïve NHPs (mock), 
three IAV-positive NHPs (culled at five days post infection) and three IAV-
positive NHPs (culled at seven days post infection) were compared. A label-
free quantitative proteomic approach was used to identify and quantify 
proteins from these samples. Each sample was simultaneously run in triplicate 
on the Q-Exactive platform to ensure reliability, reduce technical variation, and 
ensure the statistical relevance of the obtained data. Several data-processing 
steps were used to increase precision when highlighting proteins, which have 
significantly increased, decreased in abundance, or stayed the same. These 
steps included the removal of proteins identified with low confidence, including 
proteins identified by a single peptide, the p-value was set at 0.05 and proteins 
with an abundance difference of two-fold or more were recorded as being 
differentially abundant. This ensured that the final proteins selected were 
significantly differentially abundant when comparing the data set from naïve 
samples (mock) to IAV-positive samples. The data obtained from the mass 
spectrometry was analysed in three comparable sets (Table 4.1).  
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Table 4.1 D
ata com
parisons of proteom
e from
 B
A
LF from
 N
H
P and the proteom
e data observed and obtained from
 the 
com
parisons and analysis 
C
om
parisons 
Total 
num
ber 
of 
proteins 
(including 
single 
peptides) 
P
roteins 
after 
data 
processing 
steps 
N
um
ber 
of 
proteins 
significantly 
increased 
in 
abundance 
N
um
ber 
of 
proteins 
significantly 
decreased 
in 
abundance 
Figures 
N
aïve N
H
P
 vs i.a 
infected 
N
H
P
 
(5 
D
ay’s 
post 
infection) 
1038 
509 
49 
76 
4.3 
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N
aïve N
H
P
 vs i.a 
infected 
N
H
P
 
(7 
D
ay’s 
post 
infection) 
714 
509 
67 
77 
4.4 
i.a infected N
H
P
 (5 
D
ay’s 
post 
infection) 
vs 
i.a 
infected 
N
H
P
 
(7 
day’s 
post 
infection)  
1149 
721 
58 
83 
4.5 
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Figure 4.3: The volcano plot of proteins increased and decreased in 
abundance in individual broncho-alveolar lavage fluid (BALF) samples from 
inhaled aerosol (i.a) IAV-H1N1 2009 pandemic-infected NHP cynomolgus 
macaques (n=3) culled five days post-infection, compared to samples from 
naïve cynomolgus macaques (n=3). The vertical dashed lines indicate a cut-
off of two-fold change between infected and naïve, while the horizontal dashed 
line indicates a p-value of <0.05 to define cohorts of polypeptides (shaded 
areas) with significantly increased (right-hand side) or decreased (left-hand 
side) abundance in infected samples. 
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Figure 4.4: The volcano plot of proteins increased and decreased in 
abundance in individual broncho-alveolar lavage fluid (BALF) samples from 
inhaled aerosol (i.a) IAV-H1N1 2009 pandemic-infected NHP cynomolgus 
macaques (n=3) culled seven days post-infection compared to samples from 
naïve cynomolgus macaques (n=3). Vertical dashed lines indicate a cut-off of 
two-fold change between infected and naïve, while the horizontal dashed line 
indicates a p value of <0.05 to define cohorts of polypeptides (shaded areas) 
with significantly increased (right-hand side) or decreased (left-hand side) 
abundance in infected samples. 
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Figure 4.5: The volcano plot of proteins increased and decreased in 
abundance in individual broncho-alveolar lavage fluid (BALF) samples from 
inhaled aerosol (i.a) IAV-H1N1 2009 pandemic-infected NHP cynomolgus 
macaques (n=3) culled seven days post-infection compared to samples from 
IAV-H1N1 2009 pandemic infected NHP cynomolgus macaques (n=3) culled 
five days post-infection naïve cynomolgus macaques (n=3). Vertical dashed 
lines indicate a cut-off of two-fold change between infected and naïve, while 
the horizontal dashed line indicates a p-value of <0.05 to define cohorts of 
polypeptides (shaded areas) with significantly increased (right-hand side) or 
decreased (left-hand side) abundance in infected samples. 
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4.2.3 Identification and quantification of cellular proteins in BALF 
Thermo RAW files were imported into Progenesis QI (version 2.0, Nonlinear 
Dynamics). Replicate runs were time-aligned using default settings and an 
auto-selected run as a reference. Peaks were selected by the software using 
default settings and filtered to include only peaks with a charge state of 
between +2 and +6. Spectral data were transformed to .mgf files with 
Progenesis QI and exported for peptide identification using the Mascot (Matrix 
Science) search engine against a custom database that contained the 
common contamination and internal standards, H1N1_CA_2009_Mar15, and 
UniProt Homo sapiens reviewed proteins (373) (February 2015). The search 
parameters were as follows: precursor mass tolerance was set to 10ppm and 
fragment mass tolerance was set to 0.01 Da. One missed tryptic cleavage was 
permitted. Carbamidomethylation was set as a fixed modification and 
oxidation (M) was set as a variable modification (374). The false discovery 
rates were set at below 1% using Mascot Percolator and the search results 
were imported back to Progenesis. Raw abundances of replicates from 
Progenesis QI output of Naïve, day five and day seven samples were 
compared first where matching identifications with >=2 unique peptides were 
selected for normalisation using the Loess Global normalisation method 
provided by Normalyzer (375). The reported abundance is the mean of the 
biological replicates. 
 
4.2.4 Bioinformatics Analysis – Protein Pathway Analysis 
Data were analysed through the use of Ingenuity Pathway Analysis (IPA) 
(QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-
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pathway-analysis). Networks linking differentially abundant proteins and their 
effects were generated using Ingenuity Pathway Analysis (IPA) (QIAGEN Inc., 
https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis). 
The data sets used contained accession gene identifiers, corresponding 
maximum fold-change values, and P-values, which were uploaded into the 
application. To select for genes which expressions were significantly 
differentially regulated, a cut-off of 1.0 was set. The application contains a 
global molecular network onto which these genes were overlaid. These genes 
were connected based on proven studies supported by references in the 
literature, or known canonical pathways present in the application knowledge 
base.  
 
4.2.5 Protein Pathway Analysis  
The analysis of these data revealed proteins already identified in vitro (cells) 
Chapter 3. In addition to this, a focus on immune response highlighted various 
aspects similar to those observed in IAV-infected humans: i.a. induced a 
transient lymphopenia and virus-specific cellular immune responses. There 
was a significant increase in the activation of lung macrophages and innate 
immune response at five to seven days post-infection. The kinetics of infection, 
virological and immunological were broadly in line with human IAV infections.  
 
Analysis of cellular proteins in BALF – Focus on Immune response 
These data indicated that at day five and day seven post-infection proteins 
associated with the innate and adaptive immune responses had differential 
abundance when compared between these time points as well as to BALF 
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taken from the naïve animals. At day seven post-infection, there was an 
increase in type I interferons including interferon α (IFNα) and its variants, 
compared to day five post-infection. These specific proteins were not identified 
by mass spectrometry (this may be a result of low abundance compared to 
other proteins) and therefore their presence is inferred due to the known 
activation of the highlighted proteins in Table 4.2. The abundances of 
interferon induced gene products, such as IFN-induced proteins with 
tetratricopeptide repeats (IFITs) 1, 2 and 3 (Figure 4.3, 4.4 and 4.5) (262) are 
significantly higher at day seven then at day five (p-values of 0.014, 0.0054 
and 0.0049 respectively). IFN-inducible guanylate binding protein (GBP) 1 and 
2, also known to be regulated by interferon (376) were also significantly 
different (as determined by Progenesis) between day seven post-infection and 
day five post-infection (Figure 4.5).  
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Table 4.2; Analysis of proteins identified in the B
A
LF of sam
ples from
 i.a. challenged N
H
P seven days post-infection, 
com
pared to sam
ples from
 i.a. challenged N
H
P 5 days post- infection involved in im
m
une response. 
 
P
rotein accession 
significantly increased 
in abundance 
P
rotein nam
e 
Fold 
change 
P
roteins 
significantly 
decreased in 
abundance 
P
rotein nam
e 
Fold change 
P
roteins affected by 
association but not 
identified in the m
ass 
spectrom
etry data 
1 
IFIT3 
Interferon-
induced protein 
w
ith 
14.6 
S
G
TA 
S
m
all 
glutam
ine-rich 
tetratricopeptid
e repeat-
-4.1 
IFN
 alpha/beta 
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tetratricopeptide 
repeats 3 
containing 
protein alpha 
2 
IFIT1 
Interferon-
induced protein 
w
ith 
tetratricopeptide 
repeats 1 
10.1 
S
O
D
E 
E
xtracellular 
superoxide 
dism
utase 
-7.3 
IFN
 type 1 
4 
E
IF3 
E
ukaryotic 
translation 
initiation factor 3 
9.95 
D
D
A
H
2 
D
im
ethylargini
ne 
dim
ethylam
ino
hydrolase 2 
-1.6 
JA
K 
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5 
M
X1 
M
yxovirus 1 
6.9 
P
O
STN
 
P
eriostin 
-1.6 
IFN
 B
eta 
6 
IS
G
20 
Inteferon-
stim
ulated gene 
20 K
D
a 
8.5 
FH
L1 
Four and a half 
LIM
 dom
ains 
protein 1 
-1.7 
C
ollagen type II 
7 
D
D
X58 
P
robable ATP
-
dependent  
R
N
A
 helicase 
31.4 
D
H
X8 
Facilitates 
nuclear export 
of spliced 
m
R
N
A
 by 
releasing the 
R
N
A
 from
 the 
spliceosom
e 
-1.6 
M
TO
R
C
2 
8 
ID
O
1 
Indoleam
ine 
2,3-dioxygenase 
1 
3.5 
 
 
 
C
pla2 
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9 
C
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C
 
C
om
plem
ent 
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subunit C
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associated 
protein D
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A significant increase was observed at day seven, compared to day five, post-
infection in the abundance of interleukins (IL), including IL1B, IL2, IL4, IL5, IL6, 
IL10, and IL13. In addition, CXCL7 also increased in abundance at day seven 
compared to day five post-infection. Proteins associated with the activation of 
lymphocytes were identified at day five post-infection, but not at day seven 
post-infection.  
Proteins associated with the activation of macrophages were more abundant 
in BALF from NHP collected at five and seven days post-infection compared 
to BALF from naïve animals (Figure 4.3 and 4.4). However, at day seven post-
infection, proteins associated with inhibiting the activation of macrophages 
were increased in abundance compared to day five post-infection. At both day 
five and day seven post-infection, there was an increase in proteins associated 
with the activation of neutrophils, with more neutrophils present at day five. 
Proteins associated with the activation of lymphocytes were identified at day 
five post-infection but not at day seven post-infection. There was a further 
increase in viral replication in NHP seven days post infection in comparison to 
five days post infection (Figure 4.5).  
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Figure 4.6: Network pathway analysis of proteins identified in the BALF of 
samples from i.a. challenged NHP five days post-infection, compared to 
samples from naïve NHP samples. The network highlights proteins increased 
in protein abundance involved in activation of macrophages in samples five 
days post-infection compared to naive NHP samples. Proteins in green 
highlight a two-fold or more decrease in abundance in the NHP five days post-
infection compared to naïve NHP samples. Proteins in red highlight a two-fold 
or more increase in abundance. The shapes separate the different molecular 
classes. The lines with solid arrows represent a direct molecular interaction 
with one transcript initiating the other and the dashed arrows an indirect 
molecular interaction with one transcript potentially initiating the other. Strong 
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lines without an arrow show a relationship between two transcripts and dashed 
lines without an arrow show an assumed relationship between two transcripts 
molecules. Strong lines or dashed lines with a dash at the end are inhibitory 
to that transcript. The transcripts that were not highlighted were not identified 
in the dataset but are indirectly involved in these pathways. 
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Figure 4.7: Network pathway analysis of proteins identified in the BAL fluids of 
samples from i.a. challenged NHP seven days post-infection, compared to 
samples from naïve NHP samples. The network highlights the proteins 
increased in the protein abundance involved in activation of macrophages in 
samples seven days post infection, compared to naive NHP samples. Proteins 
in green highlight a two-fold or more decrease in abundance in the NHP five 
days post-infection compared to naïve NHP samples. Proteins in red highlight 
a two-fold or more increase in abundance. The shapes separate the different 
molecular classes. The lines with solid arrows represent a direct molecular 
interaction with one transcript initiating the other and the dashed arrows an 
indirect molecular interaction with one transcript potentially initiating the other. 
Strong lines without an arrow show a relationship between two transcripts and 
dashed lines without an arrow show an assumed relationship between two 
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transcripts molecules. Strong lines or dashed lines with a dash at the end are 
inhibitory to that transcript. The transcripts that were not highlighted were not 
identified in the dataset but are indirectly involved in these pathways. 
 
 
 
Figure 4.8: Network pathway analysis of proteins identified in the BALF of 
samples from i.a. challenged NHP seven days post-infection, compared to 
samples from i.a. challenged NHP five days post- infection. The network 
highlights proteins necessary to activate the replication of IAV. Proteins in 
green highlight a two-fold or more decrease in abundance in the NHP seven 
days post-infection compared to samples from NHP five days post-infection. 
Proteins in red highlight a two-fold or more increase in abundance. The shapes 
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separate the different molecular classes. The lines with solid arrows represent 
a direct molecular interaction with one transcript initiating the other and the 
dashed arrows an indirect molecular interaction with one transcript potentially 
initiating the other. Strong lines without an arrow show a relationship between 
two transcripts and dashed lines without an arrow show an assumed 
relationship between two transcripts molecules. Strong lines or dashed lines 
with a dash at the end are inhibitory to that transcript. The transcripts that were 
not highlighted were not identified in the dataset but are indirectly involved in 
these pathways. 
 
4.3 DISCUSSION  
The first aim of this thesis was to characterise IAV in vitro using a common cell 
culture model of A549 cells (Chapter 3) and observe the host proteome 
response to IAV infection. The results obtained from in vitro studies are limited 
to cellular responses and frequently omit an adaptive immune response. In 
addition, the multiple cell types present in the human/animal airway affect the 
response observed in vivo compared to in vitro. This chapter focused on 
examining the host response to IAV in a cynomolgus NHP macaque (Macaca 
Fascicularis) commonly used to study IAV. This data was subsequently 
compared to data from an in vitro cell culture model (Chapter 3). The data from 
the cynomolgus NHP macaque (Macaca Fascicularis) in this chapter was 
compared to the data obtained from the analysis of NAs in IAV positive and 
IAV-negative paediatric patients (Chapter 5). The data from the viral-host 
interactome in Chapters 3 and 4 reveals and suggests different stages of 
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infection, host interaction, and immune response. The cynomolgus NHP 
macaque (Macaca Fascicularis) is advantageous due to the semblance of the 
immune system to the human host.  
The aim of this chapter was to understand the in vivo proteome host response 
post-IAV infection in the cynomolgus NHP macaque (Macaca Fascicularis). In 
the NHP macaques, emphasis was laid on the immune response due to the 
similarity observed in human response to IAV infection. In addition to the 
immune response, host proteins, which were significantly differentially 
abundant when comparing the IAV-positive and IAV-negative conditions that 
were highlighted. Some of these proteins include IFN-induced proteins with 
tetratricopeptide repeats (IFITs) 1, 2 and 3 (Figure 4.3, 4.4 and 4.5), which had 
a significant increase in abundance at day seven compared to day five. An 
increase and activation of alveolar macrophages, monocytes, and replication 
of IAV was observed. Samples from IAV positive NHP culled five- and seven-
days post infection were compared between themselves and to samples from 
IAV-negative NHPs.  
 
The analysis of the proteome of BALF taken from IAV-positive and IAV-
negative NHP macaques revealed a vast dataset of results. Some of these 
results included protein changes that have been previously described in other 
experimental model systems and in the macaque model. The novel data this 
comparison provided was analysed and contributed to a publication (262). The 
data analysis revealed an increased and sustained expression of type I 
interferons, which are associated with infection of a highly pathogenic 
influenza virus (H5N1) (371). Studies in mice showed a correlation between 
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an increase in infectious viral load and macrophage and neutrophil depletion, 
highlighting the significance of macrophage and neutrophils in controlling IAV 
viral replication and spread (377). Another study in mice infected with a 
recombinant IAV strain, which had HA and NA from the 1918 pandemic, 
showed an increase in mortality rate along with an increase in viral replication, 
greater influx of neutrophils in the lungs, increased number of alveolar 
macrophages (AM), and increased protein expression of cytokines and 
chemokines (378, 379). These are concordant with findings within this study: 
an increase in viral replication, activation of macrophage, and influx of 
cytokines and chemokines. 
 
Investigating the reason for the virulence of the 1918 pandemic has led various 
scientists to several suggestions. Some of these suggestions include severe 
lung pathology caused by the influx of AM, neutrophils, and cytokines. These 
responses have a part to play in exacerbating the mortality of the disease on 
the host. Macrophages and neutrophils have a central part to play in the host 
defence as they respond quickly to viral infection. The proteome analysis of 
the BALF from NHP culled five- and seven-days post infection showed a 
much-elevated level of AMs in comparison to naïve NHP. Furthermore, in NHP 
culled seven days post infection, there was activation for inhibition of AMs. 
This potentially demonstrates that, at this point, the presence of AMs is 
causing more lung pathology (380, 381). An interesting study that could be 
further carried out would be exploring the maximum number of AMs required 
to induce lung pathology, at which point, could be a defining marker for the 
prediction of disease outcomes in the host. 
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IFNE was not highlighted as differentially abundant but was activated in the 
immune response pathway by other significantly differentially abundant 
proteins. Studies in mice showed the effects of various host responses on one 
another, including vascular margination of T lymphocytes induced by direct 
interaction with type I interferons (382). The data in this study is in 
concordance with our findings. The innate immune response observed in this 
study aligns with previously published studies carried out in ferrets, mice, and 
other NHPs infected with IAV. The host immune response to the viral infection 
plays a role in exacerbating the severity of the disease. The convergence of 
host responses with one another further affects the overall host response to 
viral infection. 
This chapter provides information on the proteome from BALF highlighting 
proteins differentially abundant in NHP infected with IAV. The findings in this 
study are concordant with various findings in the literature. Most importantly, 
it provides information about different stages of infection and the change in the 
proteome in BALF when comparing IAV-positive NHP to IAV-negative NHPs.  
It is important to note there were proteins concurrent throughout the chapters 
– interferon-induced proteins alongside other proteins involved in the 
replication of IAV present in vitro (Chapter 3), now in vivo in the NHP, and 
subsequently, the human nasopharyngeal aspirates (Chapter 5). The 
reoccurrence of these proteins suggests they have essential roles in an IAV-
infected host. These proteins could serve as potential biomarkers for the 
severity of the disease. The state of the immune response, if further analysed, 
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could provide specific information on the disease progression in hosts. 
Considering IAV is a respiratory infection that affects the immune system, 
immune system biomarkers could be the turning point of an indication for IAV 
disease progression.  
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RESULTS CHAPTER 5: 
CHARACTERISING THE HOST RESPONSE TO INFLUENZA A VIRUS 
INFECTION IN VIVO IN HUMANS BY ANALYSING NASOPHARYNGEAL 
ASPIRATES (NA) FROM PAEDIATRIC PATIENTS (2–13 YEAR OLDS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  266 
5.1 INTRODUCTION 
The IAV has caused millions of deaths over the years since the 1918 
pandemic. Seasonal IAV infection globally infects 5–10% of adults and 20–
30% of children. Deaths are mainly associated with high-risk groups including 
children, the elderly, and patients who are chronically ill. Annual infections 
account for 3–5 million cases of severe illness and about 250,000 to 500,000 
deaths worldwide (353). Clinical signs and symptoms are frequently used to 
detect IAV in emergency departments. This follows the Centre for Disease 
Control (CDC) guidelines. Clinical diagnoses done in these settings and 
following these guidelines had a low sensitivity of 36% and specificity of 78% 
(383). To improve sensitivity and specificity, improved methods of diagnosis 
to guide management in clinical settings are required. The response of the 
host to IAV infection is not just restricted to the cellular environment. Infection 
influences several biological processes, particularly in the respiratory tract and 
airway secretions. Understanding the biological processes behind a host 
response provides an opportunity to determine a sensitive diagnostic 
biomarker linking to a predictive outcome. This creates a diagnostic strategy, 
which is not totally reliant on the pathogen, but enables IAV infection to be 
categorised based on the host response (384-386). Host gene expression 
profiling was used in the early diagnosis of IAV-H1N1 and IAV-H3N2 (387). 
Human volunteers (aged between 20 and 41 years) were inoculated with both 
H1N1 and H3N2 strains and their gene profile monitored over seven days. 
This dataset was converted into a gene signature with the ability to detect 94% 
of IAV infected cases. This dataset was used in an emergency setting to 
differentiate between infected and non-infected patients. It was 92% accurate 
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(387). The top 50 genes identified in this dataset were mostly related to the 
host antiviral response (387). Some of these genes included multiple 
interferon response elements, STAT-1, RIG-I, the myxovirus-resistance gene 
MX1, and the OAS family (387) (388-390). In addition, some of the genes 
identified within this dataset could be combined into networks responsible for 
the development or amplification of the immune response. Whilst the effects 
of IAV infection on the host are largely indicated by the immune response 
(387), the entirety of the host expression on a cellular level still needs to be 
determined. Clusters of symptoms and certain criteria (vaccination and age) 
observed in clinical settings have allowed medical personnel to distinguish 
between IAV-H3N2 and IAV-H1N1 positive (391). Vaccinated patients 
developed pneumonia, while non-vaccinated patients had IAV. Age played a 
factor, as patients above 54.5 years had H3N2, while patients below this age 
had H1N1 (391). Whilst these findings are insightful, the population most 
vulnerable to IAV are children. Children under five (1.9/1000) have the highest 
influenza admission rate. Admission rate increases 5.7-fold for 5–24-year olds. 
Patients above 65 have the majority (72%) of influenza-related deaths in 
hospital with co-morbidities (392). The host response to IAV, particularly in 
humans, still requires extensive characterisation. This will provide data that 
informs the search of biomarkers for increased diagnostic efficiency or to 
further understand the aetiology of the virus.  
 
Respiratory disease can be predicted to alter the function of the airway and 
this would manifest in changes in the protein composition of the 
nasopharyngeal aspirates (NAs). One way to assess this is by characterising 
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the proteome of the NAs between infected and non-infected individuals. 
Several factors, such as a small sample size and non-high throughput 
methods, have limited the research on NA proteome changes infected with 
IAV (393). Other respiratory diseases, such as asthma, chronic obstructive 
pulmonary disease (COPD), and cystic fibrosis (394-396) have been 
comparatively more researched.  
 
The advancement in high resolution approaches, such as sequencing and 
proteomics, allows for a more in-depth analysis of the host response to IAV 
infection. Accordingly, this study used a label-free quantitative proteomic 
approach to identify proteins that were differentially abundant in the proteome 
of NAs from laboratory confirmed paediatric IAV cases. To increase 
robustness, samples from three separate geographical locations (Alder Hey 
Children’s Hospital (AHCH), Liverpool, UK; Great Ormond Street Hospital 
(GOSH), London, UK; and Institute Pasteur (IPD), Dakar were chosen. 
Samples from laboratory-confirmed IAV-positive patients were compared to 
matched samples from patients that tested negative for IAV and other common 
respiratory pathogens. The data indicated that both representation of virus 
abundance (Ct value) and strain (H3N2 versus H1N1) had a direct effect on 
the composition of the NAs proteome compared to IAV-negative samples. 
Furthermore, a set of proteins were identified with differing abundance that 
distinguished an infected sample from a non-infected sample and could 
therefore be used towards biomarker selection. 
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Data from this chapter mainly contributed towards the following publication: 
 
Elsa G Zekeng, Dong Xia, Stuart Armstrong…Julian A Hiscox. ‘The 
application of nasopharyngeal aspirates to evaluate proteomic changes 
in airway secretions during influenza virus infection in paediatric cases’  
 
The main aim of this chapter was to characterise the pathogenesis of IAV in 
humans through the analysis of NA samples taken from patients. The data 
was mined for the presence of potential biomarkers, which could be used to 
delineate an IAV-positive sample from an IAV-negative sample. The data was 
subsequently compared (in general discussion in Chapter 6) to data obtained 
from in vitro studies (Chapter 3) and in vivo studies (NHP macaques – Chapter 
4). This was with an aim to evaluate and understand IAV pathogenesis in each 
model system.  
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5.2 RESULTS 
 
The aim of this study was to investigate how the protein compositions of airway 
secretions in paediatric cases were altered following IAV infection. The data 
from this study primarily provided a deeper understanding of IAV pathogenesis 
in the host. Subsequently, it highlighted the proteomic differences between 
IAV-H3N2-positive, IAV-H1N1-positive, and IAV-negative samples. Finally, it 
identified potential host-protein biomarkers as a sign of infection and explored 
the part that viral load has to play in increasing these proteomic differences. 
NAs from three different sites: AHCH, GOSH, and IPD, were obtained from 
paediatric patients and were confirmed as IAV positive or negative by RT-
PCR. The workflow used to analyse NA samples in this study are shown in 
Figure 5.1. Proteins were extracted from NAs; identified and quantified via LC-
MS/MS to compare the proteomes in the various samples, followed by 
bioinformatics analyses on Ingenuity Pathway Analysis (IPA). The results 
showed that similar proteins were significantly differentially abundant across 
the sample cohorts, but had varying amounts of proteins within each cohort. 
In parallel, SDS-PAGE and ELISA were applied to selected examples to 
validate the LC-MS/MS data. To confirm protein extraction from the NAs, equal 
volumes of samples were separated by 1D SDS-PAGE and stained with 
Coomassie blue. Downstream sample analysis by western blot and ELISA 
were standardised to protein concentration.  
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Figure 5.1: Schematic workflow for the processing of proteins from 
nasopharyngeal aspirate (NA) samples. Protein concentration was measured 
via the BCA assay and proteins were extracted from the samples. The sample 
was split and a portion subjected to Coomassie staining followed by analysis 
on the mass spectrometry platform: Q-Exactive for label-free proteomics and 
subsequent data analysis. The other portion was analysed by SDS-PAGE and 
western blot for BPIFA1 and SCGB3A2 as validation of the LC-MS. 
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5.2.1 Statistical significance of age and sex ratio of patient samples from 
all cohorts for comparison 
Age and sex are associated with a host’s immune response to infection at 
large (397) and specifically IAV infection (398). For the datasets from IAV 
negative samples to be comparable to IAV positive samples across all cohorts, 
it is essential that there is no statistically significant difference between the age 
and sex ratio of the patients within these cohorts. A two-sample t-test and Chi-
squared test was performed using Minitab 17 (399) to determine whether there 
was any statistically significant difference between the age and sex ratio within 
the sample cohorts, albeit the numerical difference of patients’ age and sex. A 
two-sample t-test was performed on the ages and then a Chi-squared test on 
the gender of patients’ samples from each cohort (399, 400). A two-sample t-
test was performed to determine the association of age within the sample 
cohorts (Table 5.2). A Chi-squared test was performed to determine the 
association of gender within the sample cohorts (Table 5.3). A p-value cut off 
range was set at 0.05. A p-value below this value was said to be statistically 
significantly different. The datasets revealed in association to age, there was 
no statistically significant difference within each cohort (Table 5.2). The 
datasets revealed in association to gender, there was no statistically 
significant difference within all but one of the cohort comparisons (Table 5.3). 
The chi-squared test revealed the cohorts – IAV-H3N2 positive cohort and 
IAV-H1N1 positive cohort from IPD had a statistically significant difference in 
the patients’ gender. This indicates that the difference in gender between the 
two cohorts could affect the results obtained. Although the data between the 
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two cohorts has been compared, this is worth noting.  
 
Table 5.2: Two sample t-test on sample comparison (IAV positive and 
IAV negative) between cohorts - Great Ormond Street Hospital (GOSH), 
Institute Pasteur Dakar (IPD) and Alder Hey Children’s Hospital (AHCH) 
 
Geographical 
location 
Sample 
cohort 
Sample 
Cohort 
P-Value Result 
Interpretation 
Great Ormond 
Street 
Hospital 
(GOSH) 
IAV negative IAV H3N2 
positive 
1.00 Non-
statistically 
significant 
Institute 
Pasteur Dakar 
(IPD) 
IAV negative IAV H3N2 
positive 
0.377 Non-
statistically 
significant 
Institute 
Pasteur Dakar 
(IPD) 
IAV negative IAV H1N1 
positive 
0.840 Non-
statistically 
significant 
Institute 
Pasteur Dakar 
(IPD) 
IAV H3N2 
positive 
IAV H1N1 
positive 
0.439 Non-
statistically 
significant 
Alder Hey 
Children’s 
Hospital 
(AHCH) 
IAV negative IAV H3N2 
positive 
- - 
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Table 5.3: Chi-squared test on sample comparison (IAV positive and 
IAV negative) between cohorts - Great Ormond Street Hospital (GOSH), 
Institute Pasteur Dakar (IPD) and Alder Hey Children’s Hospital (AHCH) 
 
 
 
5.2.2 Determining the proteome of nasopharyngeal aspirates taken from 
paediatric patients either influenza virus positive or influenza virus 
negative 
To identify and quantify proteins in NAs and compare potential changes in the 
airway secretion between IAV-negative and IAV-positive paediatric cases, a 
label-free quantitative proteomic approach was used. This simultaneously 
provided information on protein identification and quantity. Samples were 
analysed on the Q–Exactive MS platform using longer gradients and an 
Geographical 
location 
Sample 
cohort 
Sample 
cohort 
P-value Result 
Interpretation 
Great Ormond 
Street 
Hospital 
(GOSH) 
IAV negative IAV H3N2 
positive 
1.00 Non-
statistically 
significant 
Institute 
Pasteur Dakar 
(IPD) 
IAV negative IAV H3N2 
positive 
0.255 Non-
statistically 
significant 
Institute 
Pasteur Dakar 
(IPD) 
IAV negative IAV H1N1 
positive 
0.174 Non-
statistically 
significant 
Institute 
Pasteur Dakar 
(IPD) 
IAV H3N2 
positive 
IAV H1N1 
positive 
0.015** Statistically 
significant 
Alder Hey 
Children’s 
Hospital 
(AHCH) 
IAV negative IAV H3N2 
positive 
- - 
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Orbitrap to acquire both MS and MS/MS spectra. To accurately identify and 
quantify proteins present in the NAs, several data processing steps were used, 
including the removal of proteins identified with low confidence and proteins 
identified by a single peptide (262). An overall p-value for confidence in 
identification was set at 0.05. Using these criteria, the analysis of IAV positive 
and IAV negative patients from all three cohorts, AHCH (Appendix 1, Table 1), 
GOSH (Appendix 1, Table 2), IPD IAV-H3N2 positive versus IAV negative 
(Appendix 1, Table 3), and IPD IAV-H1N1 positive versus IAV negative 
(Appendix 1, Table 4) identified proteins that increased in abundance, 
decreased in abundance, or remained unchanged. Note that proteins 
identified by single peptides are also included in these tables for interest.  
 
Each site was treated as a separate dataset. For AHCH, samples were 
analysed by LC-MS/MS individually, and for GOSH and IPD the IAV-H3N2 
positive samples and the IAV negative samples were pooled separately. This 
is because for GOSH and IPD, initial LC-MS/MS analysis of individual samples 
suggested poor sample quality. The overall number of proteins identified in 
each cohort was different, with 1,623, 489, and 360 proteins identified in all 
samples for AHCH, GOSH, and IPD, respectively. In this study, proteins 
whose abundance changed by two-fold or more, giving a p-value less than 
0.05 were considered to have a significant difference in abundance. This 
revealed that in the samples from AHCH, 25 proteins had significantly 
increased in abundance and 88 proteins had significantly decreased in 
abundance, in samples from IAV-H3N2-positive patients compared to IAV-
negative patients. In the samples from GOSH, 33 proteins significantly 
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increased in abundance, while 50 significantly decreased in abundance. In the 
samples from IPD, IAV-H3N2-positive compared to IAV-negative, 22 proteins 
significantly increased in abundance and 41 proteins significantly decreased 
in abundance. In the samples from IPD, IAV-H1N1-positive compared to IAV-
negative, 28 proteins significantly increased in abundance and 33 proteins 
significantly decreased in abundance. To identify changes in these large 
replicate datasets, volcano plots were used to highlight proteins that were 
reproducibly altered in abundance in IAV-H3N2-positive patients. Volcano 
plots are a type of scatterplot that aid in graphic visual representation of large 
datasets. These volcano plots contain the logarithmic ratio of protein 
intensities labelled as log two-fold change (x-axis) plotted against the negative 
logarithmic 10 p-values (y-axis). The proteins that significantly increased in 
abundance are represented by dots in the top right-hand quadrant. The 
proteins that significantly decreased in abundance are represented by dots in 
the top left-hand quadrant. Each dot below the dotted lines represent a protein 
that did not significantly change in abundance but was highlighted by the 
technique. The volcano plots were plotted for each dataset sampled and 
analysed; IAV-H3N2-positive compared to IAV-negative; AHCH (Figure 5.2A), 
GOSH (Figure 5.2B), IPD (Figure 5.2C) and IAV-H1N1-positive compared to 
IAV-negative – IPD (Figure 5.2D). 
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Figure 5.2A: The volcano plot of proteins increased and decreased in 
abundance in individual nasopharyngeal aspirate (NA) samples from IAV-
H3N2-positive samples, compared to IAV-negative samples from Alder Hey 
hospital, Liverpool. Vertical dashed lines indicate a cut-off of two-fold change 
between IAV-positive and IAV-negative, while the horizontal dashed line 
indicates a p-value of <0.05 to define cohorts of polypeptides (shaded areas) 
with significantly increased (right-hand side) or decreased (left-hand side) 
abundance in infected patient samples. 
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Figure 5.2B: The volcano plot of proteins increased and decreased in 
abundance in individual nasopharyngeal aspirate (NA) samples from IAV-
H3N2-positive samples, compared to IAV-negative samples from Great 
Ormond Street Hospital. Vertical dashed lines indicate a cut-off of two-fold 
change between IAV-positive and IAV-negative, while the horizontal dashed 
line indicates a p-value of <0.05 to define cohorts of polypeptides (shaded 
areas) with significantly increased (right-hand side) or decreased (left-hand 
side) abundance in infected patient samples. 
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Figure 5.2C: The volcano plot of proteins increased and decreased in 
abundance in individual nasopharyngeal aspirate (NA) samples from IAV-
H3N2-positive samples, compared to IAV-negative samples from Institute 
Pasteur, Dakar, Senegal. Vertical dashed lines indicate a cut-off of two-fold 
change between IAV-positive and IAV-negative, while the horizontal dashed 
line indicates a p-value of <0.05 to define cohorts of polypeptides (shaded 
areas) with significantly increased (right-hand side) or decreased (left-hand 
side) abundance in infected patient samples. 
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Figure 5.2D: The volcano plot of proteins increased and decreased in 
abundance in individual nasopharyngeal aspirate (NA) samples from IAV-
H1N1-positive samples compared to IAV-negative samples from Institute 
Pasteur Dakar, Senegal. Vertical dashed lines indicate a cut-off of two-fold 
change between IAV-positive and IAV-negative, while the horizontal dashed 
line indicates a p-value of <0.05 to define cohorts of polypeptides (shaded 
areas) with significantly increased (right-hand side) or decreased (left-hand 
side) abundance in infected patient samples. 
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MUC2 and BPIFA1 are examples of proteins highlighted in Figure 5.2A 
(samples from AHCH) to have significantly increased in abundance in IAV-
H3N2-positive samples, compared to IAV-negative samples. MUC2 functions 
in creating a mucus barrier to inhibit pathogen entry (401). BPIFA1 (a member 
of the BPI-fold containing family) is another protein involved in the host 
defence mechanism from viral entry. BPIFA1 was seen to increase post IAV 
infection in mice (402). Figure 5.2B (samples from GOSH) highlights BPIFB1, 
which increased in IAV-positive samples in comparison to IAV-negative 
samples. BPIFB1 is from the same family of proteins as BPIFA1. BPIFB1 is 
expressed in the upper respiratory tract and functions in host defence (403). 
These are examples of proteins, which increased in IAV-positive samples in 
comparison to IAV-negative samples. This suggests host response and 
defence against viral entry as two pathways that are potentially activated in 
IAV-infected paediatric cases. Figure 5.2C (samples from IPD) highlights a 
significant increase in the proteins STAT1 and ISG15 in IAV-positive samples, 
compared to IAV-negative samples. These are proteins involved in the anti-
viral response via the JAK/STAT signalling pathway induced by interferon. The 
JAK/STAT pathway induction by interferon leads to the up regulation of 
interferon stimulated genes (ISGs), such as ISG15 (31). This anti-viral 
pathway is thought to be the earliest and most potent of innate responses 
(404). 
 
The analysis of the datasets revealed proteins combined through different 
pathways responding to viral infection. These can be seen by the different 
proteins significantly increasing and decreasing in abundance in Figures 5.2A, 
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5.2B, 5.2C, and 5.2D, showing a response to viral infection through different 
pathways. The proteins highlighted in Figure 5.2C suggest early stages of viral 
infection, while the secretory proteins highlighted in Figures 5.2B and 5.2C 
suggest a later response to viral infection. In mice, BPIFA1 was decreased at 
seven days post-infection but increased at 14 days post-infection (402). 
 
5.2.3 Sample analysis via western blot 
When antibody availability was permitted, the abundance of selected proteins 
identified and quantified by the mass spectrometry was examined by western 
blot. In the first instance, the abundance of BPIFA1 was investigated in 
samples pooled from AHCH, GOSH, and IPD. This protein was identified in all 
sample sets and showed significant changes in abundance in response to 
infection in all cases, albeit evidence of opposing directions in some cohorts 
(Figure 5.2A, 5.2B, 5.2C, and 5.2D). For IPD samples, this also allowed 
comparison between IAV-H3N2-positive and IAV-H1N1-positive. For 
consistency, pooled samples were used, and equal amounts of protein was 
loaded (8 Pg). The western blot analysis from IAV-H3N2-positive samples 
compared to IAV-negative samples from AHCH and GOSH, reflected the LC-
MS/MS analysis. The abundance of BPIFA1 was greater in the IAV-H3N2 
positive pooled samples than the IAV-negative pooled samples (Figure 5.3A). 
Contrarily, in the IPD cohort, BPIFA1 was less abundant in the pooled IAV-
H3N2-positive and IAV-H1N1-positive NA samples compared to pooled IAV-
negative NA samples. This is in accordance with the LC-MS/MS data. In 
samples from AHCH, SCGB3A2 was identified, quantified and found to be 
more abundant in IAV-negative samples than IAV-positive samples. 
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SCGB3A2 comes from the Clara cell secretory protein (CCSP) family. This 
family of proteins are known to function as lung surfactants and has been 
reported to protect the lung epithelia (405, 406). Western blot analysis was 
used to investigate and compare the abundance of SCGB3A2 in individual 
samples from IAV positive and negative patients (Figure 5.3) (8 Pg of total 
protein from each patient). The data again reflected the LC-MS/MS result, in 
that the abundance of SCGB3A2 was greater in the samples taken from IAV-
negative patients compared to IAV-positive patients. 
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Figure 5.3: (A) Western blot analysis of the abundance of BPIFA1 in pooled 
nasopharyngeal aspirates samples from; IAV negative A549 cells (Lane 1), 
IAV positive A549 cells (Lane 2), IAV-negative patients (Lane 3) and IAV-
positive patients (Lane 4) from AHCH; IAV-negative patients (Lane 5) and IAV-
positive patients (Lane 6) from GOSH; IAV-negative patients (Lane 7) and 
IAV-H3N2-positive (Lane 8) and IAV-H1N1-positive (Lane 9) from IPD. (B) 
Western blot analysis of the abundance of SCGB3A2 from individual 
nasopharyngeal aspirates taken from IAV-negative patients (Lanes 1 to 5, 
corresponding to individual patients) and IAV-positive patients (lanes 6 to 11, 
corresponding to individual patients) from AHCH. 
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5.2.4 Data analysis on IPD sample cohort – comparing H1N1 strain with 
H3N2 strain 
The samples obtained from the IPD cohort provided the potential to compare 
airway secretions from IAV-H1N1, IAV-H3N2-positive, and IAV-negative 
patients. Figure 5.2D shows the comparison between IAV-H1N1-positive and 
IAV-negative samples. Plotting the fold change in abundance between IAV-
H3N2-positive samples and IAV-H1N1-positive-samples showed that, 
globally, the responses from IAV-H1N1-positive and IAV-H3N2-positive 
cohorts were similar (Figure 5.4A; Pearson R score of 0.65, P <0.0001). 
However, there was a slight, but statistically significant (P<0.001) tendency for 
proteins in the IAV-H1N1-positive samples to be present at a greater 
abundance than in the H3N2 cohort (Figure 5.4B).  
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Figure 5.4:A comparison of proteomics data obtained from the Mass 
spectrometry (Q-Exactive) platform from pooled Nasopharyngeal aspirates 
samples from H3N2 IAV positive samples (n=10), IAV H1N1 positive samples 
(n=10), and IAV negative samples (n=10) obtained from Institute Pasteur 
Dakar-Senegal. Data was graphed and analysed using the software 
GraphPad PRISM V6.0. Figure 5.4A shows a positive correlation between the 
abundance of the 200 selected proteins by our bioinformatic data analysis in 
IAV H3N2 positive samples in comparison to IAV H1N1 positive samples. Data 
was analysed by Pearson correlation and an R value of 0.6479 and P value of 
<0.0001 were obtained. Figure 5.4B shows the differential protein abundance 
of the 200 proteins selected by our bioinformatic data analysis in H3N2 IAV 
positive samples in comparison to H1N1 IAV positive samples. Using a paired 
t-test, we determined a significantly higher general abundance of the 200 host 
proteins selected by our bioinformatics data analysis in the presence of H1N1 
IAV (P<0.0001). 
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Many of the proteins were identified in the samples from IPD as significantly 
differentially abundant between IAV-positive and IAV-negative patients and 
there were similar abundance changes in the other two cohorts. However, the 
abundance of some proteins was different between the three cohorts. To 
provide a visual display of the differences between IAV-negative and patients 
positive for either IAV-H1N1 or IAV-H3N2, the protein abundance data were 
plotted as a heat map (Figure 5.5).  
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Figure 5.5: The proteomics data obtained from Mass spectrometry (Q-
Exactive) platform from pooled aspirates samples from H3N2 IAV positive 
samples (n=10), H1N1 IAV positive samples (n=10) and IAV negative samples 
(n=10) obtained from Institute Pasteur Dakar-Senegal were subjected to 
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Gene-E program. The Gene-E program clusters proteins based on relative 
abundance within all three conditions. This allows for a better relative 
representation and comparison of protein abundance per cohort compared 
with proteins interacting together within/across each cohort. Red represents 
high protein abundance, blue represents a low protein abundance, and white 
indicates an intermediary transition within the various cohorts.  
 
Figure 5.5 presents the comparison of different sample cohorts: IAV negative, 
IAV-H1N1-positive, and IAV-H3N2-positive. This figure combines proteins that 
are significantly different in abundance and are common across all three 
cohorts. It allows for a visual comparison of protein levels across all three 
cohorts. The different proteins and their abundance give insight into the host 
response to IAV-H1N1-infection and IAV-H3N2 infection. STAT1, SG2A1, and 
ISG15 are examples of some of the proteins highlighted to be significantly 
increased in abundance in the IAV-H3N2-positive cohort as well as IAV-H1N1-
positive. However, these proteins are at a higher abundance in IAV-H3N2-
positive compared to IAV-H1N1-positive and IAV-negative. SCG2A1 is a 
protein from the secretoglobin family, which has immune-regulatory functions. 
This is a function also shared by Clara cell secretory protein (CCSP). In 
neonatal human lungs with bronchopulmonary dysplasia, these proteins 
decreased in abundance (405). The host’s primary response to viral infection 
is the innate response most frequently induced by interferons. Interferons 
respond by triggering the host immune response through various pathways 
(407). The upregulation of these specific proteins have the ability to rapidly 
inhibit virus replication (404). While the differential abundance of these specific 
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proteins is seen with various viral infections, studies in mice infected with the 
influenza A H3N2 X31 strain show the importance of STAT1 in ISG induction 
and subsequently inhibiting mice from the influenza A infection (408). This 
confirms the importance of these proteins in IAV-H3N2-positive and IAV-
H1N1-positive cohorts and their increase in abundance as the host responds 
to the IAV infection. Another protein that significantly increased in abundance 
across the cohorts is cornulin (CRNN). CRNN showed an increase in 
abundance in IAV-H3N2-cohort, a comparatively lower abundance in IAV-
H1N1-positive cohort, and a slight increase in IAV-negative samples. CRNN 
is categorised as part of the newly identified stress protein family in mammals. 
These proteins defend the host against different forms of environmental 
stresses, whilst maintaining tissue integrity (409). UBA1, which is a ubiquitin-
like modifier-activating enzyme 1, significantly increased in IAV-H1N1-positive 
samples in comparison to IAV-H3N2-positive and IAV-negative samples. 
UBA1 plays a role in catalysing the first step in marking cellular proteins for 
degradation (410, 411). UBA1 is at the centre of the ubiquitin proteasome 
pathway (UPP) and is a logical target to disrupt downstream ubiquitination 
reactions (412). The UPP has been associated with the viral infection cycle as 
well as virus-host interactions (413) although the mechanism has not yet been 
elucidated. The effects of inhibiting the UPP reportedly affects replication of 
several viruses, including influenza viruses (358). No known study has directly 
linked UBA1 as part of a host response to IAV, but a study by Sun et al. (2014) 
highlighted proteasomal subunit alpha type 6 to be upregulated in an avian 
influenza virus H9 infected group. This suggests that different viruses find 
different strategies to utilise UPP to their advantage (356). Another study by 
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Byk and colleagues showed that the Dengue virus needs ubiquitination to 
uncoat its genome (414). In this study, when UBA1 was silenced, there was a 
four-fold inhibition of viral translation. This suggests the role UBA1 has to play 
in the viral process. Whilst the mechanism of the action of UBA1 and the role 
it plays in IAV infection has not been tested, UBA1 is a protein of great interest 
to potentially differentiate between IAV-H3N2-positive and IAV-H1N1-positive. 
Another protein that significantly increased in abundance in IAV-H1N1-positive 
samples in comparison to the IAV-H3N2-positive samples is CNDP2; this is a 
cytosolic non-specific dipeptidase that acts to suppress the growth of gastric 
cancer through the mitogen-activation protein kinase (MAPK) pathway. No 
known study has linked CNDP2 as a host response to IAV infection. However, 
Increased levels of CNDP2 were associated with apoptosis whilst decreased 
levels were associated with cell proliferation (415). This is another protein of 
interest to monitor and observe the trends in IAV-infected cells as in cancerous 
cells.  
 
Cofilin (COF1) was highlighted in Figure 5.5 to have an increased abundance 
in the IAV-H1N1-positive cohort compared to the IAV-H3N2-positive and IAV-
negative cohort. COF1 is essential for the normal progress of cells through 
mitosis and cytokinesis and has been found to interact with the Matrix (M) 
protein structure in RSV-infected cells. The M protein in RSV inhibits viral 
transcription (416) and through its interaction with COF1, is a potential antiviral 
target (417). COF1 was identified in human bronchial epithelial cells from 
different donors infected with IAV-H1N1 (418). COF1 could be further studied 
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to understand the viral pathogenesis as well as being a potential diagnostic 
biomarker. 
 
To further analyse the data from Figure 5.5, and the proteins that increased in 
abundance in the IAV-negative cohort in comparison to the IAV-H3N2 positive 
and IAV-H1N1 positive cohort, BPIFA1, FIBA, FIBB, and lactotransferrin (LTF) 
were highlighted across all three cohorts. These proteins were processed 
through the program – protein interaction network viewer (PINV) – for further 
data analysis. PINV is a web-based protein interaction network visualiser and 
was used to visualise these proteins within the context of proteins associated 
with IAV infection (419). Using PINV, the protein-protein interaction of FIBA, 
FIBB, FIBG, LTF, and BPIFA1 identified were examined in relation to the 
PABP-binding protein (an influenza host-binding protein) and influenza virus 
NS1A-binding protein (IVNS1ABP). On PINV, these proteins act as hubs as 
they connect to several other proteins. What is interesting to note is that each 
one of these proteins is linked by intermediary proteins to proteins involved in 
transcription regulation of IAV. This linkage forms an interactome of LTF, 
PABP-binding protein, and NS1A (Figure 5.6). A similar interactome is 
observed with proteins FIBA, FIBB, FIBG, and BPIFA1. A more detailed 
representation of the protein interactome and the intermediary proteins 
involved in these interactions can be seen in Figure 5.6A (FIBA, FIBB, FIBG 
interaction), Figure 5.6B (LTF interaction), and Figure 5.6C (BPIFA1 
interaction). The interactions between these proteins highlighted in AHCH, 
GOSH, and IPD, with PABP-binding protein and IVNS1ABP demonstrate a 
possible involvement of IAV binding to the host. This suggests these proteins 
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may be involved in the survival of the virus in the host and should be further 
investigated. This could be done through gene knockout and then confirmed 
by PCR (DNA), RT-PCR (RNA), and western blot (protein expression). These 
proteins have the potential to be further studied as diagnostic biomarkers due 
to the central role they play in enabling IAV to bind to the host. An increase in 
abundance of these proteins could suggest the presence of IAV infection.  
 
Figure 5.6A: Significantly differentially abundant proteins from datasets from 
AHCH, GOSH, and IPD, which were highlighted by the mass spectrometry (Q-
Exactive) platform, were further analysed and visualised using the Protein 
Interaction Network Viewer (PINV). This highlights the interaction between 
Fibrinogen Alpha, Fibrinogen Beta, Fibrinogen Gamma, and the influenza 
virus NS1A binding protein (IVNS1ABP) and Polyadenylate – binding protein 
2 (PABP2). These proteins are linked by transcription regulators also 
highlighted in the data from Mass spectrometry.  
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Figure 5.6B: Significantly differentially abundant proteins from datasets from 
AHCH, GOSH, and IPD, which were highlighted by the Mass spectrometry (Q-
Exactive) platform, were further analysed and visualised using the Protein 
Interaction Network Viewer (PINV). This highlights the interaction between 
Lactotransferrin, Influenza virus NS1A – binding protein (IVNS1ABP) and 
Polyadenylate – binding protein 2 (PABP2). These proteins are linked by 
proteins involved in RNA binding and transcription regulators, also highlighted 
in the data from Mass spectrometry.  
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Figure 5.6C: Significantly differentially abundant proteins from datasets from 
AHCH, GOSH, and IPD, which were highlighted by the Mass spectrometry (Q-
Exactive) platform were further analysed and visualised using the Protein 
Interaction Network Viewer (PINV). This highlights the interaction between 
BPIFA1, Influenza virus NS1A – binding protein (IVNS1ABP) and 
polyadenylate – binding protein 2 (PABP2). These proteins are linked by 
proteins involved in RNA binding, highlighted in the data from Mass 
spectrometry.  
 
Examining the pattern of protein abundance between the different strains led 
to potential strain-specific differences in IL-6 signalling. Interleukin 6 signal 
transducer (IL6ST) was highlighted to be significantly decreased in Figure 
5.2A. IL6ST is a signal transducer molecule and receptor for IL6. This led to 
the hypothesis that IL6 was differentially abundant. To test this, ELISA was 
used to measure the concentration of IL-6 in NAs from IPD cases either 
positive for H1N1 or H3N2 or negative for common respiratory pathogens. 
These data showed that while the level of IL-6 in H3N2-positive samples was 
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not significantly different from the uninfected controls, there was a statistically 
significant increase in the abundance of IL6 in the IAV-H1N1-positive cohort 
(Figure 5.7). 
 
Figure 5.7: Relative interleukin-6 (IL-6) in individual nasopharyngeal aspirates 
(NA) samples from H1N1 IAV positive samples (n=10), H3N2 IAV positive 
samples (n=10), and IAV negative samples (n=10) from Institute Pasteur. IL-
6 concentration was determined by ELISA and comparison to standard curve 
(data not shown). The software GraphPad PRISM was used to plot the Tukey’s 
plot shown and for Bonferroni’s post-test comparisons to the control. We found 
reduced IL-6 in both H1N1 IAV positive samples and H3N2 IAV positive 
samples when compared to the control (P<0.01, in both cases). 
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5.2.5 The influence of viral load on airway secretions 
The amount of virus (viral load) per patient may influence the airway 
secretome and subsequently disease severity. In some respiratory viruses 
such as adenoviruses, human metapneumovirus and parainfluenza virus, Ct 
values of NAs are correlated to clinical severity (420). To investigate whether 
IAV viral load influenced the proteome component of the airway secretome, 
protein abundance profiles were further analysed according to viral load 
(measured by Ct value) as determined at the time of diagnosis and sampling 
of NAs. Samples were separated according to Ct values between 20–25 
reflecting a higher viral load or Ct values between 26–30 reflecting a lower 
viral load, as well as into H3N2-positive (Figure 5.8A) or H1N1-positive (Figure 
5.8B) categories. It is worth noting that the samples were not all tested on the 
same day and time using the same equipment. These inconsistencies could 
affect or skew the dataset. The comparative data indicated that the abundance 
of certain proteins may or may not be affected by viral load. This was observed 
in both IAV-H3N2 and IAV-H1N1 strains. CATG (cathepsin G) is a protein 
involved in tissue remodelling at sites of inflammation, and DEF1 (defensin, 
alpha 1) is found at the epithelia of mucosal surfaces. These proteins 
decreased in abundance in patients IAV-H3N2 and IAV-H1N1 positive at both 
low and high viral loads. 
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Figure 5.8: The proteomics data obtained from Mass spectrometry (Q-
Exactive) platform from pooled Nasopharyngeal aspirates samples from IAV-
H3N2 positive samples (n=10) (A), IAV-H1N1 positive samples (n=10) and IAV 
negative samples (n=10) (B) obtained from Institute Pasteur Dakar-Senegal 
were separated based on viral titres. Low viral titre was a Ct value of 26 and 
above and high viral titre was Ct value of 20-25. After filtering for proteins 
common in all datasets they were subjected to Gene-E program. The Gene-E 
program clusters proteins based on relative abundance within all three 
conditions. This allows for a better relative representation and comparison of 
protein abundance for each cohort compared – proteins interacting together 
within/across each cohort. Red represents high protein abundance, blue low 
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protein abundance, and white, an intermediary transition within the various 
cohorts. Figure 5.8A represents proteins of differential abundance in different 
viral titres of IAV-H1N1-positive samples and Figure 5.8B represents proteins 
of differential abundance in different viral titres of IAV-H3N2-positive samples. 
 
Figure 5.9: The proteomics data obtained from all three cohorts that were IAV-
H3N2-positive: Alder Hey Children’s Hospital (AHCH), Great Ormond Street 
Hospital (GOSH), and Institute Pasteur Dakar (IPD) were compared to IAV-
negative samples. Following various data analysis steps via bioinformatics, 
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proteins present in AHCH, GOSH, and IPD that were significantly differentially 
abundant were highlighted. These proteins were subjected to Gene-E 
program. The Gene-E program clusters proteins based on relative abundance 
within all three conditions. This allows for a better relative representation and 
comparison of protein abundance per cohort compared – proteins interacting 
together within/across each cohort. Red represents high protein abundance, 
blue low protein abundance, and white an intermediary transition within the 
various cohorts.  
Figure 5.9 shows the proteins identified in all three sites - Great Ormond 
Street, Institut Paster Dakar and AlderHey Hospital. This figure allows for the 
visual comparison in the protein abundance between these three sites. Whilst 
these proteins can be considered potential biomarkers as there is an obvious 
difference in protein abundance between these sites, it is worth noting that 
there was a lack of information on the stage of IAV infection. As a result, no 
direct correlation can be made between these differences and the stage of IAV 
infection or if geographical location affects IAV infection and therefore protein 
abundance in these samples.  
 
5.2.6 Identifying correlates of infection using machine learning 
Machine learning, based on a panel of differentially abundant proteins in IAV 
negative versus IAV positive samples, potentially offered a means of 
identifying proteins that could differentiate IAV-positive from IAV-negative 
samples, based on an analysis of NAs. To ensure that the outcome was robust 
for variations between clinical centres in clinical and analytical procedures, the 
protein abundance data were collated for NAs from the three independent 
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cohort studies to identify protein biomarkers with consistent responses to 
infection. For data normalisation to be processed, measurements were 
required on all entities. This step was limited by the different protocols used. 
To circumvent this, two measurements of a sample on a protein pair were 
centred to zero. This allowed us to explore all the pair-wise combinations of 
normalised proteins and identify those providing the greatest discrimination 
between control and infected status. Subsequently, these were combined to 
provide averaged and individual profiles across the selected protein, as 
illustrated in Figure 5.10, which illustrates the outcomes for control uninfected 
and patients infected either with H1N1 or H3N2. This is indicated by a 
‘correlation difference’ defined as cor (sample profile, controls profile) – 
cor(sample profile, infected profile), which naturally falls between -2 (for 
infected) and 2 (for uninfected). Usually, the zero line can be used to separate 
the controls and infected in a prediction. If a control sample has a negative 
value in correlation difference, it will be predicted. This shows that all control 
samples, and all but two infected samples, were predicted correctly. The 
accuracy was 91.7% (22 out of 24 being correct). The two incorrect samples 
were from the IAV-H3N2-positive infection from the AHCH cohort. Albeit this, 
the two other samples were correctly predicted. The correlation difference 
values for the control samples from AHCH were also distinctly different to the 
other two sites. The IPD data allowed comparison of the predictive power for 
H1N1 with H3N2, and infected individuals were determined with equal 
success. 
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Figure 5.10: Predicting the IAV status of patients based on proteomic analysis. 
Data from independent proteomic analyses in three different clinical sites 
(Alder Hey Children’s Hospital (AHCH), Liverpool, Great Ormond Street 
Hospital (GOSH), London, and Institute Pasteur Dakar (IPD)) was collated to 
identify differentially expressed (DE) proteins between control and infected 
patients. Figure 5.10A displays normalised-by-centering profiles for a set of 4 
DE human proteins that conspicuously separated the profile of control 
(uninfected) from infected conditions. These proteins have a crucial role to 
play in innate immunity and are seen to be inversely abundant between the 
infected and non-infected cohorts. The thick solid lines represent the average 
profile across all patients from each of the two groups, whilst the thin lines 
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represent data from individual patients. Figure 5.10B displays replicate control 
and infected patients, across the three sampling sites (AHCH, GOSH and 
IPD). This shows the difference between the infected samples (red circles and 
triangles) and the uninfected samples (green circles). This gives confidence in 
the ability for this data, methodology and analysis to be used to predict proteins 
that can be potential differentiators between the infected and uninfected 
(control). These proteins can be used as potential biomarkers.   
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5.3 DISCUSSION 
The effects of IAV have been studied in various animal models and cell 
systems using high throughput techniques (219, 421-423). These studies have 
revealed extensive modification of the host transcriptome and proteome due 
to infection. To investigate the effect of IAV infection on airways in paediatric 
patients, quantitative proteomics was used to define the proteome of NAs. 
These samples were compared to samples from paediatric patients that were 
IAV negative. To our knowledge, no study has applied label-free Mass 
spectrometry on NAs taken from IAV-positive paediatric patients in 
comparison to samples from IAV-negative paediatric patients. These samples 
were taken from different cohorts to evaluate and understand the proteome 
changes involved in airway secretions upon influenza infection, and whether 
any changes were common to all three patient groups. This chapter highlights 
the benefits of label-free Mass spectrometry by providing an in-depth list of 
proteins differentially abundant in these samples, allowing for a comparison 
between IAV-negative samples, IAV-H3N2-positive, and IAV-H1N1-positive 
samples. In addition, the results in this chapter provide an in-depth 
understanding of the proteins identified with significant abundance through 
functional links and networks. These proteins were further analysed for 
commonality across cohorts and some of them narrowed down with the 
potential of biomarkers for diagnosis.  
 
In the search for proteome changes in airway secretions due to IAV infection, 
the list of statistically differentially abundant proteins was mined by looking for 
common proteins across all patient cohorts (AHCH, GOSH and IPD). This 
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revealed FIBA, FIBG, FIGG, BPIFA1, and LTF, which differed in abundance. 
This group of proteins increased in abundance in the AHCH and GOSH cohort 
but decreased in abundance in the IPD cohort (Figure 5.2). This may be 
because of the different stages of the disease progression at the time of 
infection or disease onset prior to sample collection. A similar analysis was 
observed with BPIFA1 abundance in the different cohort. Fibrinogen levels 
may be a useful marker of disease progression and severity. Fibrinogen has 
been shown to aid the binding of streptococcus pneumoniae to IAV-infected 
cells (424) during opportunistic co-infections. Studies in mice have linked the 
activation of an antifungal pathway, possibly driving allergic airway 
inflammation through fibrinogen (425). These various studies indicated the 
potential of FIBA, FIBB, and FIBG as markers for possible disease severity 
and progression through different pathways. This difference between clinical 
samples, in this case airway secretion, and cell culture model, is reflected in 
our observation that fibrinogen decreases in abundance in the NAs from 
paediatric patients infected with IAV. In contrast, in Madin-Darby canine kidney 
cells (MDCK) infected with IAV, fibrinogen was shown to increase in 
abundance (426). However, this may reflect differences in the sample type. 
This work illustrated the advantage of working with clinical material compared 
to commonly used cell culture systems (such as A549 cells – a human lung 
respiratory epithelial cell line), as not all the proteins affected by IAV will be 
expressed in cell culture – such as BPIFA1 (Figure 5.2). 
 
BPIFA1 has been proposed to abrogate IAV infection and possibly act as a 
novel target for antiviral treatment (427). The role of BPIFA1 and SCGBA1 as 
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innate defence mediators during respiratory infection have been elucidated 
(402). LTF was shown to decrease in two out of the three patient cohorts. This 
protein has been used as an experimental therapy against IAV infection. 
Studies in mice, infected with IAV and orally administered LTF, showed less 
lung damage compared to control mice. LTF has also been shown to have 
inhibitory activity against viruses such as; cytomegalovirus, herpes simplex 
virus-1 (HSV1), HIV, hepatitis B and C, poliovirus and respiratory syncytial 
virus (RSV). This shows LTF has roles in inhibiting other viruses including IAV 
(428). However, in a similar manner as BPIFA1 and FIBA, FIBB, and FIBG, 
LTF could be used as a marker for disease progression and severity.  
 
The cohort of samples obtained from IPD allowed for inter-strain comparison 
as well as IAV-positive versus IAV-negative. This comparison revealed sets of 
proteins common to IAV-H3N2-positive, IAV-H1N1-positive and IAV-negative. 
These proteins were all present in differing quantities thereby emphasising the 
effects of infectivity on the host response. Proteins such as STAT1, ISG15, 
and SG2A1 increased in abundance when compared to an IAV-negative 
cohort, regardless of the IAV-strain. These proteins have roles in transcription 
regulation of interferon pathways as well as play key roles innate immune 
response to viral infection. STAT1 and ISG15 are commonly increased in 
volume and upregulated during virus infection. The increase in abundance of 
these proteins confirms the IAV-positive infection of the samples and on-going 
viral replication. The presence of these proteins in the interactome between 
FIBA, FIBB, FIBG, LTF, SPLUNC1, PABP-binding, and IVNS1ABP suggest 
the importance and possible function of the proteins common in all three 
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cohorts in viral replication and viral survival in the host. The interaction seen 
in Figure 5.6A, 5.6B, and 5.6C between these proteins, highlights the potential 
of these proteins as biomarkers for disease severity. Alongside LTF, other 
proteins, such as LDHB, involved in the sub pathway synthesis of lactate from 
pyruvate, were particularly elevated in IAV-H1N1-positive patients. This is also 
observed in bacterial infection (429). In vitro studies in MDCK cells, which 
compared IAV-infected cells to IAV negative cells observed the increase in 
lactate release in the cell culture supernatant in H1N1-PR8 (430).  
 
The differential abundance of cellular proteins in NAs from IAV-infected 
patients may reflect both time post-infection as well as viral load. The limitation 
of this study was the inability to know when the patients were infected with 
IAV. The only information we are confident of is the symptoms they presented 
when admitted to hospital with acute illness. In this respect, it illustrates how 
animal models provide a more controlled environment to study IAV infection 
over time. However, data associated with the samples from the IPD did allow 
us to evaluate the potential role of viral load in changes in cellular protein 
levels. In IAV-H3N2-positive samples, FIBG increased in abundance in 
comparison to IAV-negative samples regardless of viral load (Figure 5.8A). In 
IAV-H1N1-positive samples, FIBG increased with a low viral load in IAV-
H1N1-positive in comparison to IAV-negative and high viral load in IAV-H1N1-
positive patients (Figure 5.8B). This further confirms the potential use of 
fibrinogen as a marker for disease progression and severity. IL6 is a well-
known and documented marker of infection with IAV-H1N1 having been 
studied in both animal models of infection and in serum from human patients 
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(431-433). Our study highlights a significant difference in the abundance of IL6 
in IAV-H1N1-infection compared to IAV-H3N2-infection. This suggests a 
difference in trajectory of host response between the two different viral strains, 
which has also been described in a mouse mode examining the level of IL6 
between IAV-H1N1 and IAV-H3N2-infected mice (434). 
 
In the search for Biomarkers, biomarkers can be divided into various groups 
including “prognostic biomarkers”. Prognostic biomarkers aim to aid with IAV 
diagnosis, facilititate this process and provide more information on the overall 
outcome of patients following infection (435). This study focused on the search 
for prognostic biomarkers. Following further studies and validation, this is to 
enhance clinicians’ ability to make decisions on treatment. This process is 
rather tedious due to the effect of IAV infection to the host’s immune system. 
However, this study was hypothesis generating and provides a good 
foundation for potential prognostic biomarkers in IAV infection.
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5.4 CONCLUSION 
This study analysed the proteome of airway secretions using NAs taken from 
paediatric patients admitted to hospital and confirmed positive (or negative) 
for IAV-infection in three different cohorts – AHCH, GOSH, and IPD. These 
samples provided a window on the in vivo effects of IAV on the airway. Mass 
spectrometry, data analysis, and confirmation via a second technique across 
all three cohorts revealed the proteins FIBA, FIBB, FIBG, and BPIFA1 to be 
differentially abundant between infected and non-infected patients. These 
proteins have been identified in various models of IAV-infection and our data 
suggests the relevance of these models to the study of human airways, but, 
more importantly, the potential for these proteins to be used in the search of 
potential biomarkers. This study also allowed for a comparison between IAV-
H3N2, IAV-H1N1, and IAV-negative samples using data from Mass 
spectrometry. This comparison revealed proteins such as STAT1, SG2A1, 
ISG15, CRNN, and COF1 as potential discriminatory biomarkers between the 
two IAV strains and IAV-negative samples. In addition, the machine learning 
conducted in this study confirmed the ability to differentiate and predict 
between IAV-H3N2 and IAV-H1N1 by highlighting certain proteins – SG2A1, 
MUC5A, BPIB1, and PERM. The importance of the UPP in IAV survival was 
further highlighted and the potential role UBA1 has to play in achieving this. 
Finally, this study illustrates how proteomic analysis of biological samples can 
be used to identify markers that may serve as potential diagnostic indicators 
for infection with IAV, despite potential problems of inconsistent protocols and 
different instrumentation between centres. 
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CHAPTER 6: 
GENERAL DISCUSSION 
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The overarching aim of this study was to investigate the global proteomic and 
transcriptomic response to IAV infection in vitro (A549 cells) and in vivo (NHP 
macaques and humans). This study characterised, the proteome of the host 
(A549 cells) in vitro following IAV infection using label-free Mass spectrometry 
for the first time and the transcriptome of the host (A549 cells) following IAV 
infection using a MinION sequencer-based approach (Chapter 3). The results 
obtained resembled previously established proteomes of the host (A549 cells) 
in vitro following IAV infection using other techniques (210, 219, 436-438). The 
data obtained from sequencing on a MinION sequencer were in concordance 
with data obtained from a previously established study that used genome-wide 
RNAi screening of IAV-infected A549 cells (328, 345). IAV infection was 
characterised by infecting A549 cells with IAV at MOI 1 and collected over a 
time frame of 3h.p.i–48h.p.i. The Avicel plaque assay (254) was used to 
quantify the virus titer at different time points after which 18h.p.i was selected 
as the time point for further experiments. 18h.p.i was selected because this 
time point showed peak viral load and less Cytopathic effect (CPE) in the cells. 
IAV infection in A549 cells was further validated by SDS-PAGE and 
immunofluorescence microscopy. A549 cells were then infected at MOI 1, 
collected at 18h.p.i and subjected to mass spectrometry. RNA was extracted 
from A549 cells infected at MOI 1, 18h.p.i and subjected to MinION 
sequencing. The datasets obtained were further analysed using IPA analysis 
and categorised based on function. One of the pathways/categories 
highlighted was a ‘replication of IAV’. Ten proteins and transcripts identified by 
Mass spectrometry and MinION sequencing were highlighted under this 
category. These ten targets had been published in the literature as host 
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proteins essential for IAV replication, they include; NUP54, RBM42, HPGD, 
GCLC ANPEP, AKAP13, RACGAP1, CREB1, MAN2B1, and PRKCI (328). 
Gaining knowledge of these host cell target’s roles in IAV replication provides 
information on the pathways IAV uses but also are potential antiviral drug 
targets. This validates and confirms the dataset highlighted in chapter 3 (in 
this thesis) and more importantly gives confidence in the technique and 
experiments used and so the targets identified should be explored further. In 
addition, these targets are potential antiviral drug targets or reveal new 
molecular pathways the IAV exploits to survive in the host. Although this study 
wasn’t aimed at conducting a full functional validation for the highlighted 
targets, these could be validated further in future work. A limited amount of 
time and financial resources for this study prevented further experiments to 
explore these targets. However, general analysis of the data via IPA 
highlighted proteins in the Trim family – TRIM25, as well as immunoglobulins, 
which were affected following IAV infection. TRIM25 induces ubiquitination of 
RIG-I that leads to increased signalling of RIG-I (346, 347). RIG-I sits upstream 
as an activator of an antiviral pathway, which induces type I IFN host protective 
innate immunity (346). Proteins and transcripts involved in major cell signalling 
pathways triggered by IAV infection (340) in the host were highlighted. This 
includes MAPK1 in the MAPK pathway (328, 340), MDM2 in the PI3/AKT 
pathway (340), all type 1-IFN induced proteins (IFIT2, IFIT3 and MX1), 
interferon stimulated genes (ISG15), and TRIM25 in the RIG-I/TLR pathway 
(276, 277, 340); finally, AKAP13, RACGAP1, PRKCI in the IP3/PKC pathway 
(340). The two techniques used; one being protein based and the other RNA 
based, show the potential of the platforms used to obtain these results. The 
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other targets should therefore be analysed further for pathways and anti-viral 
drug targets.  
This study allowed for the possibility to analyse and compare samples from in 
vitro and in vivo models, analyse them on the same platform, and explore 
whether there was coherence in the protein targets identified and highlighted 
in different hosts following IAV infection. This was the first of its kind using the 
above-mentioned techniques. IAV infection observed in an in vivo model - 
NHPs, used an infection route that modelled natural human infection. This was 
the natural inhaled aerosol route of infection (262). This is essential to ensure 
concordance with human IAV infections as they are valuable for testing and 
identifying anti-influenza targets. To understand the host response of NHP 
macaques to IAV infection and identify protein targets essential in host-IAV 
interaction; Broncho alveolar fluid (BALF) was obtained from IAV-infected 
NHP and compared to naïve NHP macaques using proteomics. The NHP 
model is useful and informative in the study of IAV and other respiratory 
pathogens. This is mainly due to its high similarity to the human immune 
system, susceptibility to non-adapted human strains, similarity to the 
respiratory tract anatomy of humans, and the broad availability of immunology 
reagents in this study (439). BALF samples were used from NHPs due to their 
similarity to NAs from humans (Chapter 5). This was essential as the data from 
both chapters would be compared; this increased confidence when comparing 
data. The main reason as stated above for using NHP as a model for the study 
of IAV was due to the robustness of its immune system and similarity to 
humans. The data obtained from BALF proteome associated with the immune 
system were a) similar to some cellular proteins (IFIT3 and MX1) highlighted 
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in vitro in A549 cells (Chapter 3) and b) had a high percentage of proteins 
involved in the immune system from NAs from humans (Chapter 5). In 
addition, STAT1 was identified and highlighted to have a significant differential 
abundance in this study following IAV infection. IAV is thought to interrupt the 
IFN J - pathway by disrupting the JAK/STAT pathway. It does this by inhibiting 
the nuclear translocation of STAT1 gamma activated by interferon gamma 
(440). Some of the pathways highlighted in the BALF proteome of NHPs are 
known to be associated in the IAV-immune response in humans were 
pathways involving type 1 IFN proteins and also the JAK/STAT pathway (404, 
440). The proteome of BALF from NHP, five days post-infection in comparison 
to naïve samples highlighted an extensive increase in proteins associated with 
macrophage activation, accumulation, and cell movement. These proteins 
include AGT, APOA1, PLG, CD44, ANXA2, ANXA1, S100A4 and S100A9 
(Chapter 4 figure 4.6). Neutrophils and macrophages are known to play a key 
role in the phagocytosis of IAV-infected cells. There is a direct correlation 
between the changes in the level of phagocytosis and the amount of IAV in 
lung tissue (441). The NHP model therefore supports the results from the in 
vitro model and also supports the changes observed in the immune response 
in the host proteome in humans. Chapter 4, figure 4.8 highlighted proteins 
involved in the replication of IAV when comparing samples from NHP seven 
days post-infection to samples from NHP five days post-infection. The proteins 
highlighted in this figure were also uncovered by Mass spectrometry in A549 
cells and categorised under ‘replication of Influenza A virus’ by Ingenuity 
Pathway Analysis (Table 3.9). The proteins common across these two 
datasets are highlighted in Table 6.0. 
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Table 6.0: P
roteins highlighted as involved in “replication of influenza A
 virus” b
y M
ass spectrom
etry w
hen 
com
paring A549 cells infected w
ith IAV com
pared to IAV negative cells and in sam
ples from
 IAV infected N
H
P
 at 
7 days post infection com
pared to 5 days post infection 
U
niprot accession ID
 
P
rotein nam
e 
P
rotein function in relation to IA
V
 
D
D
X58_H
U
M
A
N
 
P
robable ATP
-dependent R
N
A
 helicase D
D
X
58 
E
ncodes cytosolic R
N
A
 receptor R
IG
-I. 
R
IG
-I plays an essential role in IA
V
 
recognition. D
efects in the R
IG
-I encoding 
gene D
D
X58 im
pairs signalling of R
IG
-I 
(442) 
E
IF3A
_H
U
M
A
N
 
E
ukaryotic translation initiation factor 3 subunit A
 
eIF3A
 is one of m
any proteins that interact 
w
ith IA
V
 proteins (P
A
-N
155 and P
A
-N
182) 
in the host (443)  
H
S
P
90AA
1_H
U
M
A
N
 
H
eat shock protein H
SP
 90-alpha 
H
S
P
90 is a host chaperone thought to 
interact extensively w
ith influenza virus 
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enabling the folding of defective N
P
(444) 
variants 
K
P
N
B
1_H
U
M
A
N
 
Im
portin subunit beta-1 
Involved in nuclear trafficking of viral 
factors. C
ells w
ith a low
 abundance of 
K
P
N
B
1 show
 a significant decrease of N
P
 
in the cytoplasm
 (328, 445) 
M
A
P
K
1_H
U
M
A
N
 
M
itogen-activated protein kinase 1 
P
art of a pathw
ay affected by influenza 
infection. M
A
PK
s regulate the 
overproduction of IL-6 during influenza 
virus infection (446) (447) 
M
X1_H
U
M
A
N
 
Interferon-induced G
TP
-binding protein M
x1 
P
art of the antiviral response induced by 
type I and III interferons. R
esponsible for 
inhibiting infection by blocking viral 
transcription and replication (229) 
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P
A
K
2_H
U
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S
erine/threonine-protein kinase P
AK
 2 
E
ssential role in viral entry and blocking 
viral R
N
A
 replication (328) 
P
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1_H
U
M
A
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P
eptidyl-propyl cis-trans isom
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A
-
interacting 1 
R
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F-NB
 signalling through 
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 (U
P
S
. U
P
S is 
necessary for the entry of influenza virus 
into cells (448) 
R
P
L13A
_H
U
M
A
N
 
60S
 ribosom
al protein L13a 
P
ro-viral host factor that Interacts w
ith N
S
1 
and N
S2 IA
V
 proteins (449) 
R
P
S
5_H
U
M
A
N
 
40S
 ribosom
al protein S
5 
H
ost factors influenza depends on (345) 
S
TA
T1_H
U
M
A
N
 
S
ignal transducer and activator of transcription 
1-alpha/beta 
Involved in IFN
 signalling, S
TAT1 is 
suppressed in IA
V infected cells (450)  
S
U
M
O
2_H
U
M
A
N
 
S
m
all ubiquitin-related m
odifier 2 
IA
V
 infection causes an increase in 
proteins m
odified by SU
M
O
2 (451) 
 
 
 
318 
 
TU
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Tubulin beta chain 
H
as a role in intracellular viral transport 
(328) 
A
R
C
N
1_H
U
M
A
N
 
C
oatom
er subunit delta 
R
ole in inhibiting replication of influenza 
strains (452) 
C
LIC
4_H
U
M
A
N
 
C
hloride intracellular channel protein 4 
H
ost factors essential for influenza 
infection (345) 
C
O
P
A
_H
U
M
A
N
 
C
oatom
er subunit alpha 
Involved in endosom
al trafficking and early 
secretory pathw
ay (328, 445) 
C
O
P
B
2_H
U
M
A
N
 
C
oatom
er subunit beta 
P
art of the com
plex essential for the 
form
ation of transport vesicles betw
een 
early and late endosom
es (328) 
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Some of the proteins highlighted in Table 6.0 above were also identified to have 
significant difference in abundance when human NA samples were analysed 
using proteomics (Chapter 5). These proteins include; HSPB1 (a heat shock 
protein), COPA, and TUBB, were all identified in the dataset from GOSH when 
comparing IAV H3N2 infected samples to non-infected samples (Appendix 1, 
Table 2). STAT1, CLIC1 and HSPB1 were also identified in the dataset from IPD 
when comparing IAV H3N2 infected samples to non-infected samples (Appendix 
1, Table 3). TUBB, STAT1 and HSPB1 were all identified in the dataset from IPD 
when comparing IAV H1N1 infected samples to non-infected samples (Appendix 
1, Table 4). In addition to these, proteins involved in pathways such as MAPK 
pathway and in the PKR signalling pathway were identified in the dataset from 
AHCH when comparing IAV H3N2 infected samples to non-infected samples 
(Appendix 1, Table 1). These proteins are therefore consistent across all three 
hosts – A549 cells, NHPs and humans. These proteins could additionally be 
potential biomarkers to identify disease progression and severity of IAV infection. 
Each of these proteins have been identified in studies in the literature to have 
roles in IAV infection and survival in the host. It is interesting to note that some of 
these proteins (Table 6.0) were not identified by MinION sequencing in Chapter 
3. This highlights the importance of further experiments to explore individual 
targets as a potential biomarker after downstream analysis. It also shows the 
importance of using independent approaches and validation across species. 
However, when considering in vivo models, it is worth noting the NHP models 
incur a high amount of cost, require very skilled personnel to carry out these 
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experiments and are ethically controversial (453, 454). Chapter 4 brings in 
another dimension of the model for the study of IAV infection in comparison to the 
in vitro model. While the in vitro model provides information on host, cellular 
proteins found in human NAs and confirmed in vivo NHPs, NHPs give the 
opportunity to study other aspects, such as the immune response. It is essential 
that the findings observed in vitro and in vivo are compared to studies in humans. 
This is to ensure that when searching for potential anti-viral drug targets, the 
techniques and findings are efficient in IAV-infected humans. Proteomes of NAs 
from IAV-infected patients in comparison to non-infected patients were analysed. 
Samples with a wide range of C(t) values were obtained from three cohorts: 
AHCH, Liverpool, GOSH, London, and IPD, Senegal. Samples were taken from 
these cohorts to explore if any changes observed were a result of the 
geographical location. In the search for a model most reflective of the occurrences 
in humans following IAV infection, Chapter 5 highlighted already illustrated 
similarities and differences from Chapters 3 and 4 as well as novel potential 
biomarkers. Chapter 5 of this thesis established the use of Mass spectrometry as 
a technique to identify a global host proteome in NAs. The results from Mass 
spectrometry were validated by SDS-PAGE using the antibodies BPIFA1 and 
SCGB3A2. BPIFA1/SPLUNC1 has been identified as a potential biomarker for 
the diagnosis or severity of IAV (455). In Chapter 5, the abundance of BPIFA1 is 
seen to increase in some cohorts post infection (AHCH and GOSH) (Figure 5.3A) 
but seen to decrease in IPD post infection (Figure 5.3A). The reason for this is 
unknown but could be an indication of disease progression in different cohorts. 
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The Mass spectrometry data was further validated by ELISA. IL6 concentration 
was measured in IAV-H1N1 positive, IAV-H3N2 positive and IAV negative 
samples and it validated the data from Mass spectrometry. Further bioinformatic 
analysis identified proteins as potential biomarkers. Three proteins were 
highlighted during the data analysis of Chapter 5, which could play crucial roles 
as biomarkers. The host proteins: lactotransferrin, Fibrinogen A, B, and G, and 
BPIFA1/SPLUNC1 were all found to be directly associated with the influenza virus 
NS1A binding protein and polyadenylate binding protein 2. These proteins were 
also present across all three cohorts, regardless of geographical location. 
Lactotransferrin and BPIFA1/SPLUNC1 were identified with a significant 
difference in abundance in a study using 2DE proteomics to compare NA from 
IAV-infected H3N2 to mock samples (393). Lactotransferrin has natural immunity 
properties with an antiviral role and inhibits influenza infection via induced 
apoptosis (456-458). Fibrinogen in humans binds to glycoprotein on the surface 
of IAV-infected cells. Bound fibrinogen further acts as a receptor for group A 
Streptococcus (424). BPIFA1 plays a significant role in defence against IAV 
infection in the mucous. Mice deficient in BPIFA1/SPLUNC1 had lost more weight 
after infection as well as a higher viral load (455). These proteins play crucial roles 
in IAV infection and host defence. Lactoferrin’s innate immune role could limit its 
potential as a biomarker. However, Fibrinogen A, B and G and BPIFA1/SPLUNC1 
could be potential IAV biomarkers. This study presents the first time these 
proteins have been highlighted using label-free Mass spectrometry in human NAs 
across three cohorts from different geographical locations. This illustrates how 
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label free proteomic analysis of biological samples can be used to identify 
markers that may serve as potential diagnostic indicators for IAV infection. For 
research into host cellular response to IAV infection, a specific target or 
experimenting a potential drug, an in vitro A549 cellular model is recommended. 
For research into host cellular response and immune response, in vivo NHP 
macaque is the recommended model.  
 
In summary, this thesis presented an in-depth analysis of IAV infection in three 
different models by proteomic analysis. It identified and highlighted several 
proteins associated with IAV infection, which have been published in the 
literature, confirming the data. Host proteins, which play essential roles in the 
replication of IAV were identified in vitro (Chapter 3) via two independent 
approaches; Mass spectrometry and MinION sequencing, and across species in 
vitro (Chapter 3) and in vivo (Chapter 4). These proteins could serve as potential 
biomarkers for disease progression or even drug targets. Other proteins that were 
highlighted to play a role in the replication of IAV have the potential to be 
biomarkers and should be explored further for full functional validation.  
 
In addition, IAV infection was observed at different stages (Chapter 4) and 
proteins that could be targets for different stages of infection were highlighted 
(proteins involved in IAV replication). Data from in vivo and in vitro models were 
compared to data from human NA samples from patients aged 2–13 years old. 
From this data, three proteins (Chapter 5) were highlighted that could be used as 
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potential biomarkers for diagnosis of severity and predictability of outcome. 
Overall, this thesis presented the use and benefits of Mass spectrometry and 
MinION sequencing to identify a host’s global proteome and transcriptome in vitro 
and in vivo. This thesis showed the potential of a new sequencing technique using 
the MinION sequencer to observe host response to IAV infection. 
 
The main caveat faced in this thesis was limited information was provided on the 
NAs samples obtained from humans. This limited a definitive interpretation of the 
results obtained thereby focusing on comparing these results with findings in 
other studies for example mice models. When studying IAV in different models, 
we know that due to the differences in the hosts, there is an expected difference 
when observing the host proteome. Therefore, we can expect a level of change 
and difference after IAV infection only up to the capacity of the host being studied. 
Studies in vitro and in vivo have to be relatable back to humans; thus, embracing 
various facets of the host’s response to IAV infection. As a result, there is no one 
size fits all model in the study of IAV, but rather, models that can be used based 
on what is being researched.  
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